WO2019194260A1 - High-shrinkage artificial fibroin fibers, method for producing same, and method for shrinking artificial fibroin fibers - Google Patents

High-shrinkage artificial fibroin fibers, method for producing same, and method for shrinking artificial fibroin fibers Download PDF

Info

Publication number
WO2019194260A1
WO2019194260A1 PCT/JP2019/014895 JP2019014895W WO2019194260A1 WO 2019194260 A1 WO2019194260 A1 WO 2019194260A1 JP 2019014895 W JP2019014895 W JP 2019014895W WO 2019194260 A1 WO2019194260 A1 WO 2019194260A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
fibroin
seq
acid sequence
motif
Prior art date
Application number
PCT/JP2019/014895
Other languages
French (fr)
Japanese (ja)
Inventor
潤一 菅原
森田 啓介
中村 浩之
Original Assignee
Spiber株式会社
小島プレス工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spiber株式会社, 小島プレス工業株式会社 filed Critical Spiber株式会社
Publication of WO2019194260A1 publication Critical patent/WO2019194260A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01FCHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F4/00Monocomponent artificial filaments or the like of proteins; Manufacture thereof
    • D01F4/02Monocomponent artificial filaments or the like of proteins; Manufacture thereof from fibroin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Definitions

  • the present invention relates to a high-shrinkage artificial fibroin fiber, a method for producing the same, and a method for shrinking an artificial fibroin fiber.
  • Silk which is a kind of natural fibroin fiber, is known as a fiber that sufficiently satisfies the touch and has a high-class feeling.
  • fibers used in clothing, bedding, etc. are required to have softness and heat retention. Therefore, silk used for clothing, bedding, and the like is subjected to, for example, shrink processing to increase bulkiness, thereby imparting flexibility and heat retention in some cases.
  • synthetic fibers such as polyester fibers, polyamide fibers, and acrylic fibers are generally used for clothing, bedding, etc., and these synthetic fibers are brought into contact with boiling water and then left for 12 hours.
  • the shrinkage rate of 40% or more is realized (Patent Document 1).
  • the present invention relates to the following inventions, for example.
  • [1] Shrinked artificial fibroin fiber comprising modified fibroin, A highly shrinkable artificial fibroin fiber having a shrinkage rate defined by the following formula of 2% or more.
  • Shrinkage rate ⁇ 1 ⁇ (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water) ⁇ ⁇ 100 (%)
  • [3] The high-shrinkage artificial fibroin fiber according to [1] or [2], which is shrunk by contact with water having a boiling point below.
  • Shrinkage rate ⁇ 1 ⁇ (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water) ⁇ ⁇ 100 (%)
  • Shrinkage rate ⁇ 1 ⁇ (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water) ⁇ ⁇ 100 (%)
  • the method for shrinking artificial fibroin fiber according to [10] wherein the modified fibroin is a modified spider silk fibroin.
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
  • the domain sequence has an amino acid sequence with a reduced content of n motif (A) corresponding to deletion of at least one or more (A) n motifs compared to naturally occurring fibroin, [1] to [5]
  • (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • m represents an integer of 2 to 300.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the domain sequences as compared to the naturally occurring fibroin, at least the N-terminal side of two consecutive towards the C-terminal side from the (A) n motif deletions, and one (A) n motif deletions.
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , From the N-terminal side to the C-terminal side, compare the number of REP amino acid residues of two adjacent [(A) n motif-REP] units in order, and the number of REP amino acid residues with a small number of amino acid residues. Is the sum of the number of amino acid residues of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of the other REP of 1.8 to 11.3.
  • n motif represents an amino acid sequence composed of 2 to 27 amino acid residues
  • (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , Compared with naturally-occurring fibroin, the content of glycine residues corresponding to at least one or more glycine residues in REP was replaced with another amino acid residue in the domain sequence was reduced.
  • (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • m represents an integer of 2 to 300.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the domain sequence is at least one or more of at least one motif sequence selected from GGX and GPGXX in REP (where X represents an amino acid residue other than glycine).
  • the ratio of the motif sequence in which the glycine residue is substituted with another amino acid residue is 10% or more with respect to the entire motif sequence.
  • the high-shrinkage artificial fibroin fiber and the high-shrinkage artificial fibroin fiber according to [19] Production method or shrinkage method of artificial fibroin fiber.
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , XGX contained in all REPs in the sequence excluding the sequence from the domain sequence to the most C-terminal side (A) n motif to the C-terminus of the domain sequence (where X is an amino acid residue other than glycine)
  • the total number of amino acid residues in the amino acid sequence consisting of z) is z, and the domain sequence is located at the most C-terminal side (A) in the sequence excluding the sequence from the n motif to the C-terminus of the domain sequence
  • the high-shrinkage artificial fibroin fiber according to any one of [1] to [5], wherein z / w is 50.9% or more, where w is the total number of amino acid residues in
  • (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • m represents an integer of 2 to 300.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the modified fibroin corresponds to the substitution of one or more glycine residues in REP with another amino acid residue as compared with naturally occurring fibroin, and in addition, one or more amino acid residues
  • the high-shrinkage artificial fibroin fiber and the method for producing the high-shrinkage artificial fibroin fiber according to any one of [18] to [21], which have an amino acid sequence corresponding to substitution, deletion, insertion and / or addition of Or shrinkage method of artificial fibroin fiber.
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
  • the domain sequence has one or more amino acid residues in REP substituted with amino acid residues having a higher hydrophobicity index and / or one or more hydrophobicity in REP compared to naturally occurring fibroin.
  • the high shrinkage artificial fibroin fiber according to any one of [1] to [5], [6] to [9] [13]
  • the method for shrinking artificial fibroin fiber according to any one of [13].
  • (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • m represents an integer of 2 to 300.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the amino acid residue having a large hydrophobicity index is selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A).
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , (A) The average of the hydrophobicity index of four consecutive amino acid residues in all REPs included in the sequence excluding the sequence from the n motif to the C terminus of the domain sequence from the domain sequence. P is the total number of amino acid residues contained in the region where the value is 2.6 or more, and the sequence from the (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence is excluded from the domain sequence.
  • n motif represents an amino acid sequence composed of 2 to 27 amino acid residues
  • (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • n represents an integer of 2 to 300.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the high shrinkage artificial fibroin fiber In addition to corresponding to insertion of an amino acid residue having a large sex index, it further has an amino acid sequence corresponding to substitution, deletion, insertion and / or addition of one or more amino acid residues, [23 ]
  • the modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif; Glutamine residue content corresponding to the domain sequence having one or more glutamine residues in REP deleted or substituted with other amino acid residues compared to naturally occurring fibroin Has a reduced amino acid sequence, [1] to [5]
  • the high shrinkage artificial fibroin fiber according to any one of [1] to [5], [6] to [9] [13]
  • the method for shrinking artificial fibroin fiber according to any one of [13].
  • (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues is 80% with respect to the total number of amino acid residues in n motif. That's it.
  • REP indicates an amino acid sequence composed of 10 to 200 amino acid residues.
  • m represents an integer of 2 to 300.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the other amino acid residues are isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M), alanine (A), glycine (G), threonine ( Any one of [28] to [30], which is an amino acid residue selected from the group consisting of T), serine (S), tryptophan (W), tyrosine (Y), proline (P), and histidine (H)
  • the modified fibroin is a highly shrinkable artificial fibroin fiber according to any one of [28] to [31], wherein the hydrophobicity of REP is ⁇ 0.8 or more,shrinking method of artificial fibroin fiber.
  • the high-shrinkage artificial fibroin fiber or high-shrinkage artificial fiber according to any one of [28] to [32], which has an amino acid sequence corresponding to substitution, deletion, insertion and / or addition of a plurality of amino acid residues A method for producing fibroin fibers or a method for shrinking artificial fibroin fibers.
  • the present invention it is possible to provide a high-shrinkage artificial fibroin fiber that has a sufficiently high shrinkage rate, is excellent in touch and flexibility, and can be produced safely, and a method for producing the same. According to the present invention, it is also possible to provide a method for shrinking artificial fibroin fibers, which can safely obtain artificial fibroin fibers with a sufficiently high shrinkage rate.
  • the highly contracted artificial fibroin fiber according to the present invention is a contracted artificial fibroin fiber containing modified fibroin.
  • the modified fibroin according to the present embodiment has a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif. It is a protein containing.
  • an amino acid sequence (N-terminal sequence and C-terminal sequence) may be further added to either one or both of the N-terminal side and the C-terminal side of the domain sequence.
  • the N-terminal sequence and the C-terminal sequence are not limited to these, but are typically regions having no amino acid motif repeat characteristic of fibroin and consisting of about 100 amino acids.
  • modified fibroin means an artificially produced fibroin (artificial fibroin).
  • the modified fibroin may be a fibroin whose domain sequence is different from the amino acid sequence of naturally occurring fibroin or may be the same as the amino acid sequence of naturally occurring fibroin.
  • Natural fibroin as used herein is also represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif.
  • a protein comprising a domain sequence to be processed.
  • the “modified fibroin” may be one that uses the amino acid sequence of naturally-occurring fibroin as it is, or a modified amino acid sequence based on the amino acid sequence of naturally-occurring fibroin (for example, a cloned naturally-derived fibroin).
  • the amino acid sequence may be modified by modifying the gene sequence of fibroin), or artificially designed and synthesized without relying on natural fibroin (for example, a nucleic acid encoding the designed amino acid sequence). It may be one having a desired amino acid sequence by chemical synthesis.
  • domain sequence refers to a fibroin-specific crystal region (typically corresponding to the (A) n motif in the amino acid sequence) and an amorphous region (typically in the REP of the amino acid sequence).
  • (A) n motif represents an amino acid sequence mainly composed of alanine residues, and the number of amino acid residues is 2 to 27.
  • the number of amino acid residues of the n motif may be an integer of 2 to 20, 4 to 27, 4 to 20, 8 to 20, 10 to 20, 4 to 16, 8 to 16, or 10 to 16 .
  • the ratio of the number of alanine residues to the total number of amino acid residues in the (A) n motif may be 40% or more, such as 60% or more, 70% or more, 80% or more, 83% or more, 85% or more, It may be 86% or more, 90% or more, 95% or more, or 100% (meaning that it is composed only of alanine residues).
  • a plurality of (A) n motifs present in the domain sequence may be composed of at least seven alanine residues alone.
  • REP indicates an amino acid sequence composed of 2 to 200 amino acid residues.
  • REP may be an amino acid sequence composed of 10 to 200 amino acid residues, 10 to 40, 10 to 60, 10 to 80, 10 to 100, 10 to 120, 10 to 140, 10 to 160, or It may be an amino acid sequence composed of 10 to 180 amino acid residues.
  • m represents an integer of 2 to 300, 8 to 300, 10 to 300, 20 to 300, 40 to 300, 60 to 300, 80 to 300, 100 to 300, 10 to 200, 20 to 200, 20 to 180, It may be an integer from 20 to 160, 20 to 140, or 20 to 120.
  • a plurality of (A) n motifs may have the same or different amino acid sequences.
  • Plural REPs may have the same amino acid sequence or different amino acid sequences.
  • the modified fibroin according to the present embodiment is, for example, an amino acid sequence corresponding to, for example, substitution, deletion, insertion and / or addition of one or a plurality of amino acid residues to the cloned gene sequence of naturally derived fibroin. It can be obtained by modifying the above. Substitution, deletion, insertion and / or addition of amino acid residues can be carried out by methods well known to those skilled in the art such as partial-directed mutagenesis. Specifically, Nucleic Acid Res. 10, 6487 (1982), Methods in Enzymology, 100, 448 (1983), and the like.
  • Naturally-derived fibroin is a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif.
  • Specific examples include fibroin produced by insects or spiders.
  • fibroin produced by insects include, for example, Bombyx mori, Kwako (Bombyx mandarina), Tenaea (Antheraea palaniii), and ⁇ ⁇ (Eriothyraminey).
  • Silkworms produced by silkworms such as Samia cythia, chestnut worms (Caligula japonica), Chuser moth (Antherea mylitta), Antheraea assama, and vespax (Vespaxia spp.) Hornet silk protein.
  • fibroin produced by insects include silkworm fibroin L chain (GenBank accession number M76430 (base sequence) and AAA27840.1 (amino acid sequence)).
  • Fibroin produced by spiders includes, for example, spiders belonging to the genus spider (Araneus spp.) Such as the spider spider, the spider spider, the red spider spider, and the bean spider, the genus spiders of the genus Araneus, the spider spider spider, the spider spider genus e Spiders, spiders such as spiders, spiders belonging to the genus Spider, spiders belonging to the genus Pronos, spiders belonging to the genus Trinofunda, such as Torinofundamas (genus Cyrtarachne) Spiders belonging to the genus (Gasteracantha), spiders belonging to the genus Spider (Ordgarius genus), such as the spiders, the spiders, and the spiders belonging to the genus Ordgarius Spiders belonging to the genus Argiope, such as the genus Argiope, spiders belonging to the genus Arachnura, such as the white-tailed spider, spiders belonging to the
  • Spiders belonging to the genus Azumigumi (Menosira)
  • spiders belonging to the genus Dyschiriognatha (genus Dyschiriognatha) such as the common spider spider, the black spider spider, the genus Spider genus belonging to the genus Spider belonging to the genus and the genus Spider belonging to the genus Spider belonging to the genus
  • Produced by spiders belonging to the family Tetragnathidae such as spiders belonging to the genus Prostenops
  • Examples include spider silk protein.
  • the spider silk protein include dragline proteins such as MaSp (MaSp1 and MaSp2) and ADF (ADF3 and ADF4), MiSp (MiSp1 and MiSp2), and the like.
  • spider silk proteins produced by spiders include, for example, fibroin-3 (adf-3) [derived from Araneus diadematus] (GenBank accession numbers AAC47010 (amino acid sequence), U47855 (base sequence)), fibroin-4 (adf-4) [derived from Araneus diadematus] (GenBank accession number AAC47011 (amino acid sequence), U47856 (base sequence)), dragline silk protein spiroin 1 [derived from Nephila clavipes] (GenBank amino acid sequence 4) ), U37520 (base sequence)), major ampulate spidro n 1 [derived from Latroductus hesperus] (GenBank accession number ABR68856 (amino acid sequence), EF595246 (base sequence)), dragline silk protein spidrin 2 [derived from Nephila clavata (GenBank accession number AAL32 base sequence 45 AAL32 base sequence amino acid 44, amino acid sequence 44 AAL47)
  • Naturally derived fibroin include fibroin whose sequence information is registered in NCBI GenBank.
  • sequence information is registered in NCBI GenBank.
  • spidin, sample, fibroin, “silk and polypeptide”, or “silk and protein” is described as a keyword in DEFINITION from sequences including INV as DIVISION among the sequence information registered in NCBI GenBank. It can be confirmed by extracting a character string of a specific product from the sequence, CDS, and a sequence in which the specific character string is described from SOURCE to TISSUE TYPE.
  • the modified fibroin according to the present embodiment may be a modified silk fibroin (a modified amino acid sequence of a silk protein produced by a silkworm), or a modified spider silk fibroin (a spider silk protein produced by a spider). It may be a modified amino acid sequence).
  • a modified spider silk fibroin is preferable.
  • the modified spider silk fibroin is excellent in heat retention, moisture absorption heat generation and / or flame retardancy.
  • modified fibroin examples include a modified fibroin derived from a large sphincter bookmarker protein produced in a large spider gland (first modified fibroin), a domain sequence with a reduced content of glycine residues Modified fibroin (second modified fibroin) having (A) modified fibroin (third modified fibroin) having a domain sequence with reduced content of n motif, content of glycine residue, and (A) n Modified fibroin with reduced motif content (fourth modified fibroin), modified fibroin having a domain sequence that includes a region with a large hydrophobic index locally (fifth modified fibroin), and glutamine residue content Are modified fibroins having a reduced domain sequence (sixth modified fibroin).
  • Examples of the first modified fibroin include a protein comprising a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • (A) the number of amino acid residues of the n motif is preferably an integer of 3 to 20, more preferably an integer of 4 to 20, still more preferably an integer of 8 to 20, and an integer of 10 to 20 Is more preferable, an integer of 4 to 16 is still more preferable, an integer of 8 to 16 is particularly preferable, and an integer of 10 to 16 is most preferable.
  • the number of amino acid residues constituting REP is preferably 10 to 200 residues, more preferably 10 to 150 residues, and 20 to 100 residues.
  • the total number of glycine residues, serine residues and alanine residues contained in the amino acid sequence represented by the formula 1: [(A) n motif-REP] m is an amino acid residue.
  • the total number is preferably 40% or more, more preferably 60% or more, and even more preferably 70% or more.
  • the first modified fibroin comprises an amino acid sequence unit represented by Formula 1: [(A) n motif-REP] m , and the C-terminal sequence is represented by any one of SEQ ID NOs: 1 to 3 or It may be a polypeptide that is an amino acid sequence having 90% or more homology with the amino acid sequence shown in any one of SEQ ID NOs: 1 to 3.
  • the amino acid sequence shown in SEQ ID NO: 1 is identical to the amino acid sequence consisting of 50 amino acids at the C-terminal of the amino acid sequence of ADF3 (GI: 1263287, NCBI), and the amino acid sequence shown in SEQ ID NO: 2 is the sequence
  • the amino acid sequence shown in SEQ ID NO: 1 is identical to the amino acid sequence obtained by removing 20 residues from the C-terminal, and the amino acid sequence shown in SEQ ID NO: 3 has 29 residues removed from the C-terminal of the amino acid sequence shown in SEQ ID NO: 1. It is identical to the amino acid sequence.
  • modified fibroin As a more specific example of the first modified fibroin, (1-i) an amino acid sequence represented by SEQ ID NO: 4 (recombinant spider silk protein ADF3KaiLargeNRSH1), or (1-ii) an amino acid sequence represented by SEQ ID NO: 4 and 90 Mention may be made of modified fibroin comprising an amino acid sequence having a sequence identity of at least%. The sequence identity is preferably 95% or more.
  • the amino acid sequence represented by SEQ ID NO: 4 is an amino acid sequence of ADF3 in which an amino acid sequence (SEQ ID NO: 5) consisting of a start codon, a His10 tag and an HRV3C protease (Human rhinovirus 3C protease) recognition site is added to the N-terminus.
  • the 13th repeat region was increased to approximately double, and the translation was mutated to terminate at the 1154th amino acid residue.
  • the C-terminal amino acid sequence of the amino acid sequence shown in SEQ ID NO: 4 is identical to the amino acid sequence shown in SEQ ID NO: 3.
  • the modified fibroin (1-i) may be composed of the amino acid sequence represented by SEQ ID NO: 4.
  • the second modified fibroin has an amino acid sequence whose domain sequence has a reduced content of glycine residues compared to naturally occurring fibroin. It can be said that the second modified fibroin has an amino acid sequence corresponding to at least one or more glycine residues in REP substituted with another amino acid residue as compared with naturally occurring fibroin. .
  • the second modified fibroin has a domain sequence of GGX and GPGXX in REP (where G is a glycine residue, P is a proline residue, and X is an amino acid residue other than glycine) as compared to naturally occurring fibroin.
  • G is a glycine residue
  • P is a proline residue
  • X is an amino acid residue other than glycine
  • at least one glycine residue in at least one or more of the motif sequences is substituted with another amino acid residue. May be.
  • the ratio of the motif sequence in which the above glycine residue is replaced with another amino acid residue may be 10% or more with respect to the entire motif sequence.
  • the second modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , and is located on the most C-terminal side from the domain sequence (A) from the n motif to the domain sequence.
  • the number of alanine residues relative to the total number of amino acid residues in the n motif may be 83% or more, preferably 86% or more, more preferably 90% or more, and 95% or more. More preferably, it is 100% (meaning that it is composed only of alanine residues).
  • the second modified fibroin is preferably one in which the content ratio of the amino acid sequence consisting of XGX is increased by substituting one glycine residue of the GGX motif with another amino acid residue.
  • the content ratio of the amino acid sequence consisting of GGX in the domain sequence is preferably 30% or less, more preferably 20% or less, still more preferably 10% or less, % Or less is even more preferable, 4% or less is even more preferable, and 2% or less is particularly preferable.
  • the content ratio of the amino acid sequence consisting of GGX in the domain sequence can be calculated by the same method as the method for calculating the content ratio (z / w) of the amino acid sequence consisting of XGX below.
  • a fibroin modified fibroin or naturally-occurring fibroin containing a domain sequence represented by Formula 1: [(A) n motif-REP] m , (A) n located closest to the C-terminal side from the domain sequence
  • An amino acid sequence consisting of XGX is extracted from all REPs included in the sequence excluding the sequence from the motif to the C-terminal of the domain sequence.
  • z / w (%) can be calculated by dividing z by w.
  • z / w is preferably 50.9% or more, more preferably 56.1% or more, further preferably 58.7% or more, and 70% or more. It is still more preferable that it is 80% or more. Although there is no restriction
  • the second modified fibroin is obtained by, for example, modifying a cloned natural fibroin gene sequence so as to encode another amino acid residue by substituting at least a part of a base sequence encoding a glycine residue.
  • a glycine residue in GGX motif and GPGXX motif may be selected as a glycine residue to be modified, or substitution may be performed so that z / w is 50.9% or more.
  • an amino acid sequence satisfying the above-described aspect can be designed from the amino acid sequence of naturally derived fibroin, and a nucleic acid encoding the designed amino acid sequence can be obtained by chemical synthesis.
  • one or more amino acid residues are further substituted or deleted.
  • the amino acid sequence corresponding to the insertion and / or addition may be modified.
  • the other amino acid residue is not particularly limited as long as it is an amino acid residue other than a glycine residue, but a valine (V) residue, a leucine (L) residue, an isoleucine (I) residue, M) hydrophobic amino acid residues such as proline (P) residue, phenylalanine (F) residue and tryptophan (W) residue, glutamine (Q) residue, asparagine (N) residue, serine (S ) Residues, hydrophilic amino acid residues such as lysine (K) residues and glutamic acid (E) residues are preferred, and valine (V) residues, leucine (L) residues, isoleucine (I) residues, F) residue and glutamine (Q) residue are more preferred, and glutamine (Q) residue is still more preferred.
  • the second modified fibroin examples include (2-i) SEQ ID NO: 6 (Met-PRT380), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525) or SEQ ID NO: 9 (Met -PRT799), or (2-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, Mention may be made of modified fibroin.
  • the modified fibroin (2-i) will be described.
  • the amino acid sequence represented by SEQ ID NO: 6 is obtained by substituting GQX for all GGX in the REP of the amino acid sequence represented by SEQ ID NO: 10 (Met-PRT313) corresponding to naturally occurring fibroin.
  • the amino acid sequence represented by SEQ ID NO: 7 is the amino acid sequence represented by SEQ ID NO: 6, wherein every two (A) n motifs are deleted from the N-terminal side to the C-terminal side, and further before the C-terminal sequence.
  • One [(A) n motif-REP] is inserted into the.
  • the amino acid sequence represented by SEQ ID NO: 8 has two alanine residues inserted at the C-terminal side of each (A) n motif of the amino acid sequence represented by SEQ ID NO: 7, and a part of glutamine (Q) residues. Substituted with a serine (S) residue and a part of the amino acid at the C-terminal side was deleted so as to be almost the same as the molecular weight of SEQ ID NO: 7.
  • the amino acid sequence represented by SEQ ID NO: 9 is a region of 20 domain sequences present in the amino acid sequence represented by SEQ ID NO: 7 (however, several amino acid residues on the C-terminal side of the region are substituted). Is obtained by adding a predetermined hinge sequence and a His tag sequence to the C-terminus of the sequence repeated four times.
  • the value of z / w in the amino acid sequence represented by SEQ ID NO: 10 (corresponding to naturally occurring fibroin) is 46.8%.
  • the z / w values of the amino acid sequence shown by SEQ ID NO: 6, the amino acid sequence shown by SEQ ID NO: 7, the amino acid sequence shown by SEQ ID NO: 8, and the amino acid sequence shown by SEQ ID NO: 9 are 58.7%, 70.1%, 66.1% and 70.0%.
  • the value of x / y at the ratio of the amino acid sequences shown in SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 (described later) 1: 1.8 to 11.3 is: 15.0%, 15.0%, 93.4%, 92.7% and 89.8%, respectively.
  • the modified fibroin (2-i) may be composed of the amino acid sequence represented by SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the modified fibroin (2-ii) includes an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the modified fibroin of (2-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the modified fibroin of (2-ii) has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and is contained in REP (XGX ( Where X is an amino acid residue other than glycine.) Z / w where z is the total number of amino acid residues of the amino acid sequence consisting of z and w is the total number of amino acid residues of REP in the domain sequence. Is preferably 50.9% or more.
  • the second modified fibroin may contain a tag sequence at one or both of the N-terminal and C-terminal. This makes it possible to isolate, immobilize, detect and visualize the modified fibroin.
  • tag sequences include affinity tags that use specific affinity (binding property, affinity) with other molecules.
  • affinity tag include a histidine tag (His tag).
  • His tag is a short peptide with about 4 to 10 histidine residues, and has the property of binding specifically to metal ions such as nickel. Therefore, the isolation of modified fibroin by metal chelating chromatography (chelating metal chromatography) Can be used.
  • Specific examples of the tag sequence include the amino acid sequence represented by SEQ ID NO: 11 (amino acid sequence including His tag sequence and hinge sequence).
  • GST glutathione-S-transferase
  • MBP maltose-binding protein
  • an “epitope tag” using an antigen-antibody reaction can also be used.
  • a peptide (epitope) exhibiting antigenicity as a tag sequence, an antibody against the epitope can be bound.
  • HA peptide sequence of hemagglutinin of influenza virus
  • myc tag peptide sequence of hemagglutinin of influenza virus
  • FLAG tag peptide sequence of hemagglutinin of influenza virus
  • a tag sequence that can be separated with a specific protease can also be used.
  • the modified fibroin from which the tag sequence has been separated can also be recovered.
  • modified fibroin containing a tag sequence (2-iii) the amino acid represented by SEQ ID NO: 12 (PRT380), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799)
  • Examples include (2-iv) modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in (2-iv) SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. .
  • amino acid sequences represented by SEQ ID NO: 16 are SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.
  • amino acid sequence shown in SEQ ID NO: 11 is added to the N-terminus of the amino acid sequence shown.
  • the modified fibroin may be composed of the amino acid sequence represented by SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the modified fibroin (2-iv) includes an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the modified fibroin of (2-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the modified fibroin (2-iv) has an XGX (which has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 and is contained in REP ( Where X is an amino acid residue other than glycine.) Z / w where z is the total number of amino acid residues of the amino acid sequence consisting of z and w is the total number of amino acid residues of REP in the domain sequence. Is preferably 50.9% or more.
  • the second modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host.
  • the sequence of the secretion signal can be appropriately set according to the type of host.
  • the third modified fibroin has an amino acid sequence in which the domain sequence has a reduced content of (A) n motif compared to naturally occurring fibroin. It can be said that the domain sequence of the third modified fibroin has an amino acid sequence corresponding to the deletion of at least one or more (A) n motifs, as compared to naturally occurring fibroin.
  • the third modified fibroin may have an amino acid sequence corresponding to 10% to 40% deletion of the (A) n motif from naturally occurring fibroin.
  • the third modification fibroin its domain sequence, compared to the naturally occurring fibroin, at least from the N-terminal side toward the C-terminal one to three (A) n motif every one (A) n motif May have an amino acid sequence corresponding to deletion of.
  • the third modified fibroin has a domain sequence that is at least two consecutive from the N-terminal side to the C-terminal side compared to the naturally occurring fibroin (A) deletion of the n motif, and one (A ) It may have an amino acid sequence corresponding to the deletion of the n motif repeated in this order.
  • the third modified fibroin may have an amino acid sequence whose domain sequence corresponds to that at least every two (A) n motifs are deleted from the N-terminal side to the C-terminal side. .
  • the third modified fibroin includes a domain sequence represented by Formula 1: [(A) n motif-REP] m , and two adjacent [(A) n motifs from the N-terminal side toward the C-terminal side. -REP]
  • the ratio of the number of amino acid residues in the other REP is 1.8 to
  • x the maximum total value of the total number of amino acid residues of two adjacent [(A) n motif-REP] units that becomes 11.3
  • x the total number of amino acid residues in the domain sequence is y
  • it may have an amino acid sequence in which x / y is 20% or more, 30% or more, 40% or more, or 50% or more.
  • the number of alanine residues relative to the total number of amino acid residues in the n motif may be 83% or more, preferably 86% or more, more preferably 90% or more, and 95% or more. More preferably, it is 100% (meaning that it is composed only of alanine residues).
  • FIG. 1 shows a domain sequence obtained by removing the N-terminal sequence and the C-terminal sequence from the modified fibroin.
  • the domain sequence is from the N-terminal side (left side): (A) n motif-first REP (50 amino acid residues)-(A) n motif-second REP (100 amino acid residues)-(A) n Motif-third REP (10 amino acid residues)-(A) n motif-fourth REP (20 amino acid residues)-(A) n motif-fifth REP (30 amino acid residues)-(A) It has a sequence called n motif.
  • FIG. 1 includes pattern 1 (comparison between the first REP and the second REP, and comparison between the third REP and the fourth REP), pattern 2 (comparison between the first REP and the second REP, and 4th REP and 5th REP), pattern 3 (2nd REP and 3rd REP comparison, 4th REP and 5th REP comparison), pattern 4 (first REP and Comparison of the second REP).
  • pattern 1 compare between the first REP and the second REP, and comparison between the third REP and the fourth REP
  • pattern 2 comparison between the first REP and the second REP, and 4th REP and 5th REP
  • pattern 3 (2nd REP and 3rd REP comparison, 4th REP and 5th REP comparison
  • pattern 4 first REP and Comparison of the second REP
  • the number of amino acid residues of each REP in the two adjacent [(A) n motif-REP] units selected is compared.
  • each pattern the number of all amino acid residues of two adjacent [(A) n motif-REP] units indicated by solid lines is added (not only REP but also (A) the number of amino acid residues of the n motif. is there.). Then, the total value added is compared, and the total value (maximum value of the total value) of the pattern having the maximum total value is set as x. In the example shown in FIG. 1, the total value of pattern 1 is the maximum.
  • x / y (%) can be calculated by dividing x by the total number of amino acid residues y of the domain sequence.
  • x / y is preferably 50% or more, more preferably 60% or more, still more preferably 65% or more, and even more preferably 70% or more. Preferably, it is still more preferably 75% or more, and particularly preferably 80% or more. There is no restriction
  • x / y is preferably 89.6% or more, and when the jagged ratio is 1: 1.8 to 3.4, x / y / Y is preferably 77.1% or more, and when the jagged ratio is 1: 1.9 to 8.4, x / y is preferably 75.9% or more, and the jagged ratio is 1 In the case of 1.9 to 4.1, x / y is preferably 64.2% or more.
  • a plurality of third modified fibroins are present in the domain sequence (A)
  • x / y is 46.4% or more It is preferably 50% or more, more preferably 55% or more, still more preferably 60% or more, still more preferably 70% or more, and more preferably 80% or more. It is particularly preferred.
  • x / y in naturally derived fibroin will be described.
  • 663 types of fibroin (of which 415 types were derived from spiders) were extracted.
  • x / y is calculated from the amino acid sequence of naturally derived fibroin composed of the domain sequence represented by Formula 1: [(A) n motif-REP] m by the above-described calculation method.
  • FIG. 3 shows the results when the jagged ratio is 1: 1.9 to 4.1.
  • the horizontal axis indicates x / y (%), and the vertical axis indicates frequency.
  • x / y in naturally derived fibroin is less than 64.2% (the highest, 64.14%).
  • one or a plurality of sequences encoding the n motif is deleted so that x / y is 64.2% or more from the cloned gene sequence of naturally occurring fibroin.
  • an amino acid sequence corresponding to the deletion of one or more (A) n motifs is designed so that x / y is 64.2% or more from the amino acid sequence of naturally occurring fibroin. It can also be obtained by chemically synthesizing a nucleic acid encoding the amino acid sequence.
  • one or more amino acid residues are further substituted, deleted, inserted and / or added.
  • the amino acid sequence corresponding to this may be modified.
  • third modified fibroin examples include (3-i) SEQ ID NO: 17 (Met-PRT399), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), or SEQ ID NO: 9 (Met -PRT799), or (3-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, Mention may be made of modified fibroin.
  • the modified fibroin (3-i) will be described.
  • the amino acid sequence represented by SEQ ID NO: 17 is derived from the amino acid sequence represented by SEQ ID NO: 10 (Met-PRT313) corresponding to naturally-occurring fibroin from the N-terminal side to the C-terminal side every two (A) n
  • the motif is deleted, and one [(A) n motif-REP] is inserted before the C-terminal sequence.
  • the amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 is as described in the second modified fibroin.
  • the value of x / y in the amino acid sequence represented by SEQ ID NO: 10 (corresponding to naturally-occurring fibroin) at a jagged ratio of 1: 1.8 to 11.3 is 15.0%.
  • the value of x / y in the amino acid sequence shown by SEQ ID NO: 17 and the amino acid sequence shown by SEQ ID NO: 7 are both 93.4%.
  • the value of x / y in the amino acid sequence represented by SEQ ID NO: 8 is 92.7%.
  • the value of x / y in the amino acid sequence represented by SEQ ID NO: 9 is 89.8%.
  • the z / w values in the amino acid sequences shown in SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 are 46.8%, 56.2%, 70.1% and 66. respectively. 1% and 70.0%.
  • the modified fibroin (3-i) may consist of the amino acid sequence represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the modified fibroin (3-ii) includes an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
  • the modified fibroin of (3-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the modified fibroin of (3-ii) has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and from the N-terminal side to the C-terminal side
  • the number of amino acid residues of REP of two adjacent [(A) n motif-REP] units is sequentially compared, and the number of amino acid residues of REP having a small number of amino acid residues is 1, the other
  • x / y is 64.2% or more, where x is the maximum total value of the total number of bases and y is the total number of amino acid residues in the domain sequence.
  • the third modified fibroin may contain the tag sequence described above at one or both of the N-terminal and C-terminal.
  • modified fibroin containing a tag sequence 3-iii) amino acids represented by SEQ ID NO: 18 (PRT399), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799)
  • a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the sequence or (3-iv) the amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. .
  • amino acid sequences represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 are SEQ ID NO: 11 at the N-terminus of the amino acid sequences represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively. Are added to the amino acid sequence (including His tag sequence and hinge sequence).
  • the modified fibroin may be composed of the amino acid sequence represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the modified fibroin (3-iv) comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
  • the modified fibroin of (3-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the modified fibroin (3-iv) has a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, and from the N-terminal side to the C-terminal side.
  • the other X is the maximum total value of the total number of amino acid residues of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of REP of 1.8 to 11.3.
  • x / y is preferably 64.2% or more.
  • the third modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host.
  • the sequence of the secretion signal can be appropriately set according to the type of host.
  • the fourth modified fibroin has an amino acid sequence whose domain sequence has a reduced glycine residue content in addition to (A) a reduced content of the n motif compared to naturally occurring fibroin. It is what you have.
  • the domain sequence of the fourth modified fibroin has at least one or more (A) n motifs deleted as compared to naturally occurring fibroin, and at least one or more glycine residues in the REP. It can be said to have an amino acid sequence corresponding to the substitution with another amino acid residue. That is, the fourth modified fibroin is a modified fibroin having the characteristics of the second modified fibroin described above and the third modified fibroin. Specific embodiments and the like are as described in the second modified fibroin and the third modified fibroin.
  • SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), SEQ ID NO: 9 (Met-PRT799), SEQ ID NO: 13 (PRT410) ), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799), or (4-ii) SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15
  • a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by Specific embodiments of the modified fibroin comprising the amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 are as described above.
  • the fifth modified fibroin has a domain sequence in which one or more amino acid residues in REP are replaced with amino acid residues having a higher hydrophobicity index and / or REP compared to naturally occurring fibroin. It may have an amino acid sequence including a region having a large hydrophobicity index corresponding to the insertion of one or more amino acid residues having a large hydrophobicity index.
  • the region where the hydrophobic index is locally large is preferably composed of 2 to 4 amino acid residues.
  • the amino acid residue having a large hydrophobicity index is an amino acid selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A). More preferably, it is a residue.
  • the fifth modified fibroin has one or more amino acid residues in REP substituted with amino acid residues having a higher hydrophobicity index and / or one or more in REP compared to naturally occurring fibroin.
  • substitution, deletion, insertion and / or addition of one or more amino acid residues as compared with naturally occurring fibroin There may be amino acid sequence modifications corresponding to the above.
  • the fifth modified fibroin is obtained by removing one or more hydrophilic amino acid residues (for example, amino acid residues having a negative hydrophobicity index) in the REP from the cloned natural fibroin gene sequence. It can be obtained by substituting a group (for example, an amino acid residue having a positive hydrophobicity index) and / or inserting one or more hydrophobic amino acid residues in REP.
  • hydrophilic amino acid residues for example, amino acid residues having a negative hydrophobicity index
  • a group for example, an amino acid residue having a positive hydrophobicity index
  • one or more hydrophilic amino acid residues in REP are substituted with hydrophobic amino acid residues from the amino acid sequence of naturally occurring fibroin, and / or one or more hydrophobic amino acid residues in REP It can also be obtained by designing an amino acid sequence corresponding to insertion of, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
  • one or more hydrophilic amino acid residues in REP have been replaced with hydrophobic amino acid residues from the amino acid sequence of naturally occurring fibroin and / or one or more hydrophobic amino acids in REP
  • the amino acid sequence corresponding to the substitution, deletion, insertion and / or addition of one or more amino acid residues may be further modified.
  • the fifth modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , and is located on the most C-terminal side (A) from the n motif to the C terminus of the domain sequence.
  • p is the total number of amino acid residues included in the region where the average value of the hydrophobicity index of four consecutive amino acid residues is 2.6 or more
  • (A) When the total number of amino acid residues contained in the sequence excluding the sequence from the n motif to the C terminus of the domain sequence, which is located at the most C-terminal side, from the domain sequence is q, p / q is 6 It may have an amino acid sequence that is 2% or more.
  • hydrophobicity index of amino acid residues As for the hydrophobicity index of amino acid residues, a known index (Hydropathy index: Kyte J, & Doolittle R (1982) “A simple method for displaying the hydropathic character of bio.p. 7”. 105-132). Specifically, the hydrophobicity index (hydropathic index, hereinafter also referred to as “HI”) of each amino acid is as shown in Table 1 below.
  • a sequence obtained by removing the sequence from the domain sequence represented by Formula 1: [(A) n motif-REP] m to the most C-terminal side from the domain (A) n motif to the C terminus of the domain sequence. (Hereinafter referred to as “array A”).
  • array A the average value of the hydrophobicity index of four consecutive amino acid residues is calculated.
  • the average value of the hydrophobicity index is obtained by dividing the total HI of each amino acid residue contained in the four consecutive amino acid residues by 4 (number of amino acid residues).
  • the average value of the hydrophobicity index is obtained for all four consecutive amino acid residues (each amino acid residue is used for calculating the average value 1 to 4 times). Next, a region where the average value of the hydrophobicity index of four consecutive amino acid residues is 2.6 or more is specified. Even if a certain amino acid residue corresponds to a plurality of “four consecutive amino acid residues whose average value of hydrophobicity index is 2.6 or more”, it should be included as one amino acid residue in the region. become.
  • the total number of amino acid residues contained in the region is p.
  • the total number of amino acid residues contained in sequence A is q.
  • the average value of the hydrophobicity index of four consecutive amino acid residues is 2
  • p / q is preferably 6.2% or more, more preferably 7% or more, further preferably 10% or more, and preferably 20% or more. Even more preferably, it is still more preferably 30% or more.
  • the upper limit of p / q is not particularly limited, but may be 45% or less, for example.
  • the fifth modified fibroin is, for example, one or a plurality of hydrophilic amino acid residues (for example, a hydrophobicity index) in the REP so that the amino acid sequence of the naturally-derived fibroin thus cloned satisfies the above p / q condition. Is replaced with a hydrophobic amino acid residue (for example, an amino acid residue with a positive hydrophobicity index) and / or one or more hydrophobic amino acid residues are inserted in the REP By doing so, it can be obtained by locally modifying the amino acid sequence to include a region having a large hydrophobicity index.
  • hydrophilic amino acid residues for example, a hydrophobicity index
  • an amino acid sequence satisfying the above p / q conditions can be designed from the amino acid sequence of naturally derived fibroin, and a nucleic acid encoding the designed amino acid sequence can be obtained by chemical synthesis.
  • one or more amino acid residues in REP were replaced with amino acid residues having a higher hydrophobicity index and / or one or more amino acid residues in REP.
  • modifications corresponding to substitution, deletion, insertion and / or addition of one or more amino acid residues may be performed. .
  • the amino acid residue having a large hydrophobicity index is not particularly limited, but isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A ) are preferred, and valine (V), leucine (L) and isoleucine (I) are more preferred.
  • the fifth modified fibroin (5-i) the amino acid sequence represented by SEQ ID NO: 19 (Met-PRT720), SEQ ID NO: 20 (Met-PRT665) or SEQ ID NO: 21 (Met-PRT666), Or (5-ii) a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
  • the modified fibroin (5-i) will be described.
  • the amino acid sequence represented by SEQ ID NO: 19 consists of 3 amino acid residues for every other REP with respect to the amino acid sequence represented by SEQ ID NO: 7 (Met-PRT410), excluding the domain sequence of the terminal on the C-terminal side.
  • An amino acid sequence (VLI) is inserted at two positions, a part of glutamine (Q) residues is substituted with a serine (S) residue, and a part of amino acids on the C-terminal side is deleted.
  • the amino acid sequence represented by SEQ ID NO: 20 is an amino acid sequence represented by SEQ ID NO: 8 (Met-PRT525) with one amino acid sequence (VLI) consisting of 3 amino acid residues inserted every other REP. is there.
  • the amino acid sequence shown in SEQ ID NO: 21 is obtained by inserting two amino acid sequences (VLI) each consisting of 3 amino acid residues into the amino acid sequence shown in SEQ ID NO: 8 every other REP.
  • the modified fibroin (5-i) may be composed of the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
  • the modified fibroin (5-ii) comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
  • the modified fibroin of (5-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the modified fibroin of (5-ii) has a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21, and is located on the most C-terminal side (A) n
  • the amino acids included in the region where the average value of the hydrophobicity index of 4 consecutive amino acid residues is 2.6 or more P is the total number of residues
  • P / q is preferably 6.2% or more.
  • the fifth modified fibroin may contain a tag sequence at one or both of the N-terminal and C-terminal.
  • modified fibroin containing the tag sequence examples include (5-iii) the amino acid sequence represented by SEQ ID NO: 22 (PRT720), SEQ ID NO: 23 (PRT665) or SEQ ID NO: 24 (PRT666), or (5-iv And a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24.
  • amino acid sequences represented by SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 are the amino acid sequences represented by SEQ ID NO: 11 (His tag) at the N-terminus of the amino acid sequences represented by SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21, respectively. Including a sequence and a hinge sequence).
  • the modified fibroin may be composed of the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.
  • the modified fibroin (5-iv) comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24.
  • the modified fibroin of (5-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m .
  • the sequence identity is preferably 95% or more.
  • the modified fibroin of (5-iv) has a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24, and is located on the most C-terminal side (A) n
  • the amino acids included in the region where the average value of the hydrophobicity index of 4 consecutive amino acid residues is 2.6 or more P is the total number of residues
  • P / q is preferably 6.2% or more.
  • the fifth modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host.
  • the sequence of the secretion signal can be appropriately set according to the type of host.
  • the sixth modified fibroin has an amino acid sequence in which the content of glutamine residues is reduced compared to naturally occurring fibroin.
  • the sixth modified fibroin preferably contains at least one motif selected from GGX motif and GPGXX motif in the amino acid sequence of REP.
  • the content ratio of the GPGXX motif is usually 1% or more, may be 5% or more, and is preferably 10% or more.
  • the upper limit of GPGXX motif content rate 50% or less may be sufficient and 30% or less may be sufficient.
  • GPGXX motif content is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m
  • Formula 2 [(A) n motif-REP] m- (A) fibroin (modified fibroin or naturally derived) containing a domain sequence represented by the n motif In fibroin), the number of GPGXX motifs contained in the region in all REPs contained in the sequence excluding the sequence from the domain sequence (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence.
  • the number obtained by multiplying the total number by three is s, and is located at the most C-terminal side.
  • the sequence from the n motif to the C-terminal of the domain sequence is determined from the domain sequence.
  • the content ratio of the GPGXX motif is calculated as s / t, where t is the total number of amino acid residues of all REPs excluding the n motif. It is.
  • “A sequence located at the most C-terminal side (A) excluding the sequence from the n motif to the C-terminal of the domain sequence from the domain sequence” (A)
  • the sequence from the n motif to the C terminus of the domain sequence ”(sequence corresponding to REP) may include a sequence that is not highly correlated with the sequence characteristic of fibroin, and m is small In this case (that is, when the domain sequence is short), the calculation result of the content ratio of the GPGXX motif is affected, so this influence is excluded.
  • the “GPGXX motif” is located at the C-terminus of REP, even if “XX” is, for example, “AA”, it is treated as “GPGXX motif”.
  • FIG. 5 is a schematic diagram showing the domain sequence of the modified fibroin.
  • all REPs are “a sequence located at the most C-terminal side (A)
  • the sequence from the n motif to the C-terminal of the domain sequence is excluded from the domain sequence” (the sequence indicated by “region A” in FIG. ))
  • the sixth modified fibroin preferably has a glutamine residue content of 9% or less, more preferably 7% or less, still more preferably 4% or less, and particularly preferably 0%. .
  • the “glutamine residue content” is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m
  • Formula 2 [(A) n motif-REP] m-
  • A) the sequence from the n- motif to the C-terminal of the domain sequence located on the most C-terminal side is included.
  • the total number of glutamine residues contained in the region is u
  • the sequence from the (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence is excluded from the domain sequence
  • (A) n The glutamine residue content is calculated as u / t, where t is the total number of amino acid residues in all REPs excluding the motif.
  • the reason why "A sequence located at the most C-terminal side (A) excluding the sequence from the n motif to the C-terminus of the domain sequence from the domain sequence" is the reason described above. It is the same.
  • the sixth modified fibroin corresponds to its domain sequence having one or more glutamine residues in REP deleted or replaced with other amino acid residues compared to naturally occurring fibroin. It may have an amino acid sequence.
  • the “other amino acid residue” may be an amino acid residue other than a glutamine residue, but is preferably an amino acid residue having a larger hydrophobicity index than the glutamine residue. Table 1 shows the hydrophobicity index of amino acid residues.
  • amino acid residues having a larger hydrophobicity index than glutamine residues include isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M ) Amino acid residues selected from alanine (A), glycine (G), threonine (T), serine (S), tryptophan (W), tyrosine (Y), proline (P) and histidine (H). it can.
  • an amino acid residue selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A) is more preferable. More preferably, it is an amino acid residue selected from isoleucine (I), valine (V), leucine (L) and phenylalanine (F).
  • the hydrophobicity of REP is preferably ⁇ 0.8 or more, more preferably ⁇ 0.7 or more, still more preferably 0 or more, and 0.3 or more. It is still more preferable that it is and it is especially preferable that it is 0.4 or more.
  • the “hydrophobicity of REP” is a value calculated by the following method.
  • Formula 1 [(A) n motif-REP] m
  • Formula 2 [(A) n motif-REP] m-
  • A) the sequence from the n- motif to the C-terminal of the domain sequence located on the most C-terminal side is included.
  • the sum of the hydrophobicity index of each amino acid residue in the region is represented by v, and the sequence from the (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence is excluded from the domain sequence, and ( A) The hydrophobicity of REP is calculated as v / t, where t is the total number of amino acid residues of all REPs excluding the n motif.
  • t is the total number of amino acid residues of all REPs excluding the n motif.
  • the sixth modified fibroin has its domain sequence deleted one or more glutamine residues in REP and / or one or more glutamine residues in REP compared to naturally occurring fibroin.
  • modifications corresponding to substitution of other amino acid residues there may also be amino acid sequence modifications corresponding to substitution, deletion, insertion and / or addition of one or more amino acid residues. .
  • the sixth modified fibroin is, for example, deleting one or more glutamine residues in REP from the cloned gene sequence of naturally occurring fibroin and / or other one or more glutamine residues in REP. It can obtain by substituting to the amino acid residue.
  • one or more glutamine residues in REP are deleted from the amino acid sequence of naturally occurring fibroin, and / or one or more glutamine residues in REP are replaced with other amino acid residues.
  • it can also be obtained by designing a corresponding amino acid sequence and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
  • sixth modified fibroin examples include (6-i) SEQ ID NO: 25 (Met-PRT888), SEQ ID NO: 26 (Met-PRT965), SEQ ID NO: 27 (Met-PRT889), SEQ ID NO: 28 (Met -PRT916), a modified fibroin comprising the amino acid sequence shown in SEQ ID NO: 29 (Met-PRT918), SEQ ID NO: 30 (Met-PRT699), SEQ ID NO: 31 (Met-PRT698) or SEQ ID NO: 32 (Met-PRT966), or (6-ii) 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32 Mention may be made of modified fibroin comprising an amino acid sequence having.
  • the (6-i) modified fibroin will be described.
  • the amino acid sequence represented by SEQ ID NO: 25 is obtained by substituting VL for QQ in the amino acid sequence represented by SEQ ID NO: 7 (Met-PRT410).
  • the amino acid sequence represented by SEQ ID NO: 26 is obtained by substituting all QQs in the amino acid sequence represented by SEQ ID NO: 7 with TS and replacing the remaining Q with A.
  • the amino acid sequence represented by SEQ ID NO: 27 is obtained by substituting all QQs in the amino acid sequence represented by SEQ ID NO: 7 with VL and replacing the remaining Q with I.
  • the amino acid sequence represented by SEQ ID NO: 28 is obtained by replacing all QQs in the amino acid sequence represented by SEQ ID NO: 7 with VI and replacing the remaining Q with L.
  • the amino acid sequence represented by SEQ ID NO: 29 is one in which all QQs in the amino acid sequence represented by SEQ ID NO: 7 are substituted with VF, and the remaining Q is substituted with I.
  • the amino acid sequence represented by SEQ ID NO: 30 is obtained by substituting VL for all QQs in the amino acid sequence represented by SEQ ID NO: 8 (Met-PRT525).
  • the amino acid sequence shown in SEQ ID NO: 31 is obtained by substituting all QQs in the amino acid sequence shown in SEQ ID NO: 8 with VL and replacing the remaining Q with I.
  • amino acid sequences represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32 all have a glutamine residue content of 9% or less. Yes (Table 2).
  • the modified fibroin (6-i) comprises the amino acid sequence represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32. There may be.
  • the modified fibroin of (6-ii) is 90% or more of the amino acid sequence represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32 An amino acid sequence having the following sequence identity is included.
  • the modified fibroin of (6-ii) is also represented by the formula 1: [(A) n motif-REP] m or the formula 2: [(A) n motif-REP] m- (A) n motif.
  • the sequence identity is preferably 95% or more.
  • the modified fibroin (6-ii) preferably has a glutamine residue content of 9% or less.
  • the modified fibroin (6-ii) preferably has a GPGXX motif content of 10% or more.
  • the sixth modified fibroin may contain a tag sequence at one or both of the N-terminal and C-terminal. This makes it possible to isolate, immobilize, detect and visualize the modified fibroin.
  • modified fibroin containing a tag sequence (6-iii) SEQ ID NO: 33 (PRT888), SEQ ID NO: 34 (PRT965), SEQ ID NO: 35 (PRT889), SEQ ID NO: 36 (PRT916), SEQ ID NO: 37 (PRT918), SEQ ID NO: 38 (PRT699), SEQ ID NO: 39 (PRT698) or modified fibroin comprising the amino acid sequence shown by SEQ ID NO: 40 (PRT966), or (6-iv) SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 or SEQ ID NO: 40.
  • amino acid sequences represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40 are SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, respectively.
  • the amino acid sequence represented by SEQ ID NO: 11 was added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32. Is.
  • SEQ ID NO: 33 SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39.
  • amino acid sequence represented by SEQ ID NO: 40 has a glutamine residue content of 9% or less (Table 3).
  • the modified fibroin (6-iii) comprises the amino acid sequence represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40. There may be.
  • the modified fibroin of (6-iv) has 90% or more of the amino acid sequence represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 or SEQ ID NO: 40
  • An amino acid sequence having the following sequence identity is included.
  • the modified fibroin of (6-iv) is also a domain represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif.
  • the sequence identity is preferably 95% or more.
  • the modified fibroin (6-iv) preferably has a glutamine residue content of 9% or less.
  • the modified fibroin (6-iv) preferably has a GPGXX motif content of 10% or more.
  • the sixth modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host.
  • the sequence of the secretion signal can be appropriately set according to the type of host.
  • the modified fibroin has at least two or more of the characteristics of the first modified fibroin, the second modified fibroin, the third modified fibroin, the fourth modified fibroin, the fifth modified fibroin, and the sixth modified fibroin. It may be a modified fibroin having the following characteristics.
  • the limit oxygen index (LOI) value of the modified fibroin according to this embodiment may be 18 or more, 20 or more, 22 or more, 24 or more, 26 or more, 28 or more, 29 or more, or 30 or more.
  • the LOI value is a value measured in accordance with “Test method for powdered or low melting point synthetic resin” described in “Fire Safety No. 50 (May 31, 1995)”. is there.
  • required according to the following formula A of the modified fibroin which concerns on this embodiment may be more than 0.025 degreeC / g.
  • Formula A: Maximum moisture absorption exotherm ⁇ (maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) ⁇ (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment) ⁇ (° C.) / Sample weight (g)
  • a low humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 40%
  • a high humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 90%.
  • the maximum moisture absorption exotherm of the modified fibroin according to this embodiment is 0.026 ° C./g or more, 0.027 ° C./g or more, 0.028 ° C./g or more, 0.029 ° C./g or more, 0.030 ° C. / G or more, 0.035 ° C./g or more, or 0.040 ° C./g or more.
  • limiting in particular in the upper limit of the maximum moisture absorption heat generation degree Usually, it is 0.060 degrees C / g or less.
  • the modified fibroin according to the present embodiment may have a heat retention index determined according to the following formula B of 0.20 or more.
  • Thermal insulation index Heat retention ratio (%) / Sample weight (g / m 2 )
  • the heat retention rate means a heat retention rate measured by a dry contact method using a Thermolab II type tester (under wind of 30 cm / second), and is measured by a method described in a reference example described later. Is the value to be
  • the heat retention index of the modified fibroin according to this embodiment may be 0.22 or more, may be 0.24 or more, may be 0.26 or more, may be 0.28 or more, and may be 0. .30 or more and 0.32 or more.
  • exponent there is no restriction
  • exponent For example, it may be 0.60 or less or 0.40 or less.
  • the modified fibroin according to any of the above embodiments is, for example, a host transformed with an expression vector having a nucleic acid sequence encoding the modified fibroin and one or more regulatory sequences operably linked to the nucleic acid sequence. Can be produced by expressing the nucleic acid.
  • the method for producing the nucleic acid encoding the modified fibroin is not particularly limited.
  • the nucleic acid is produced by a method such as amplification by polymerase chain reaction (PCR), cloning, modification by genetic engineering techniques, or chemical synthesis. can do.
  • the method for chemically synthesizing nucleic acids is not particularly limited. For example, based on the amino acid sequence information of fibroin obtained from the NCBI web database, etc., AKTA oligopilot plus 10/100 (GE Healthcare Japan Co., Ltd.) A gene can be chemically synthesized by a method of linking oligonucleotides that are synthesized automatically by PCR or the like.
  • a nucleic acid encoding the modified fibroin consisting of an amino acid sequence in which an amino acid sequence consisting of a start codon and a His10 tag is added to the N terminus of the above amino acid sequence is synthesized. May be.
  • Regulatory sequences are sequences that control the expression of modified fibroin in the host (for example, promoters, enhancers, ribosome binding sequences, transcription termination sequences, etc.), and can be appropriately selected depending on the type of host.
  • an inducible promoter that functions in the host cell and can induce expression of the modified fibroin may be used.
  • An inducible promoter is a promoter that can control transcription by the presence of an inducer (expression inducer), absence of a repressor molecule, or physical factors such as an increase or decrease in temperature, osmotic pressure or pH value.
  • the type of expression vector can be appropriately selected according to the type of host, such as a plasmid vector, virus vector, cosmid vector, fosmid vector, artificial chromosome vector, and the like.
  • a vector that can replicate autonomously in a host cell or can be integrated into a host chromosome and contains a promoter at a position where a nucleic acid encoding a modified fibroin can be transcribed is preferably used.
  • any of prokaryotes and eukaryotes such as yeast, filamentous fungi, insect cells, animal cells and plant cells can be preferably used.
  • prokaryotic hosts include bacteria belonging to the genus Escherichia, Brevibacillus, Serratia, Bacillus, Microbacterium, Brevibacterium, Corynebacterium, Pseudomonas and the like.
  • microorganisms belonging to the genus Escherichia include Escherichia coli.
  • microorganisms belonging to the genus Brevibacillus include Brevibacillus agri and the like.
  • microorganisms belonging to the genus Serratia include Serratia liqufaciens and the like.
  • microorganisms belonging to the genus Bacillus include Bacillus subtilis.
  • microorganisms belonging to the genus Microbacterium include microbacterium / ammonia film.
  • microorganisms belonging to the genus Brevibacterium include Brevibacterium divaricatam.
  • microorganisms belonging to the genus Corynebacterium include Corynebacterium ammoniagenes.
  • microorganisms belonging to the genus Pseudomonas include Pseudomonas putida.
  • vectors for introducing a nucleic acid encoding a modified fibroin include, for example, pBTrp2 (manufactured by Boehringer Mannheim), pGEX (manufactured by Pharmacia), pUC18, pBluescriptII, pSupex, pET22b, pCold, pUB110, pNCO2 (Japanese Patent Laid-Open No. 2002-238696) and the like can be mentioned.
  • Examples of eukaryotic hosts include yeast and filamentous fungi (molds, etc.).
  • yeast include yeasts belonging to the genus Saccharomyces, Pichia, Schizosaccharomyces and the like.
  • Examples of the filamentous fungi include filamentous fungi belonging to the genus Aspergillus, the genus Penicillium, the genus Trichoderma and the like.
  • examples of a vector into which a nucleic acid encoding a modified fibroin is introduced include YEp13 (ATCC37115) and YEp24 (ATCC37051).
  • a method for introducing the expression vector into the host cell any method can be used as long as it is a method for introducing DNA into the host cell.
  • a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)]
  • electroporation method electroporation method
  • spheroplast method protoplast method
  • lithium acetate method competent method, and the like.
  • a method for expressing a nucleic acid by a host transformed with an expression vector in addition to direct expression, secretory production, fusion protein expression, etc. can be performed according to the method described in Molecular Cloning 2nd edition, etc. .
  • the modified fibroin can be produced, for example, by culturing a host transformed with an expression vector in a culture medium, generating and accumulating the modified fibroin in the culture medium, and collecting from the culture medium.
  • the method for culturing a host in a culture medium can be performed according to a method usually used for culturing a host.
  • the culture medium contains a carbon source, nitrogen source, inorganic salts, etc. that can be assimilated by the host, and can efficiently culture the host. If so, either a natural medium or a synthetic medium may be used.
  • Any carbon source may be used as long as it can be assimilated by the above-mentioned transformed microorganism.
  • Examples thereof include glucose, fructose, sucrose, and carbohydrates such as molasses, starch and starch hydrolyzate, acetic acid and propionic acid, etc.
  • Organic acids and alcohols such as ethanol and propanol can be used.
  • the nitrogen source examples include ammonium salts of inorganic acids or organic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, and ammonium phosphate, other nitrogen-containing compounds, and peptone, meat extract, yeast extract, corn steep liquor, Casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented cells and digested products thereof can be used.
  • inorganic salts for example, monopotassium phosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate and calcium carbonate can be used.
  • Cultivation of prokaryotes such as E. coli or eukaryotes such as yeast can be performed under aerobic conditions such as shaking culture or deep aeration and agitation culture.
  • the culture temperature is, for example, 15 to 40 ° C.
  • the culture time is usually 16 hours to 7 days.
  • the pH of the culture medium during the culture is preferably maintained at 3.0 to 9.0.
  • the pH of the culture medium can be adjusted using an inorganic acid, an organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like.
  • antibiotics such as ampicillin and tetracycline may be added to the culture medium as necessary.
  • an inducer may be added to the medium as necessary.
  • isopropyl- ⁇ -D-thiogalactopyranoside is used when cultivating a microorganism transformed with an expression vector using the lac promoter
  • indole acrylic is used when culturing a microorganism transformed with an expression vector using the trp promoter.
  • An acid or the like may be added to the medium.
  • Isolation and purification of the expressed modified fibroin can be performed by a commonly used method.
  • the host cells are recovered by centrifugation after culturing, suspended in an aqueous buffer, and then subjected to an ultrasonic crusher, a French press, a manton.
  • the host cells are disrupted with a Gaurin homogenizer, dynomill, etc. to obtain a cell-free extract.
  • a method usually used for protein isolation and purification that is, a solvent extraction method, a salting-out method using ammonium sulfate, a desalting method, an organic solvent, etc.
  • Precipitation method anion exchange chromatography method using a resin such as diethylaminoethyl (DEAE) -Sepharose, DIAION HPA-75 (manufactured by Mitsubishi Kasei), and a positive using a resin such as S-Sepharose FF (manufactured by Pharmacia)
  • Electrophoretic methods such as ion exchange chromatography, hydrophobic chromatography using resins such as butyl sepharose and phenyl sepharose, gel filtration using molecular sieve, affinity chromatography, chromatofocusing, isoelectric focusing Using methods such as these alone or in combination, purification It is possible to obtain the goods.
  • the modified fibroin when expressed by forming an insoluble substance in the cell, the host cell is similarly collected, crushed, and centrifuged to collect the modified fibroin insoluble substance as a precipitate fraction.
  • the recovered insoluble form of modified fibroin can be solubilized with a protein denaturant.
  • a purified preparation of modified fibroin can be obtained by the same isolation and purification method as described above.
  • the modified fibroin when secreted extracellularly, the modified fibroin can be recovered from the culture supernatant. That is, a culture supernatant is obtained by treating the culture with a technique such as centrifugation, and a purified preparation can be obtained from the culture supernatant by using the same isolation and purification method as described above.
  • the artificial fibroin fiber according to this embodiment is obtained by spinning the above-described modified fibroin and contains the above-described modified fibroin as a main component.
  • the artificial fibroin fiber according to this embodiment may have a LOI value of 18 or more, 20 or more, 22 or more, 24 or more, or 26 or more. 28 or more, 29 or more, or 30 or more.
  • the artificial fibroin fiber according to the present embodiment may have a maximum moisture absorption exotherm calculated according to the following formula A of more than 0.025 ° C./g.
  • a low humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 40%
  • a high humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 90%.
  • the artificial fibroin fiber according to this embodiment may have a maximum heat absorption exotherm of 0.026 ° C./g or more, 0.027 ° C./g or more, and 0.028 ° C./g or more. Or 0.029 ° C./g or more, 0.030 ° C./g or more, 0.035 ° C./g or more, or 0.040 ° C./g or more. It may be. Although there is no restriction
  • the artificial fibroin fiber according to the present embodiment may have a heat retention index determined according to the following formula B of 0.20 or more.
  • the heat retention index of the artificial fibroin fiber according to this embodiment may be 0.22 or more, may be 0.24 or more, may be 0.26 or more, may be 0.28 or more, It may be 0.30 or more, and may be 0.32 or more.
  • exponent there is no restriction
  • exponent For example, it may be 0.60 or less or 0.40 or less.
  • the artificial fibroin fiber according to the present embodiment can be produced by a known spinning method. That is, for example, when producing an artificial fibroin fiber containing a modified fibroin as a main component, first, the modified fibroin produced according to the above-described method is converted into dimethyl sulfoxide (DMSO), N, N-dimethylformamide (DMF), A dope solution is prepared by adding to a solvent such as formic acid or hexafluoroisopropanol (HFIP) together with an inorganic salt as a dissolution accelerator, if necessary, and dissolving. Next, the target artificial fibroin fiber can be obtained by spinning using this dope solution by a known spinning method such as wet spinning, dry spinning, dry wet spinning or melt spinning. Preferred spinning methods include wet spinning or dry wet spinning.
  • a known spinning method such as wet spinning, dry spinning, dry wet spinning or melt spinning.
  • Preferred spinning methods include wet spinning or dry wet spinning.
  • FIG. 6 is an explanatory view schematically showing an example of a spinning device for producing artificial fibroin fibers.
  • a spinning device 10 illustrated in FIG. 6 is an example of a spinning device for dry and wet spinning, and includes an extrusion device 1, an undrawn yarn production device 2, a wet heat drawing device 3, and a drying device 4.
  • the dope solution 6 stored in the storage tank 7 is pushed out from the base 9 by the gear pump 8.
  • the dope solution may be filled into a cylinder and extruded from a nozzle using a syringe pump.
  • the extruded dope liquid 6 is supplied into the coagulating liquid 11 in the coagulating liquid tank 20 through the air gap 19, the solvent is removed, the modified fibroin is coagulated, and a fibrous coagulated body is formed.
  • the fibrous solidified body is supplied into the hot water 12 in the drawing bath 21 and drawn.
  • the draw ratio is determined by the speed ratio between the supply nip roller 13 and the take-up nip roller 14.
  • the stretched fibrous solidified body is supplied to the drying device 4 and dried in the yarn path 22, and an artificial fibroin fiber is obtained as the wound thread body 5.
  • Reference numerals 18a to 18g denote thread guides.
  • the coagulation liquid 11 may be any solvent that can be desolvated, and examples thereof include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol and 2-propanol, and acetone.
  • the coagulation liquid 11 may appropriately contain water.
  • the temperature of the coagulation liquid 11 is preferably 0 to 30 ° C.
  • the extrusion speed is preferably 0.2 to 6.0 ml / hour per hole, and 1.4 to 4.0 ml / hour More preferably it is time.
  • the distance that the coagulated protein passes through the coagulation liquid 11 may be a length that allows efficient desolvation, for example, 200 to 500 mm. It is.
  • the take-up speed of the undrawn yarn may be, for example, 1 to 20 m / min, and preferably 1 to 3 m / min.
  • the residence time in the coagulating liquid 11 may be, for example, 0.01 to 3 minutes, and preferably 0.05 to 0.15 minutes.
  • stretching pre-stretching
  • the coagulating liquid tank 20 may be provided in multiple stages, and the stretching may be performed in each stage or a specific stage as necessary.
  • the stretching performed when obtaining the artificial fibroin fiber for example, dry stretching is also adopted in addition to the pre-stretching performed in the coagulating liquid tank 20 and the wet heat stretching performed in the stretching bath 21.
  • Wet heat stretching can be performed in warm water, in a solution obtained by adding an organic solvent or the like to warm water, or in steam heating.
  • the temperature may be, for example, 50 to 90 ° C., and preferably 75 to 85 ° C.
  • undrawn yarn or predrawn yarn
  • Dry heat stretching can be performed using an electric tubular furnace, a dry heat plate, or the like.
  • the temperature may be, for example, 140 ° C. to 270 ° C., and preferably 160 ° C. to 230 ° C.
  • an undrawn yarn or predrawn yarn
  • an undrawn yarn can be drawn, for example, 0.5 to 8 times, and preferably 1 to 4 times.
  • Wet heat stretching and dry heat stretching may be performed independently, or may be performed in multiple stages or in combination. That is, the first stage stretching is performed by wet heat stretching, the second stage stretching is performed by dry heat stretching, or the first stage stretching is performed by wet heat stretching, the second stage stretching is performed by wet heat stretching, and the third stage stretching is performed by dry heat stretching.
  • wet heat stretching and dry heat stretching can be appropriately combined.
  • the final draw ratio of the lower limit of the undrawn yarn (or predrawn yarn) is preferably more than 1 time, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times. Above, 7 times or more, 8 times or more, 9 times or more, and upper limit is preferably 40 times or less, 30 times or less, 20 times or less, 15 times or less, 14 times or less, 13 times or less 12 times or less, 11 times or less, and 10 times or less.
  • the artificial fibroin fiber is a fiber spun at a draw ratio of 2 times or more, the shrinkage rate when the artificial fibroin fiber is brought into a wet state by being brought into contact with water becomes higher.
  • the high shrinkage artificial fibroin fiber according to the present embodiment is obtained by shrinking the above-described artificial fibroin fiber.
  • the above-mentioned artificial fibroin fiber is sufficiently shrunk by being brought into a wet state by being brought into contact with water, and can be shrunk at a sufficiently high shrinkage rate under milder conditions than conventionally known synthetic fibers.
  • the shrinkage rate defined by the following formula is 2% or more.
  • Shrinkage rate ⁇ 1 ⁇ (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water) ⁇ ⁇ 100 (%)
  • the shrinkage rate of the high shrinkage artificial fibroin fiber according to the present embodiment is 2.5% or more, 3% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more, 5.5% or more. Or 6% or more.
  • the upper limit of the shrinkage rate is not particularly limited, but 80% or less, 60% or less, 40% or less, 20% or less, 10% or less, 7% or less, 6% or less, 5% or less, 4% or less, or 3% or less It may be.
  • the high shrinkage artificial fibroin fiber according to this embodiment may have a LOI value of 18 or more, 20 or more, 22 or more, 24 or more, or 26 or more. It may be 28 or more, 29 or more, or 30 or more.
  • the high-shrinkage artificial fibroin fiber according to this embodiment may have a maximum moisture absorption exotherm calculated according to the following formula A of more than 0.025 ° C./g.
  • Maximum moisture absorption exotherm ⁇ (maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) ⁇ (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment) ⁇ (° C.) / Sample weight (g)
  • a low humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 40%
  • a high humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 90%.
  • the high-shrinkage artificial fibroin fiber according to this embodiment may have a maximum moisture absorption exotherm of 0.026 ° C./g or more, 0.027 ° C./g or more, or 0.028 ° C./g or more. May be 0.029 ° C / g or more, 0.030 ° C / g or more, 0.035 ° C / g or more, and 0.040 ° C / g. It may be g or more. Although there is no restriction
  • required according to the following formula B may be 0.20 or more as for the high shrinkage artificial fibroin fiber which concerns on this embodiment.
  • Thermal insulation index Heat retention ratio (%) / Sample weight (g / m 2 )
  • the heat retention index of the high shrinkage artificial fibroin fiber according to the present embodiment may be 0.22 or more, may be 0.24 or more, may be 0.26 or more, and may be 0.28 or more. It may be 0.30 or more and may be 0.32 or more. Although there is no restriction
  • the method for producing high-shrinkage artificial fibroin fibers includes a step (hereinafter, also referred to as “shrinking step”) in which the artificial fibroin fibers containing the modified fibroin are brought into contact with water having a boiling point below.
  • the artificial fibroin fiber is brought into a wet state by bringing the artificial fibroin fiber into contact with water having a boiling point (hereinafter also referred to as “contact step”).
  • the wet state means a state in which at least a part of the artificial fibroin fiber is wet with water.
  • the shrinkage ratio of the artificial fibroin fiber in the shrinking process can be arbitrarily controlled according to the size of the draw ratio in the manufacturing process of the artificial fibroin fiber described above, for example.
  • the temperature of the water contacted with the artificial fibroin fiber in the contact step may be less than the boiling point. Thereby, the handleability and the workability of the shrinking process are improved. Further, from the viewpoint of sufficiently shortening the shrinkage time, the lower limit value of the water temperature is preferably 10 ° C or higher, more preferably 40 ° C or higher, and further preferably 70 ° C or higher. . The upper limit of the water temperature is preferably 90 ° C. or lower.
  • the method for bringing water into contact with the artificial fibroin fiber is not particularly limited.
  • the method include, for example, a method of immersing the artificial fibroin fiber in water, a method of spraying water on the artificial fibroin fiber at room temperature or in a heated steam state, and the high humidity where the artificial fibroin fiber is filled with water vapor. Examples include exposure to the environment.
  • the method of immersing artificial fibroin fiber in water is preferable in the contact step because the shrinkage time can be effectively shortened and the processing equipment can be simplified.
  • the contact step when the artificial fibroin fiber is brought into contact with water in a relaxed state, the artificial fibroin fiber may not only contract but also shrink like a wave.
  • the contact step is performed in a state where the artificial fibroin fiber is not relaxed, for example, the artificial fibroin fiber is brought into contact with water below the boiling point while being tensioned (pulled) in the fiber axis direction. May be.
  • the wet highly shrinkable artificial fibroin fiber may be dried (hereinafter also referred to as “drying step”).
  • the drying step is a step of drying the high shrinkage artificial fibroin fiber that has undergone the shrinkage step. Drying may be, for example, natural drying or forced drying using a drying facility. As the drying equipment, any known drying equipment of contact type or non-contact type can be used.
  • the drying temperature is not limited as long as it is lower than the temperature at which, for example, the protein contained in the high-shrinkage artificial fibroin fiber is decomposed or the high-shrinkage artificial fibroin fiber is thermally damaged. However, in general, the temperature is in the range of 20 to 150 ° C., and the temperature is preferably in the range of 50 to 100 ° C.
  • the temperature in this range allows the high shrinkage artificial fibroin fiber to dry more quickly and efficiently without thermal damage of the high shrinkage artificial fibroin fiber or degradation of the protein contained in the high shrinkage artificial fibroin fiber. Is done.
  • the drying time is appropriately set according to the drying temperature or the like, and for example, a time that can eliminate as much as possible the influence on the quality and physical properties of the high shrinkage artificial fibroin fiber due to overdrying is adopted.
  • a high-shrinkage artificial fibroin fiber having a shrinkage rate of 2% or more can be obtained through the shrinking step.
  • FIG. 7 is an explanatory view schematically showing an example of a production apparatus for producing high-shrinkage artificial fibroin fibers.
  • the manufacturing apparatus 40 shown in FIG. 7 includes a feed roller 42 that feeds out artificial fibroin fibers, a winder 44 that winds up the highly shrinkable artificial fibroin fibers 38, a water bath 46 that performs a shrinking process, and a dryer 48 that performs a drying process. And is configured.
  • the feed roller 42 can be attached with a wound product of the artificial fibroin fiber 36, and the artificial fibroin fiber 36 is continuously formed from the wound product of the artificial fibroin fiber 36 by rotation of an electric motor (not shown).
  • the winder 44 continuously and automatically turns the artificial fibroin fiber 36 (high-shrinking artificial fibroin fiber 38), which is fed from the feed roller 42 and then contracted through the contact step and the drying step, by the rotation of an electric motor (not shown). It can be wound up.
  • the feeding speed of the artificial fibroin fiber 36 by the feed roller 42 and the winding speed of the highly shrinkable artificial fibroin fiber 38 by the winder 44 can be controlled independently of each other.
  • the water bath 46 and the dryer 48 are arranged side by side between the feed roller 42 and the winder 44 on the upstream side and the downstream side in the feeding direction of the artificial fibroin fiber 36.
  • 7 includes relay rollers 50 and 52 that relay the artificial fibroin fiber 36 before and after contraction, which travels from the feed roller 42 toward the winder 44.
  • the water bath 46 has a heater 54, and hot water 47 heated by the heater 54 is accommodated in the water bath 46.
  • a tension roller 56 is installed in the water bath 46 so as to be immersed in the hot water 47.
  • the artificial fibroin fiber 36 fed out from the feed roller 42 travels toward the winder 44 while being immersed in the hot water 47 while being wound around the tension roller 56 in the water bath 46. It has become.
  • the immersion time of the artificial fibroin fiber 36 in the hot water 47 is appropriately controlled according to the traveling speed of the artificial fibroin fiber 36.
  • the dryer 48 has a pair of hot rollers 58.
  • the pair of hot rollers 58 can be wound around the artificial fibroin fiber 36 that moves away from the water bath 46 and travels toward the winder 44 side.
  • the artificial fibroin fiber 36 immersed in the hot water 47 in the water bath 46 is heated by the pair of hot rollers 58 in the dryer 48 and dried, and then sent out further toward the winder 44. It has become.
  • the artificial fibroin fiber 36 spun using the spinning apparatus 10 shown in FIG. 6 is used.
  • the wound material is attached to the feed roller 42.
  • the artificial fibroin fiber 36 is continuously fed from the feed roller 42 and immersed in hot water 47 in the water bath 46.
  • the winding speed of the winder 44 is set slower than the feeding speed of the feed roller 42.
  • the high shrinkage artificial fibroin fiber 38 is heated by the pair of hot rollers 58 of the dryer 48. Thereby, the high shrinkage artificial fibroin fiber 38 can be dried. At this time, by controlling the ratio between the feed speed of the feed roller 42 and the winding speed of the winder 44, the high-shrinkage artificial fibroin fiber 38 can be further shrunk, and the length can be kept unchanged. The obtained high-shrinkage artificial fibroin fiber 38 is wound up by a winder 44 to obtain a wound product of the high-shrinkage artificial fibroin fiber 38.
  • the high-shrinkage artificial fibroin fiber 38 may be dried using a drying facility consisting of only a heat source such as a dry heat plate 64 as shown in FIG. Also in this case, by adjusting the relative speed of the feed speed of the feed roller 42 and the winding speed of the winder 44 in the same manner as in the case of using a pair of hot rollers 58 as a drying facility, a high shrinkage artificial structure is achieved.
  • the fibroin fiber 38 can be further shrunk or the length can be kept unchanged.
  • the drying means is constituted by the dry heat plate 64. Further, the dryer 48 is not essential.
  • the target high-shrinkage artificial fibroin fiber 38 can be manufactured automatically, continuously, and extremely easily.
  • FIG. 8 is an explanatory view schematically showing another example of a production apparatus for producing high-shrinkage artificial fibroin fibers.
  • FIG. 8A shows a processing apparatus that performs the shrinking process included in the manufacturing apparatus
  • FIG. 8B shows a drying apparatus that performs the drying process included in the manufacturing apparatus.
  • the manufacturing apparatus shown in FIG. 8 has a processing device 60 that performs a shrinking process on the artificial fibroin fiber 36 and a drying device 62 that dries the resulting high-shrinkage artificial fibroin fiber 38, and these are independent of each other. It is said that.
  • the processing device 60 shown in FIG. 8A omits the dryer 48 from the manufacturing device 40 shown in FIG. 7 and replaces the feed roller 42, the water bath 46, and the winder 44 with an artificial. It has a structure in which the fibroin fibers 36 are arranged in order from the upstream side to the downstream side in the traveling direction.
  • the artificial fibroin fiber 36 fed from the feed roller 42 is immersed in hot water 47 in the water bath 46 and contracted.
  • the high-shrinkage artificial fibroin fiber 38 obtained by shrinkage is wound up by a winder 44.
  • the 8B includes a feed roller 42 and a winder 44, and a dry heat plate 64.
  • the dry heat plate 64 is disposed between the feed roller 42 and the winder 44 so that the dry heat surface 66 is in contact with the high-shrinkage artificial fibroin fiber 38 and extends in the running direction.
  • the high-shrinkage artificial fibroin fiber 38 can be further shrunk by controlling the ratio of the feed speed of the feed roller 42 and the wind-up speed of the winder 44, for example. , You can not change the length.
  • the artificial fibroin fiber 36 is contracted by the processing apparatus 60 to obtain the desired high-shrinking artificial fibroin fiber 38, and then the high-shrinking artificial fibroin fiber 38 is obtained by the drying apparatus 62. Can be dried.
  • the processing apparatus 60 may be configured with only the water bath 46 by omitting the feed roller 42 and the winder 44 from the processing apparatus 60 shown in FIG.
  • a manufacturing apparatus having such a processing apparatus for example, high-shrinkage artificial fibroin fibers are manufactured in a so-called batch type.
  • the drying apparatus 62 shown in FIG.8 (b) is not essential.
  • the high-shrinkage artificial fibroin fiber according to the present invention is shrunk at a high shrinkage rate, it is excellent in touch and flexibility, and is suitable as a fiber used for, for example, clothing and bedding.
  • the manufacturing method of the high shrinkage artificial fibroin fiber of the present invention described above includes a step of shrinking an artificial fibroin fiber containing modified fibroin by bringing it into contact with water having a boiling point below, and the shrinkage rate defined by the following formula is 2 %, It can also be regarded as a shrinkage method of artificial fibroin fiber.
  • Shrinkage rate ⁇ 1 ⁇ (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water) ⁇ ⁇ 100 (%)
  • the nucleic acids encoding the four types of designed modified fibroin were synthesized respectively.
  • the nucleic acid was added with an NdeI site at the 5 'end and an EcoRI site downstream of the stop codon.
  • These four types of nucleic acids were cloned into a cloning vector (pUC118). Thereafter, the nucleic acid was cleaved by restriction enzyme treatment with NdeI and EcoRI, and then recombined with the protein expression vector pET-22b (+) to obtain an expression vector.
  • Escherichia coli BLR (DE3) was transformed with the obtained pET-22b (+) expression vector.
  • the transformed Escherichia coli was cultured in 2 mL of LB medium containing ampicillin for 15 hours.
  • the culture solution was added to 100 mL of a seed culture medium (Table 4) containing ampicillin so that the OD 600 was 0.005.
  • the culture temperature was kept at 30 ° C., and flask culture was performed until the OD 600 reached 5 (about 15 hours) to obtain a seed culture solution.
  • the seed culture was added to a jar fermenter to which 500 mL of production medium (Table 5) was added so that the OD 600 was 0.05.
  • the culture solution temperature was maintained at 37 ° C., and the culture was performed at a constant pH of 6.9.
  • the dissolved oxygen concentration in the culture solution was maintained at 20% of the dissolved oxygen saturation concentration.
  • a feed solution (glucose 455 g / 1 L, Yeast Extract 120 g / 1 L) was added at a rate of 1 mL / min.
  • the culture solution temperature was maintained at 37 ° C., and the culture was performed at a constant pH of 6.9.
  • the culture was performed for 20 hours while maintaining the dissolved oxygen concentration in the culture solution at 20% of the dissolved oxygen saturation concentration.
  • 1M isopropyl- ⁇ -thiogalactopyranoside (IPTG) was added to the culture solution to a final concentration of 1 mM to induce expression of the target modified fibroin.
  • the culture solution was centrifuged, and the cells were collected. SDS-PAGE was performed using cells prepared from the culture solution before and after IPTG addition, and the appearance of a band corresponding to the size of the target modified fibroin depending on the addition of IPTG Expression was confirmed.
  • the washed precipitate was suspended in 8M guanidine buffer (8M guanidine hydrochloride, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, 1 mM Tris-HCl, pH 7.0) to a concentration of 100 mg / mL, and 60 ° C. And stirred for 30 minutes with a stirrer to dissolve. After dissolution, dialysis was performed with water using a dialysis tube (cellulose tube 36/32 manufactured by Sanko Junyaku Co., Ltd.). White aggregated protein obtained after dialysis was collected by centrifugation. Water was removed from the recovered aggregated protein with a freeze dryer to obtain the desired modified fibroin freeze-dried powder.
  • 8M guanidine buffer 8M guanidine hydrochloride, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, 1 mM Tris-HCl, pH 7.0
  • spun and drawn artificial fibroin fibers were produced by dry and wet spinning using a spinning device similar to the spinning device 10 shown in FIG.
  • the spinning device used is a spinning device 10 shown in FIG. 6, and a second undrawn yarn production device (a first bath) and a wet heat drawing device 3 (third bath) are further provided between the undrawn yarn production device 2 (first bath) and the wet heat drawing device 3 (third bath).
  • a second bath The dry and wet spinning conditions are as follows. Extrusion nozzle diameter: 0.2 mm Liquid and temperature in the first to third baths: see Table 6 Total draw ratio: see Table 6 Drying temperature: 60 ° C.
  • a plurality of artificial fibroin fibers each having a length of 30 cm were cut out from the wound product of artificial fibroin fibers obtained in Production Examples 1 to 19.
  • the plurality of artificial fibroin fibers were bundled to obtain an artificial fibroin fiber bundle having a fineness of 150 denier.
  • a 0.8 g lead weight was attached to each artificial fibroin fiber bundle, and in this state, each artificial fibroin fiber bundle was immersed in water at a temperature shown in Tables 7 to 10 for 10 minutes (contact step). Thereafter, the length of each artificial fibroin fiber bundle was measured in water.
  • the high-shrinkage artificial fibroin fiber of the present invention had a sufficiently high shrinkage rate and was excellent in touch and flexibility. In addition, since it can manufacture by the contact step made to contact with water below boiling point, it can manufacture safely.
  • a modified fibroin (PRT799) freeze-dried powder was added to a LiCl solution in DMSO (concentration: 4.0% by mass) to a concentration of 24% by mass, and dissolved by mixing for 3 hours using a shaker. It was. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution (spinning stock solution).
  • the spinning dope is filtered through a metal filter with an opening of 5 ⁇ m at 90 ° C., then left to stand in a 30 mL stainless syringe and defoamed, and then in a 100 mass% methanol coagulation bath from a solid nozzle with a needle diameter of 0.2 mm.
  • the discharge temperature was 90 ° C.
  • the obtained raw yarn was wound up and naturally dried to obtain modified fibroin fiber (raw fiber).
  • a knitted fabric (thickness: 180 denier, number of gauges: 18) was manufactured by circular knitting using a circular knitting machine using twisted yarns obtained by twisting raw material fibers. 20 g of the obtained knitted fabric was cut out and used as a test piece.
  • the flammability test was conducted in accordance with “Test method for powdered or low melting point synthetic resin” described in “Fire Safety No. 50 (May 31, 1995)”. The test was performed under conditions of a temperature of 22 ° C., a relative humidity of 45%, and an atmospheric pressure of 1021 hPa. Table 11 shows the measurement results (oxygen concentration (%), combustion rate (%), and converted combustion rate (%)).
  • the critical oxygen index (LOI) value of the knitted fabric knitted with the modified fibroin (PRT799) fiber was 27.2.
  • the LOI value is 26 or more, it is considered to be flame retardant. It can be seen that the modified fibroin is excellent in flame retardancy.
  • PRT918 is a hydrophobically modified fibroin having the amino acid sequence set forth in SEQ ID NO: 37 and having an average HI greater than zero.
  • modified fibroin solution By adding a lyophilized powder of modified fibroin (PRT918 and PRT799) to a LiCl solution in DMSO (concentration: 4.0% by mass) to a concentration of 24% by mass and mixing for 3 hours using a shaker, Dissolved. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution (spinning stock solution).
  • the spinning dope is filtered through a metal filter having a mesh size of 5 ⁇ m at 60 ° C., then left to stand in a 30 mL stainless syringe and defoamed, and then in a 100 mass% methanol coagulation bath from a solid nozzle having a needle diameter of 0.2 mm.
  • the discharge temperature was 60 ° C.
  • the obtained raw yarn was wound up and naturally dried to obtain modified fibroin fiber (raw fiber).
  • Table 12 shows the thickness and gauge number of the knitted fabric using PRT918 fiber or PRT799 fiber. The thickness and the number of gauges of the knitted fabric using other raw material fibers were adjusted so that the cover factor was almost the same as the cover factor of the knitted fabric of the modified fibroin fiber. Specifically, it is as shown in Table 12.
  • test piece 2 pieces of knitted fabric cut to 10 cm ⁇ 10 cm were put together, and four sides were sewn together to obtain a test piece (sample). After leaving the test piece in a low humidity environment (temperature 20 ⁇ 2 ° C., relative humidity 40 ⁇ 5%) for 4 hours or more, it is transferred to a high humidity environment (temperature 20 ⁇ 2 ° C., relative humidity 90 ⁇ 5%). The temperature was measured at intervals of 1 minute by a temperature sensor attached to the center of the interior for 30 minutes.
  • FIG. 9 is a graph showing an example of the results of the hygroscopic exothermic test.
  • the horizontal axis of the graph represents the time (minutes) left in the high humidity environment, with the time when the sample was transferred from the low humidity environment to the high humidity environment as 0.
  • the vertical axis of the graph indicates the temperature (sample temperature) measured by the temperature sensor.
  • the point indicated by M corresponds to the maximum value of the sample temperature.
  • Table 13 shows the calculation results of the maximum moisture absorption exotherm.
  • modified fibroin (PRT918 and PRT799) fibers have a higher maximum heat absorption exotherm and superior hygroscopic heat generation compared to existing materials.
  • PRT966 is a hydrophobically modified fibroin having the amino acid sequence set forth in SEQ ID NO: 40 and having an average HI greater than zero.
  • modified fibroin solution By adding a lyophilized powder of modified fibroin (PRT966 and PRT799) to a LiCl solution in DMSO (concentration: 4.0% by mass) to a concentration of 24% by mass, and mixing for 3 hours using a shaker, Dissolved. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution (spinning stock solution).
  • the spinning dope is filtered through a metal filter having a mesh size of 5 ⁇ m at 60 ° C., then left to stand in a 30 mL stainless syringe and defoamed, and then in a 100 mass% methanol coagulation bath from a solid nozzle having a needle diameter of 0.2 mm.
  • the discharge temperature was 60 ° C.
  • the obtained raw yarn was wound up and naturally dried to obtain modified fibroin fiber (raw fiber).
  • Table 14 shows the count, the number of twists, the number of gauges, and the basis weight of the knitted fabric using PRT966 fiber and PRT799 fiber.
  • the thickness and the number of gauges of the knitted fabric using other raw material fibers were adjusted so that the cover factor was almost the same as the cover factor of the knitted fabric of the modified fibroin fiber. Specifically, it is as shown in Table 14.
  • Thermal insulation was evaluated using a dry contact method using a KES-F7 Thermolab II tester manufactured by Kato Tech.
  • the dry contact method is a method assuming that the skin and clothes are directly touched in a dry state.
  • One knitted fabric cut into a 20 cm ⁇ 20 cm rectangle was used as a test piece (sample).
  • the test piece was set on a hot plate set at a constant temperature (30 ° C.), and the amount of heat (a) dissipated through the test piece was determined under the condition of the wind speed in the wind tunnel of 30 cm / second. With no test piece set, the amount of heat (b) dissipated under the same conditions as above was determined, and the heat retention rate (%) was calculated according to the following formula.
  • Thermal insulation rate (%) (1 ⁇ a / b) ⁇ 100
  • Table 15 shows the calculation results of the heat retention index. It can be evaluated that the higher the heat retention index, the better the heat retention material.
  • modified fibroin (PRT966 and PRT799) fibers have a higher heat retention index and superior heat retention compared to existing materials.

Abstract

The purpose of the present invention is to provide high-shrinkage artificial fibroin fibers that have a sufficiently high shrinkage rate, that feel excellent against the skin and have excellent softness, and that can be produced safely. These high-shrinkage artificial fibroin fibers comprise a modified fibroin, are shrunken artificial fibroin fibers, and have a shrinkage rate of 2% or more as defined by the formula indicated below. Shrinkage rate = {1 – (length of artificial fibroin fibers that have become moist after being brought into contact with water/length of artificial fibroin fibers after being spun and prior to being brought into contact with water)} × 100 (%)

Description

高収縮人造フィブロイン繊維及びその製造方法、並びに人造フィブロイン繊維の収縮方法High shrinkage artificial fibroin fiber, method for producing the same, and method for shrinking artificial fibroin fiber
 本発明は、高収縮人造フィブロイン繊維及びその製造方法、並びに人造フィブロイン繊維の収縮方法に関する。 The present invention relates to a high-shrinkage artificial fibroin fiber, a method for producing the same, and a method for shrinking an artificial fibroin fiber.
 一般に、衣料、寝具等に使用される繊維には、高い肌触り性が求められる。肌触り性を充分に満足し、且つ高級感のある繊維として、天然のフィブロイン繊維の一種であるシルク等が知られている。 In general, fibers used for clothing, bedding, etc. are required to have a high touch. Silk, which is a kind of natural fibroin fiber, is known as a fiber that sufficiently satisfies the touch and has a high-class feeling.
 また、衣料、寝具等に使用される繊維には、柔らかさ及び保温性等も同時に求められる。そのため、衣料、寝具等に用いられるシルクは、例えば、収縮加工が施されて嵩高性が高められ、それによって柔軟性及び保温性が付与される場合がある。 Also, fibers used in clothing, bedding, etc. are required to have softness and heat retention. Therefore, silk used for clothing, bedding, and the like is subjected to, for example, shrink processing to increase bulkiness, thereby imparting flexibility and heat retention in some cases.
 一方、例えば、衣料、寝具等には、ポリエステル繊維、ポリアミド繊維及びアクリル繊維等の合成繊維が汎用的に使用されおり、これらの合成繊維は、沸騰水に接触させ、その後12時間放置することで、40%以上の収縮率を実現している(特許文献1)。 On the other hand, for example, synthetic fibers such as polyester fibers, polyamide fibers, and acrylic fibers are generally used for clothing, bedding, etc., and these synthetic fibers are brought into contact with boiling water and then left for 12 hours. The shrinkage rate of 40% or more is realized (Patent Document 1).
特開2009-121003号公報JP 2009-112003 A
 しかしながら、従来の繊維は、水に接触させるだけではほとんど収縮せず、水に接触させた後乾燥させることで初めて充分に収縮する場合があった。 However, conventional fibers hardly contracted only by being brought into contact with water, and sometimes contracted sufficiently only after being brought into contact with water and then dried.
 また、特許文献1に記載された収縮方法は、高温の沸騰水を取り扱うために大きな危険が伴うものであった。 Further, the shrinkage method described in Patent Document 1 is accompanied by a great danger in handling hot boiling water.
 本発明は、充分に高い収縮率を有し、肌触り性及び柔軟性に優れ、しかも安全に製造が可能な高収縮人造フィブロイン繊維、及びその製造方法を提供することを目的とする。本発明はまた、人造フィブロイン繊維を充分に高い収縮率で、安全に得ることができる、人造フィブロイン繊維の収縮方法を提供することも目的とする。 An object of the present invention is to provide a highly shrinkable artificial fibroin fiber having a sufficiently high shrinkage ratio, excellent in touch and flexibility, and capable of being produced safely, and a method for producing the same. Another object of the present invention is to provide a method for shrinking artificial fibroin fibers, which can safely obtain artificial fibroin fibers with a sufficiently high shrinkage rate.
 本発明は、例えば、以下の各発明に関する。
[1]
 改変フィブロインを含む、収縮された人造フィブロイン繊維であって、
 下記式で定義される収縮率が2%以上である、高収縮人造フィブロイン繊維。
 収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
[2]
 上記改変フィブロインが、改変クモ糸フィブロインである、[1]に記載の高収縮人造フィブロイン繊維。
[3]
 沸点未満の水との接触により収縮されたものである、[1]又は[2]に記載の高収縮人造フィブロイン繊維。
[4]
 上記水の温度が、10~90℃である、[3]に記載の高収縮人造フィブロイン繊維。
[5]
 上記収縮率が7%以下である、[3]又は[4]に記載の高収縮人造フィブロイン繊維。
[6]
 改変フィブロインを含む人造フィブロイン繊維を、沸点未満の水と接触させて、収縮させる工程を備え、
 下記式で定義される収縮率が2%以上である、高収縮人造フィブロイン繊維の製造方法。
 収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
[7]
 上記改変フィブロインが、改変クモ糸フィブロインである、[6]に記載の高収縮人造フィブロイン繊維の製造方法。
[8]
 上記水の温度が、10~90℃である、[6]又は[7]に記載の高収縮人造フィブロイン繊維の製造方法。
[9]
 上記収縮率が7%以下である、[6]~[8]のいずれかに記載の高収縮人造フィブロイン繊維の製造方法。
[10]
 改変フィブロインを含む人造フィブロイン繊維を、沸点未満の水と接触させて、収縮させる工程を備え、
 下記式で定義される収縮率が2%以上である、人造フィブロイン繊維の収縮方法。
 収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
[11]
 上記改変フィブロインが、改変クモ糸フィブロインである、[10]に記載の人造フィブロイン繊維の収縮方法。
[12]
 上記水の温度が、10~90℃である、[10]又は[11]に記載の人造フィブロイン繊維の収縮方法。
[13]
 上記収縮率が7%以下である、[10]~[12]のいずれかに記載の人造フィブロイン繊維の収縮方法。
[14]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
 上記ドメイン配列が、天然由来のフィブロインと比較して、少なくとも1又は複数の(A)モチーフが欠失したことに相当する、(A)モチーフの含有量が低減されたアミノ酸配列を有する、
[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[15]
 上記ドメイン配列が、天然由来のフィブロインと比較して、少なくともN末端側からC末端側に向かって1~3つの(A)モチーフ毎に1つの(A)モチーフが欠失したことに相当するアミノ酸配列を有する、[14]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[16]
 上記ドメイン配列が、天然由来のフィブロインと比較して、少なくともN末端側からC末端側に向かって2つ連続した(A)モチーフの欠失、及び1つの(A)モチーフの欠失がこの順に繰り返されたことに相当するアミノ酸配列を有する、[14]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[17]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
 N末端側からC末端側に向かって、隣合う2つの[(A)モチーフ-REP]ユニットのREPのアミノ酸残基数を順次比較して、アミノ酸残基数が少ないREPのアミノ酸残基数を1としたとき、他方のREPのアミノ酸残基数の比が1.8~11.3となる隣合う2つの[(A)モチーフ-REP]ユニットのアミノ酸残基数を足し合わせた合計値の最大値をxとし、上記ドメイン配列の総アミノ酸残基数をyとしたときに、x/yが50%以上である、[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[18]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
 上記ドメイン配列が、天然由来のフィブロインと比較して、少なくともREP中の1又は複数のグリシン残基が別のアミノ酸残基に置換されたことに相当する、グリシン残基の含有量が低減されたアミノ酸配列を有する、
[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[19]
 上記ドメイン配列が、天然由来のフィブロインと比較して、REP中のGGX及びGPGXX(但し、Xはグリシン以外のアミノ酸残基を示す。)から選ばれる少なくとも一つのモチーフ配列において、少なくとも1又は複数の当該モチーフ配列中の1つのグリシン残基が別のアミノ酸残基に置換されたことに相当するアミノ酸配列を有する、[18]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[20]
 グリシン残基が別のアミノ酸残基に置換されたモチーフ配列の割合が、全モチーフ配列に対して、10%以上である、[19]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[21]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
 上記ドメイン配列から、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を除いた配列中の全REPに含まれるXGX(但し、Xはグリシン以外のアミノ酸残基を示す。)からなるアミノ酸配列の総アミノ酸残基数をzとし、上記ドメイン配列から、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を除いた配列中の総アミノ酸残基数をwとしたときに、z/wが50.9%以上である、[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[22]
 上記改変フィブロインが、天然由来のフィブロインと比較して、REP中の1又は複数のグリシン残基が別のアミノ酸残基に置換されたことに相当するのに加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列を有する、[18]~[21]のいずれか一つに記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[23]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
 上記ドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のアミノ酸残基が疎水性指標の大きいアミノ酸残基に置換されたこと、及び/又はREP中に1又は複数の疎水性指標の大きいアミノ酸残基が挿入されたことに相当する、局所的に疎水性指標の大きい領域を含むアミノ酸配列を有する、
[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[24]
 上記局所的に疎水性指標の大きい領域が、連続する2~4アミノ酸残基で構成されている、[23]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[25]
 上記疎水性指標の大きいアミノ酸残基が、イソロイシン(I)、バリン(V)、ロイシン(L)、フェニルアラニン(F)、システイン(C)、メチオニン(M)及びアラニン(A)から選ばれる、[23]又は[24]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[26]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
 最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を上記ドメイン配列から除いた配列に含まれる全てのREPにおいて、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域に含まれるアミノ酸残基の総数をpとし、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を上記ドメイン配列から除いた配列に含まれるアミノ酸残基の総数をqとしたときに、p/qが6.2%以上である、[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[27]
 上記改変フィブロインが、天然由来のフィブロインと比較して、REP中の1又は複数のアミノ酸残基が疎水性指標の大きいアミノ酸残基に置換されたこと、及び/又はREP中に1又は複数の疎水性指標の大きいアミノ酸残基が挿入されたことに相当するのに加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列を有する、[23]~[26]のいずれか一つに記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[28]
 上記改変フィブロインが、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含み、
 上記ドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のグルタミン残基を欠失したこと、又は他のアミノ酸残基に置換したことに相当する、グルタミン残基の含有量が低減されたアミノ酸配列を有する、
[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[式1及び式2中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が80%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
[29]
 上記改変フィブロインが、REP中にGPGXX(但し、Xはグリシン残基以外のアミノ酸残基を示す。)モチーフを含み、GPGXXモチーフ含有率が10%以上である、[28]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[30]
 上記改変フィブロインのグルタミン残基含有率が9%以下である、[28]又は[29]に記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[31]
 上記他のアミノ酸残基が、イソロイシン(I)、バリン(V)、ロイシン(L)、フェニルアラニン(F)、システイン(C)、メチオニン(M)、アラニン(A)、グリシン(G)、スレオニン(T)、セリン(S)、トリプトファン(W)、チロシン(Y)、プロリン(P)及びヒスチジン(H)からなる群より選択されるアミノ酸残基である、[28]~[30]のいずれか一つに記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[32]
 上記改変フィブロインは、REPの疎水性度が-0.8以上である、[28]~[31]のいずれか一つに記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[33]
 上記改変フィブロインが、天然由来のフィブロインと比較して、REP中の1又は複数のグルタミン残基を欠失したこと、又は他のアミノ酸残基に置換したことに相当するのに加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列を有する、[28]~[32]のいずれか一つに記載の高収縮人造フィブロイン繊維、高収縮人造フィブロイン繊維の製造方法、又は人造フィブロイン繊維の収縮方法。
[34]
 上記改変フィブロインが、26.0以上の限界酸素指数(LOI)値を有する、[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
[35]
 上記改変フィブロインの、下記式Aに従って求められる最高吸湿発熱度が0.025℃/g超である、[1]~[5]のいずれか一つに記載の高収縮人造フィブロイン繊維、[6]~[9]のいずれか一つに記載の高収縮人造フィブロイン繊維の製造方法、又は[10]~[13]のいずれか一つに記載の人造フィブロイン繊維の収縮方法。
 式A:最高吸湿発熱度={(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移したときの試料温度の最高値)-(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移すときの試料温度)}(℃)/試料重量(g)
[式A中、低湿度環境は、温度20℃及び相対湿度40%の環境を意味し、高湿度環境は、温度20℃及び相対湿度90%の環境を意味する。]
The present invention relates to the following inventions, for example.
[1]
Shrinked artificial fibroin fiber comprising modified fibroin,
A highly shrinkable artificial fibroin fiber having a shrinkage rate defined by the following formula of 2% or more.
Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
[2]
The high-shrinkage artificial fibroin fiber according to [1], wherein the modified fibroin is a modified spider silk fibroin.
[3]
The high-shrinkage artificial fibroin fiber according to [1] or [2], which is shrunk by contact with water having a boiling point below.
[4]
The high-shrinkage artificial fibroin fiber according to [3], wherein the temperature of the water is 10 to 90 ° C.
[5]
The high shrinkage artificial fibroin fiber according to [3] or [4], wherein the shrinkage rate is 7% or less.
[6]
A step of contacting an artificial fibroin fiber containing modified fibroin with water having a boiling point lower than that,
The manufacturing method of the high shrinkage artificial fibroin fiber whose shrinkage rate defined by a following formula is 2% or more.
Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
[7]
The method for producing a high-shrinkage artificial fibroin fiber according to [6], wherein the modified fibroin is a modified spider silk fibroin.
[8]
The method for producing a high shrinkage artificial fibroin fiber according to [6] or [7], wherein the temperature of the water is 10 to 90 ° C.
[9]
The method for producing high-shrinkage artificial fibroin fiber according to any one of [6] to [8], wherein the shrinkage rate is 7% or less.
[10]
A step of contacting an artificial fibroin fiber containing modified fibroin with water having a boiling point lower than that,
A shrinkage method of artificial fibroin fiber, wherein the shrinkage rate defined by the following formula is 2% or more.
Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
[11]
The method for shrinking artificial fibroin fiber according to [10], wherein the modified fibroin is a modified spider silk fibroin.
[12]
The method for shrinking artificial fibroin fiber according to [10] or [11], wherein the temperature of the water is 10 to 90 ° C.
[13]
The method for shrinking artificial fibroin fiber according to any one of [10] to [12], wherein the shrinkage ratio is 7% or less.
[14]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
The domain sequence has an amino acid sequence with a reduced content of n motif (A) corresponding to deletion of at least one or more (A) n motifs compared to naturally occurring fibroin,
[1] to [5] The high shrinkage artificial fibroin fiber according to any one of [1] to [5], [6] to [9] [13] The method for shrinking artificial fibroin fiber according to any one of [13].
[In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[15]
The domain sequences, as compared to the naturally occurring fibroin, equivalent to at least the N-terminal side to the C-terminal one to three (A) n motif every one (A) n motifs lacking The high-shrinkage artificial fibroin fiber according to [14], the method for producing a high-shrinkage artificial fibroin fiber, or the method for shrinking an artificial fibroin fiber.
[16]
The domain sequences, as compared to the naturally occurring fibroin, at least the N-terminal side of two consecutive towards the C-terminal side from the (A) n motif deletions, and one (A) n motif deletions The high-shrinkage artificial fibroin fiber according to [14], the method for producing a high-shrinkage artificial fibroin fiber, or the method for shrinking an artificial fibroin fiber, which has an amino acid sequence corresponding to repetition in this order.
[17]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
From the N-terminal side to the C-terminal side, compare the number of REP amino acid residues of two adjacent [(A) n motif-REP] units in order, and the number of REP amino acid residues with a small number of amino acid residues. Is the sum of the number of amino acid residues of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of the other REP of 1.8 to 11.3. The high value according to any one of [1] to [5], wherein x / y is 50% or more, where x is the maximum value and y is the total number of amino acid residues in the domain sequence. Shrinkable artificial fibroin fiber, production method of high shrinkage artificial fibroin fiber according to any one of [6] to [9], or shrinkage of artificial fibroin fiber according to any one of [10] to [13] Method.
[In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[18]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
Compared with naturally-occurring fibroin, the content of glycine residues corresponding to at least one or more glycine residues in REP was replaced with another amino acid residue in the domain sequence was reduced. Having an amino acid sequence,
[1] to [5] The high shrinkage artificial fibroin fiber according to any one of [1] to [5], [6] to [9] [13] The method for shrinking artificial fibroin fiber according to any one of [13].
[In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[19]
Compared with naturally occurring fibroin, the domain sequence is at least one or more of at least one motif sequence selected from GGX and GPGXX in REP (where X represents an amino acid residue other than glycine). The high-shrinkage artificial fibroin fiber according to [18], which has an amino acid sequence corresponding to substitution of one glycine residue in the motif sequence with another amino acid residue, Or the shrinkage | contraction method of artificial fibroin fiber.
[20]
The ratio of the motif sequence in which the glycine residue is substituted with another amino acid residue is 10% or more with respect to the entire motif sequence. The high-shrinkage artificial fibroin fiber and the high-shrinkage artificial fibroin fiber according to [19] Production method or shrinkage method of artificial fibroin fiber.
[21]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
XGX contained in all REPs in the sequence excluding the sequence from the domain sequence to the most C-terminal side (A) n motif to the C-terminus of the domain sequence (where X is an amino acid residue other than glycine) The total number of amino acid residues in the amino acid sequence consisting of z) is z, and the domain sequence is located at the most C-terminal side (A) in the sequence excluding the sequence from the n motif to the C-terminus of the domain sequence The high-shrinkage artificial fibroin fiber according to any one of [1] to [5], wherein z / w is 50.9% or more, where w is the total number of amino acid residues in [6] to [6] [9] The method for producing high-shrinkage artificial fibroin fiber according to any one of [9], or the method for shrinking artificial fibroin fiber according to any one of [10] to [13].
[In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[22]
The modified fibroin corresponds to the substitution of one or more glycine residues in REP with another amino acid residue as compared with naturally occurring fibroin, and in addition, one or more amino acid residues The high-shrinkage artificial fibroin fiber and the method for producing the high-shrinkage artificial fibroin fiber according to any one of [18] to [21], which have an amino acid sequence corresponding to substitution, deletion, insertion and / or addition of Or shrinkage method of artificial fibroin fiber.
[23]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
The domain sequence has one or more amino acid residues in REP substituted with amino acid residues having a higher hydrophobicity index and / or one or more hydrophobicity in REP compared to naturally occurring fibroin. Having an amino acid sequence including a region having a large hydrophobic index, which corresponds to insertion of an amino acid residue having a large sex index,
[1] to [5] The high shrinkage artificial fibroin fiber according to any one of [1] to [5], [6] to [9] [13] The method for shrinking artificial fibroin fiber according to any one of [13].
[In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[24]
The high-shrinkage artificial fibroin fiber, the method for producing high-shrinkage artificial fibroin fiber according to [23], or the artificial fibroin, wherein the region having a large local hydrophobicity index is composed of continuous 2 to 4 amino acid residues Fiber shrinkage method.
[25]
The amino acid residue having a large hydrophobicity index is selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A). 23] or [24], a highly shrinkable artificial fibroin fiber, a method for producing a highly shrinkable artificial fibroin fiber, or a method for shrinking an artificial fibroin fiber.
[26]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ,
(A) The average of the hydrophobicity index of four consecutive amino acid residues in all REPs included in the sequence excluding the sequence from the n motif to the C terminus of the domain sequence from the domain sequence. P is the total number of amino acid residues contained in the region where the value is 2.6 or more, and the sequence from the (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence is excluded from the domain sequence. The high shrinkage artificial fibroin fiber according to any one of [1] to [5], wherein p / q is 6.2% or more, where q is the total number of amino acid residues contained in the sequence, [6] to [9] The method for producing high-shrinkage artificial fibroin fibers according to any one of [6] to [9], or the method for shrinking artificial fibroin fibers according to any one of [10] to [13].
[In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[27]
In the modified fibroin, one or more amino acid residues in REP are replaced with amino acid residues having a higher hydrophobicity index and / or one or more hydrophobic groups in REP compared to naturally occurring fibroin. In addition to corresponding to insertion of an amino acid residue having a large sex index, it further has an amino acid sequence corresponding to substitution, deletion, insertion and / or addition of one or more amino acid residues, [23 ] The high shrinkage artificial fibroin fiber, the method for producing the high shrinkage artificial fibroin fiber, or the method for shrinking the artificial fibroin fiber according to any one of [1] to [26].
[28]
The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif;
Glutamine residue content corresponding to the domain sequence having one or more glutamine residues in REP deleted or substituted with other amino acid residues compared to naturally occurring fibroin Has a reduced amino acid sequence,
[1] to [5] The high shrinkage artificial fibroin fiber according to any one of [1] to [5], [6] to [9] [13] The method for shrinking artificial fibroin fiber according to any one of [13].
[In Formula 1 and Formula 2, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues is 80% with respect to the total number of amino acid residues in n motif. That's it. REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
[29]
The high-shrinkage artificial structure according to [28], wherein the modified fibroin includes a GPGXX (where X represents an amino acid residue other than a glycine residue) motif in REP, and the content ratio of the GPGXX motif is 10% or more. A method for producing fibroin fiber, high shrinkage artificial fibroin fiber, or a method for shrinking artificial fibroin fiber.
[30]
The method for producing high-shrinkage artificial fibroin fiber, high-shrinkage artificial fibroin fiber, or method for shrinking artificial fibroin fiber according to [28] or [29], wherein the modified fibroin has a glutamine residue content of 9% or less.
[31]
The other amino acid residues are isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M), alanine (A), glycine (G), threonine ( Any one of [28] to [30], which is an amino acid residue selected from the group consisting of T), serine (S), tryptophan (W), tyrosine (Y), proline (P), and histidine (H) One of the high shrinkage artificial fibroin fibers, the method for producing the high shrinkage artificial fibroin fibers, or the method for shrinking the artificial fibroin fibers.
[32]
The modified fibroin is a highly shrinkable artificial fibroin fiber according to any one of [28] to [31], wherein the hydrophobicity of REP is −0.8 or more, Shrinking method of artificial fibroin fiber.
[33]
In addition to the modified fibroin corresponding to the deletion of one or more glutamine residues in REP or substitution with other amino acid residues as compared to naturally occurring fibroin, The high-shrinkage artificial fibroin fiber or high-shrinkage artificial fiber according to any one of [28] to [32], which has an amino acid sequence corresponding to substitution, deletion, insertion and / or addition of a plurality of amino acid residues A method for producing fibroin fibers or a method for shrinking artificial fibroin fibers.
[34]
The high-shrinkage artificial fibroin fiber according to any one of [1] to [5], wherein the modified fibroin has a limiting oxygen index (LOI) value of 26.0 or more, and any of [6] to [9] The method for producing high shrinkage artificial fibroin fiber according to any one of the above, or the method for shrinking artificial fibroin fiber according to any one of [10] to [13].
[35]
The high-shrinkage artificial fibroin fiber according to any one of [1] to [5], wherein the modified fibroin has a maximum moisture absorption exotherm calculated according to the following formula A of more than 0.025 ° C./g, [6] The method for producing high-shrinkage artificial fibroin fibers according to any one of [9] to [9], or the method for shrinking artificial fibroin fibers according to any one of [10] to [13].
Formula A: Maximum moisture absorption exotherm = {(maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) − (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment)} (° C.) / Sample weight (g)
[In Formula A, a low humidity environment means an environment with a temperature of 20 ° C. and a relative humidity of 40%, and a high humidity environment means an environment with a temperature of 20 ° C. and a relative humidity of 90%. ]
 本発明によれば、充分に高い収縮率を有し、肌触り性及び柔軟性に優れ、しかも安全に製造が可能な高収縮人造フィブロイン繊維、及びその製造方法の提供が可能となる。本発明によればまた、人造フィブロイン繊維を充分に高い収縮率で、安全に得ることができる、人造フィブロイン繊維の収縮方法の提供が可能となる。 According to the present invention, it is possible to provide a high-shrinkage artificial fibroin fiber that has a sufficiently high shrinkage rate, is excellent in touch and flexibility, and can be produced safely, and a method for producing the same. According to the present invention, it is also possible to provide a method for shrinking artificial fibroin fibers, which can safely obtain artificial fibroin fibers with a sufficiently high shrinkage rate.
改変フィブロインのドメイン配列の一例を示す模式図である。It is a schematic diagram which shows an example of the domain arrangement | sequence of a modified fibroin. 天然由来のフィブロインのz/w(%)の値の分布を示す図である。It is a figure which shows distribution of the value of z / w (%) of the fibroin derived from nature. 天然由来のフィブロインのx/y(%)の値の分布を示す図である。It is a figure which shows distribution of the value of x / y (%) of naturally derived fibroin. 改変フィブロインのドメイン配列の一例を示す模式図である。It is a schematic diagram which shows an example of the domain arrangement | sequence of a modified fibroin. 改変フィブロインのドメイン配列の一例を示す模式図である。It is a schematic diagram which shows an example of the domain arrangement | sequence of a modified fibroin. 人造フィブロイン繊維を製造するための紡糸装置の一例を概略的に示す説明図である。It is explanatory drawing which shows roughly an example of the spinning apparatus for manufacturing artificial fibroin fiber. 高収縮人造フィブロイン繊維を製造するための製造装置の一例を概略的に示す説明図である。It is explanatory drawing which shows roughly an example of the manufacturing apparatus for manufacturing a highly shrinkable artificial fibroin fiber. 高収縮人造フィブロイン繊維を製造するための製造装置の一例を概略的に示す説明図である。It is explanatory drawing which shows roughly an example of the manufacturing apparatus for manufacturing a highly shrinkable artificial fibroin fiber. 吸湿発熱性試験の結果の一例を示すグラフである。It is a graph which shows an example of the result of a hygroscopic exothermic test.
 以下、本発明を実施するための形態について詳細に説明する。ただし、本発明は以下の実施形態に限定されるものではない。 Hereinafter, embodiments for carrying out the present invention will be described in detail. However, the present invention is not limited to the following embodiments.
〔高収縮人造フィブロイン繊維〕
 本発明に係る高収縮人造フィブロイン繊維は、改変フィブロインを含む、収縮された人造フィブロイン繊維である。本実施形態に係る高収縮人造フィブロイン繊維は、下記式で定義される収縮率が2%以上である。
 収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
[High shrinkage artificial fibroin fiber]
The highly contracted artificial fibroin fiber according to the present invention is a contracted artificial fibroin fiber containing modified fibroin. The high shrinkage artificial fibroin fiber according to this embodiment has a shrinkage rate defined by the following formula of 2% or more.
Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
<改変フィブロイン>
 本実施形態に係る改変フィブロインは、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むタンパク質である。改変フィブロインは、ドメイン配列のN末端側及びC末端側のいずれか一方又は両方に更にアミノ酸配列(N末端配列及びC末端配列)が付加されていてもよい。N末端配列及びC末端配列は、これに限定されるものではないが、典型的には、フィブロインに特徴的なアミノ酸モチーフの反復を有さない領域であり、100残基程度のアミノ酸からなる。
<Modified fibroin>
The modified fibroin according to the present embodiment has a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif. It is a protein containing. In the modified fibroin, an amino acid sequence (N-terminal sequence and C-terminal sequence) may be further added to either one or both of the N-terminal side and the C-terminal side of the domain sequence. The N-terminal sequence and the C-terminal sequence are not limited to these, but are typically regions having no amino acid motif repeat characteristic of fibroin and consisting of about 100 amino acids.
 本明細書において「改変フィブロイン」とは、人為的に製造されたフィブロイン(人造フィブロイン)を意味する。改変フィブロインは、そのドメイン配列が、天然由来のフィブロインのアミノ酸配列とは異なるフィブロインであってもよく、天然由来のフィブロインのアミノ酸配列と同一であるフィブロインであってもよい。本明細書でいう「天然由来のフィブロイン」もまた、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むタンパク質である。 As used herein, “modified fibroin” means an artificially produced fibroin (artificial fibroin). The modified fibroin may be a fibroin whose domain sequence is different from the amino acid sequence of naturally occurring fibroin or may be the same as the amino acid sequence of naturally occurring fibroin. “Natural fibroin” as used herein is also represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif. A protein comprising a domain sequence to be processed.
 「改変フィブロイン」は、天然由来のフィブロインのアミノ酸配列をそのまま利用したものであってもよく、天然由来のフィブロインのアミノ酸配列に依拠してそのアミノ酸配列を改変したもの(例えば、クローニングした天然由来のフィブロインの遺伝子配列を改変することによりアミノ酸配列を改変したもの)であってもよく、また天然由来のフィブロインに依らず人工的に設計及び合成したもの(例えば、設計したアミノ酸配列をコードする核酸を化学合成することにより所望のアミノ酸配列を有するもの)であってもよい。 The “modified fibroin” may be one that uses the amino acid sequence of naturally-occurring fibroin as it is, or a modified amino acid sequence based on the amino acid sequence of naturally-occurring fibroin (for example, a cloned naturally-derived fibroin). The amino acid sequence may be modified by modifying the gene sequence of fibroin), or artificially designed and synthesized without relying on natural fibroin (for example, a nucleic acid encoding the designed amino acid sequence). It may be one having a desired amino acid sequence by chemical synthesis.
 本明細書において「ドメイン配列」とは、フィブロイン特有の結晶領域(典型的には、アミノ酸配列の(A)モチーフに相当する。)と非晶領域(典型的には、アミノ酸配列のREPに相当する。)を生じるアミノ酸配列であり、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるアミノ酸配列を意味する。ここで、(A)モチーフは、アラニン残基を主とするアミノ酸配列を示し、アミノ酸残基数は2~27である。(A)モチーフのアミノ酸残基数は、2~20、4~27、4~20、8~20、10~20、4~16、8~16、又は10~16の整数であってよい。また、(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数の割合は40%以上であればよく、60%以上、70%以上、80%以上、83%以上、85%以上、86%以上、90%以上、95%以上、又は100%(アラニン残基のみで構成されることを意味する。)であってもよい。ドメイン配列中に複数存在する(A)モチーフは、少なくとも7つがアラニン残基のみで構成されてもよい。REPは2~200アミノ酸残基から構成されるアミノ酸配列を示す。REPは、10~200アミノ酸残基から構成されるアミノ酸配列であってもよく、10~40、10~60、10~80、10~100、10~120、10~140、10~160、又は10~180アミノ酸残基から構成されるアミノ酸配列であってもよい。mは2~300の整数を示し、8~300、10~300、20~300、40~300、60~300、80~300、100~300、10~200、20~200、20~180、20~160、20~140、又は20~120の整数であってもよい。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。 In the present specification, the “domain sequence” refers to a fibroin-specific crystal region (typically corresponding to the (A) n motif in the amino acid sequence) and an amorphous region (typically in the REP of the amino acid sequence). Amino acid sequence that gives rise to the following formula: Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) amino acid represented by n motif Means an array. Here, (A) n motif represents an amino acid sequence mainly composed of alanine residues, and the number of amino acid residues is 2 to 27. (A) The number of amino acid residues of the n motif may be an integer of 2 to 20, 4 to 27, 4 to 20, 8 to 20, 10 to 20, 4 to 16, 8 to 16, or 10 to 16 . In addition, the ratio of the number of alanine residues to the total number of amino acid residues in the (A) n motif may be 40% or more, such as 60% or more, 70% or more, 80% or more, 83% or more, 85% or more, It may be 86% or more, 90% or more, 95% or more, or 100% (meaning that it is composed only of alanine residues). A plurality of (A) n motifs present in the domain sequence may be composed of at least seven alanine residues alone. REP indicates an amino acid sequence composed of 2 to 200 amino acid residues. REP may be an amino acid sequence composed of 10 to 200 amino acid residues, 10 to 40, 10 to 60, 10 to 80, 10 to 100, 10 to 120, 10 to 140, 10 to 160, or It may be an amino acid sequence composed of 10 to 180 amino acid residues. m represents an integer of 2 to 300, 8 to 300, 10 to 300, 20 to 300, 40 to 300, 60 to 300, 80 to 300, 100 to 300, 10 to 200, 20 to 200, 20 to 180, It may be an integer from 20 to 160, 20 to 140, or 20 to 120. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences.
 本実施形態に係る改変フィブロインは、例えば、クローニングした天然由来のフィブロインの遺伝子配列に対し、例えば、1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列の改変を行うことで得ることができる。アミノ酸残基の置換、欠失、挿入及び/又は付加は、部分特異的突然変異誘発法等の当業者に周知の方法により行うことができる。具体的には、Nucleic Acid Res.10,6487(1982)、Methods in Enzymology,100,448(1983)等の文献に記載されている方法に準じて行うことができる。 The modified fibroin according to the present embodiment is, for example, an amino acid sequence corresponding to, for example, substitution, deletion, insertion and / or addition of one or a plurality of amino acid residues to the cloned gene sequence of naturally derived fibroin. It can be obtained by modifying the above. Substitution, deletion, insertion and / or addition of amino acid residues can be carried out by methods well known to those skilled in the art such as partial-directed mutagenesis. Specifically, Nucleic Acid Res. 10, 6487 (1982), Methods in Enzymology, 100, 448 (1983), and the like.
 天然由来のフィブロインは、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むタンパク質であり、具体的には、例えば、昆虫又はクモ類が産生するフィブロインが挙げられる。 Naturally-derived fibroin is a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif. Specific examples include fibroin produced by insects or spiders.
 昆虫が産生するフィブロインとしては、例えば、ボンビックス・モリ(Bombyx mori)、クワコ(Bombyx mandarina)、天蚕(Antheraea yamamai)、柞蚕(Anteraea pernyi)、楓蚕(Eriogyna pyretorum)、蓖蚕(Pilosamia Cynthia ricini)、樗蚕(Samia cynthia)、栗虫(Caligura japonica)、チュッサー蚕(Antheraea mylitta)、ムガ蚕(Antheraea assama)等のカイコが産生する絹タンパク質、及びスズメバチ(Vespa simillima xanthoptera)の幼虫が吐出するホーネットシルクタンパク質が挙げられる。 Examples of fibroin produced by insects include, for example, Bombyx mori, Kwako (Bombyx mandarina), Tenaea (Antheraea palaniii), and 楓 蚕 (Eriothyraminey). ), Silkworms produced by silkworms, such as Samia cythia, chestnut worms (Caligula japonica), Chuser moth (Antherea mylitta), Antheraea assama, and vespax (Vespaxia spp.) Hornet silk protein.
 昆虫が産生するフィブロインのより具体的な例としては、例えば、カイコ・フィブロインL鎖(GenBankアクセッション番号M76430(塩基配列)、及びAAA27840.1(アミノ酸配列))が挙げられる。 More specific examples of fibroin produced by insects include silkworm fibroin L chain (GenBank accession number M76430 (base sequence) and AAA27840.1 (amino acid sequence)).
 クモ類が産生するフィブロインとしては、例えば、オニグモ、ニワオニグモ、アカオニグモ、アオオニグモ及びマメオニグモ等のオニグモ属(Araneus属)に属するクモ、ヤマシロオニグモ、イエオニグモ、ドヨウオニグモ及びサツマノミダマシ等のヒメオニグモ属(Neoscona属)に属するクモ、コオニグモモドキ等のコオニグモモドキ属(Pronus属)に属するクモ、トリノフンダマシ及びオオトリノフンダマシ等のトリノフンダマシ属(Cyrtarachne属)に属するクモ、トゲグモ及びチブサトゲグモ等のトゲグモ属(Gasteracantha属)に属するクモ、マメイタイセキグモ及びムツトゲイセキグモ等のイセキグモ属(Ordgarius属)に属するクモ、コガネグモ、コガタコガネグモ及びナガコガネグモ等のコガネグモ属(Argiope属)に属するクモ、キジロオヒキグモ等のオヒキグモ属(Arachnura属)に属するクモ、ハツリグモ等のハツリグモ属(Acusilas属)に属するクモ、スズミグモ、キヌアミグモ及びハラビロスズミグモ等のスズミグモ属(Cytophora属)に属するクモ、ゲホウグモ等のゲホウグモ属(Poltys属)に属するクモ、ゴミグモ、ヨツデゴミグモ、マルゴミグモ及びカラスゴミグモ等のゴミグモ属(Cyclosa属)に属するクモ、及びヤマトカナエグモ等のカナエグモ属(Chorizopes属)に属するクモが産生するスパイダーシルクタンパク質、並びにアシナガグモ、ヤサガタアシナガグモ、ハラビロアシダカグモ及びウロコアシナガグモ等のアシナガグモ属(Tetragnatha属)に属するクモ、オオシロカネグモ、チュウガタシロカネグモ及びコシロカネグモ等のシロカネグモ属(Leucauge属)に属するクモ、ジョロウグモ及びオオジョロウグモ等のジョロウグモ属(Nephila属)に属するクモ、キンヨウグモ等のアズミグモ属(Menosira属)に属するクモ、ヒメアシナガグモ等のヒメアシナガグモ属(Dyschiriognatha属)に属するクモ、クロゴケグモ、セアカゴケグモ、ハイイロゴケグモ及びジュウサンボシゴケグモ等のゴケグモ属(Latrodectus属)に属するクモ、及びユープロステノプス属(Euprosthenops属)に属するクモ等のアシナガグモ科(Tetragnathidae科)に属するクモが産生するスパイダーシルクタンパク質が挙げられる。スパイダーシルクタンパク質としては、例えば、MaSp(MaSp1及びMaSp2)、ADF(ADF3及びADF4)等の牽引糸タンパク質、MiSp(MiSp1及びMiSp2)等が挙げられる。 Fibroin produced by spiders includes, for example, spiders belonging to the genus spider (Araneus spp.) Such as the spider spider, the spider spider, the red spider spider, and the bean spider, the genus spiders of the genus Araneus, the spider spider spider, the spider spider genus e Spiders, spiders such as spiders, spiders belonging to the genus Spider, spiders belonging to the genus Pronos, spiders belonging to the genus Trinofunda, such as Torinofundamas (genus Cyrtarachne) Spiders belonging to the genus (Gasteracantha), spiders belonging to the genus Spider (Ordgarius genus), such as the spiders, the spiders, and the spiders belonging to the genus Ordgarius Spiders belonging to the genus Argiope, such as the genus Argiope, spiders belonging to the genus Arachnura, such as the white-tailed spider, spiders belonging to the genus Acusilas such as the common spider, the spider belonging to the genus Acusilas, and the genus Spider Spiders belonging to (genus Cytophora), spiders belonging to the genus Spider belonging to the genus Spider (genus Poltys) such as spiders, genus Spider, spiders belonging to the genus Spider belonging to the genus Cyclosa (genus Cyclosa), and spiders belonging to the genus Cyclosa (genus Cyclosa) Spider silk proteins produced by spiders belonging to the genus Chorizopes), and Asina, such as Asagaaga spider, Yasagata Asaga spider, Harabiro Ashida spider and Urokoa Asaga spider Spiders belonging to the genus Tetragnata, spiders belonging to the genus Spider genus (Leucage genus) such as the white spider spider and the white spider spider, the spider genus belonging to the genus Spider genus (Nephila spp. Spiders belonging to the genus Azumigumi (Menosira), spiders belonging to the genus Dyschiriognatha (genus Dyschiriognatha) such as the common spider spider, the black spider spider, the genus Spider genus belonging to the genus Spider belonging to the genus and the genus Spider belonging to the genus Spider belonging to the genus, and Produced by spiders belonging to the family Tetragnathidae such as spiders belonging to the genus Prostenops Examples include spider silk protein. Examples of the spider silk protein include dragline proteins such as MaSp (MaSp1 and MaSp2) and ADF (ADF3 and ADF4), MiSp (MiSp1 and MiSp2), and the like.
 クモ類が産生するスパイダーシルクタンパク質のより具体的な例としては、例えば、fibroin-3(adf-3)[Araneus diadematus由来](GenBankアクセッション番号AAC47010(アミノ酸配列)、U47855(塩基配列))、fibroin-4(adf-4)[Araneus diadematus由来](GenBankアクセッション番号AAC47011(アミノ酸配列)、U47856(塩基配列))、dragline silk protein spidroin 1[Nephila clavipes由来](GenBankアクセッション番号AAC04504(アミノ酸配列)、U37520(塩基配列))、major ampullate spidroin 1[Latrodectus hesperus由来](GenBankアクセッション番号ABR68856(アミノ酸配列)、EF595246(塩基配列))、dragline silk protein spidroin 2[Nephila clavata由来](GenBankアクセッション番号AAL32472(アミノ酸配列)、AF441245(塩基配列))、major ampullate spidroin 1[Euprosthenops australis由来](GenBankアクセッション番号CAJ00428(アミノ酸配列)、AJ973155(塩基配列))、及びmajor ampullate spidroin 2[Euprosthenops australis](GenBankアクセッション番号CAM32249.1(アミノ酸配列)、AM490169(塩基配列))、minor ampullate silk protein 1[Nephila clavipes](GenBankアクセッション番号AAC14589.1(アミノ酸配列))、minor ampullate silk protein 2[Nephila clavipes](GenBankアクセッション番号AAC14591.1(アミノ酸配列))、minor ampullate spidroin-like protein[Nephilengys cruentata](GenBankアクセッション番号ABR37278.1(アミノ酸配列)等が挙げられる。 More specific examples of spider silk proteins produced by spiders include, for example, fibroin-3 (adf-3) [derived from Araneus diadematus] (GenBank accession numbers AAC47010 (amino acid sequence), U47855 (base sequence)), fibroin-4 (adf-4) [derived from Araneus diadematus] (GenBank accession number AAC47011 (amino acid sequence), U47856 (base sequence)), dragline silk protein spiroin 1 [derived from Nephila clavipes] (GenBank amino acid sequence 4) ), U37520 (base sequence)), major ampulate spidro n 1 [derived from Latroductus hesperus] (GenBank accession number ABR68856 (amino acid sequence), EF595246 (base sequence)), dragline silk protein spidrin 2 [derived from Nephila clavata (GenBank accession number AAL32 base sequence 45 AAL32 base sequence amino acid 44, amino acid sequence 44 AAL47) )), Major ampulerate spiroin 1 [from Euprosthenops australis] (GenBank accession numbers CAJ00428 (amino acid sequence), AJ973155 (base sequence)), and major amplospiroid 2 [Euprostenaplas ] (GenBank accession number CAM32249.1 (amino acid sequence), AM490169 (base sequence)), minor sample silk protein 1 [Nephila clubs] (GenBank accession number AAC145891 (amino acid sequence)), minor sample 2 [minolampulapple 2] Nephila clavies] (GenBank accession number AAC14591.1 (amino acid sequence)), minor sample spirodin-like protein [Nephilegenes cruentata] (GenBank accession number ABR37278.1 (amino acid sequence), etc.
 天然由来のフィブロインのより具体的な例としては、更に、NCBI GenBankに配列情報が登録されているフィブロインを挙げることができる。例えば、NCBI GenBankに登録されている配列情報のうちDIVISIONとしてINVを含む配列の中から、DEFINITIONにspidroin、ampullate、fibroin、「silk及びpolypeptide」、又は「silk及びprotein」がキーワードとして記載されている配列、CDSから特定のproductの文字列、SOURCEからTISSUE TYPEに特定の文字列の記載された配列を抽出することにより確認することができる。 More specific examples of naturally derived fibroin include fibroin whose sequence information is registered in NCBI GenBank. For example, spidin, sample, fibroin, “silk and polypeptide”, or “silk and protein” is described as a keyword in DEFINITION from sequences including INV as DIVISION among the sequence information registered in NCBI GenBank. It can be confirmed by extracting a character string of a specific product from the sequence, CDS, and a sequence in which the specific character string is described from SOURCE to TISSUE TYPE.
 本実施形態に係る改変フィブロインは、改変絹(シルク)フィブロイン(カイコが産生する絹タンパク質のアミノ酸配列を改変したもの)であってもよく、改変クモ糸フィブロイン(クモ類が産生するスパイダーシルクタンパク質のアミノ酸配列を改変したもの)であってもよい。改変フィブロインとしては、改変クモ糸フィブロインが好ましい。改変クモ糸フィブロインは、保温性、吸湿発熱性及び/又は難燃性にも優れる。 The modified fibroin according to the present embodiment may be a modified silk fibroin (a modified amino acid sequence of a silk protein produced by a silkworm), or a modified spider silk fibroin (a spider silk protein produced by a spider). It may be a modified amino acid sequence). As the modified fibroin, a modified spider silk fibroin is preferable. The modified spider silk fibroin is excellent in heat retention, moisture absorption heat generation and / or flame retardancy.
 改変フィブロインの具体的な例として、クモの大瓶状腺で産生される大吐糸管しおり糸タンパク質に由来する改変フィブロイン(第1の改変フィブロイン)、グリシン残基の含有量が低減されたドメイン配列を有する改変フィブロイン(第2の改変フィブロイン)、(A)モチーフの含有量が低減されたドメイン配列を有する改変フィブロイン(第3の改変フィブロイン)、グリシン残基の含有量、及び(A)モチーフの含有量が低減された改変フィブロイン(第4の改変フィブロイン)、局所的に疎水性指標の大きい領域を含むドメイン配列を有する改変フィブロイン(第5の改変フィブロイン)、並びにグルタミン残基の含有量が低減されたドメイン配列を有する改変フィブロイン(第6の改変フィブロイン)が挙げられる。 Specific examples of the modified fibroin include a modified fibroin derived from a large sphincter bookmarker protein produced in a large spider gland (first modified fibroin), a domain sequence with a reduced content of glycine residues Modified fibroin (second modified fibroin) having (A) modified fibroin (third modified fibroin) having a domain sequence with reduced content of n motif, content of glycine residue, and (A) n Modified fibroin with reduced motif content (fourth modified fibroin), modified fibroin having a domain sequence that includes a region with a large hydrophobic index locally (fifth modified fibroin), and glutamine residue content Are modified fibroins having a reduced domain sequence (sixth modified fibroin).
 第1の改変フィブロインとしては、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質が挙げられる。第1の改変フィブロインにおいて、(A)モチーフのアミノ酸残基数は、3~20の整数が好ましく、4~20の整数がより好ましく、8~20の整数が更に好ましく、10~20の整数が更により好ましく、4~16の整数が更によりまた好ましく、8~16の整数が特に好ましく、10~16の整数が最も好ましい。第1の改変フィブロインは、式1中、REPを構成するアミノ酸残基の数は、10~200残基であることが好ましく、10~150残基であることがより好ましく、20~100残基であることが更に好ましく、20~75残基であることが更により好ましい。第1の改変フィブロインは、式1:[(A)モチーフ-REP]で表されるアミノ酸配列中に含まれるグリシン残基、セリン残基及びアラニン残基の合計残基数がアミノ酸残基数全体に対して、40%以上であることが好ましく、60%以上であることがより好ましく、70%以上であることが更に好ましい。 Examples of the first modified fibroin include a protein comprising a domain sequence represented by Formula 1: [(A) n motif-REP] m . In the first modified fibroin, (A) the number of amino acid residues of the n motif is preferably an integer of 3 to 20, more preferably an integer of 4 to 20, still more preferably an integer of 8 to 20, and an integer of 10 to 20 Is more preferable, an integer of 4 to 16 is still more preferable, an integer of 8 to 16 is particularly preferable, and an integer of 10 to 16 is most preferable. In the first modified fibroin, in Formula 1, the number of amino acid residues constituting REP is preferably 10 to 200 residues, more preferably 10 to 150 residues, and 20 to 100 residues. More preferably, it is more preferably 20 to 75 residues. In the first modified fibroin, the total number of glycine residues, serine residues and alanine residues contained in the amino acid sequence represented by the formula 1: [(A) n motif-REP] m is an amino acid residue. The total number is preferably 40% or more, more preferably 60% or more, and even more preferably 70% or more.
 第1の改変フィブロインは、式1:[(A)モチーフ-REP]で表されるアミノ酸配列の単位を含み、かつC末端配列が配列番号1~3のいずれかに示されるアミノ酸配列又は配列番号1~3のいずれかに示されるアミノ酸配列と90%以上の相同性を有するアミノ酸配列であるポリペプチドであってもよい。 The first modified fibroin comprises an amino acid sequence unit represented by Formula 1: [(A) n motif-REP] m , and the C-terminal sequence is represented by any one of SEQ ID NOs: 1 to 3 or It may be a polypeptide that is an amino acid sequence having 90% or more homology with the amino acid sequence shown in any one of SEQ ID NOs: 1 to 3.
 配列番号1に示されるアミノ酸配列は、ADF3(GI:1263287、NCBI)のアミノ酸配列のC末端の50残基のアミノ酸からなるアミノ酸配列と同一であり、配列番号2に示されるアミノ酸配列は、配列番号1に示されるアミノ酸配列のC末端から20残基取り除いたアミノ酸配列と同一であり、配列番号3に示されるアミノ酸配列は、配列番号1に示されるアミノ酸配列のC末端から29残基取り除いたアミノ酸配列と同一である。 The amino acid sequence shown in SEQ ID NO: 1 is identical to the amino acid sequence consisting of 50 amino acids at the C-terminal of the amino acid sequence of ADF3 (GI: 1263287, NCBI), and the amino acid sequence shown in SEQ ID NO: 2 is the sequence The amino acid sequence shown in SEQ ID NO: 1 is identical to the amino acid sequence obtained by removing 20 residues from the C-terminal, and the amino acid sequence shown in SEQ ID NO: 3 has 29 residues removed from the C-terminal of the amino acid sequence shown in SEQ ID NO: 1. It is identical to the amino acid sequence.
 第1の改変フィブロインのより具体的な例として、(1-i)配列番号4(recombinant spider silk protein ADF3KaiLargeNRSH1)で示されるアミノ酸配列、又は(1-ii)配列番号4で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。配列同一性は、95%以上であることが好ましい。 As a more specific example of the first modified fibroin, (1-i) an amino acid sequence represented by SEQ ID NO: 4 (recombinant spider silk protein ADF3KaiLargeNRSH1), or (1-ii) an amino acid sequence represented by SEQ ID NO: 4 and 90 Mention may be made of modified fibroin comprising an amino acid sequence having a sequence identity of at least%. The sequence identity is preferably 95% or more.
 配列番号4で示されるアミノ酸配列は、N末端に開始コドン、His10タグ及びHRV3Cプロテアーゼ(Human rhinovirus 3Cプロテアーゼ)認識サイトからなるアミノ酸配列(配列番号5)を付加したADF3のアミノ酸配列において、第1~13番目の反復領域をおよそ2倍になるように増やすとともに、翻訳が第1154番目アミノ酸残基で終止するように変異させたものである。配列番号4で示されるアミノ酸配列のC末端のアミノ酸配列は、配列番号3で示されるアミノ酸配列と同一である。 The amino acid sequence represented by SEQ ID NO: 4 is an amino acid sequence of ADF3 in which an amino acid sequence (SEQ ID NO: 5) consisting of a start codon, a His10 tag and an HRV3C protease (Human rhinovirus 3C protease) recognition site is added to the N-terminus. The 13th repeat region was increased to approximately double, and the translation was mutated to terminate at the 1154th amino acid residue. The C-terminal amino acid sequence of the amino acid sequence shown in SEQ ID NO: 4 is identical to the amino acid sequence shown in SEQ ID NO: 3.
 (1-i)の改変フィブロインは、配列番号4で示されるアミノ酸配列からなるものであってもよい。 The modified fibroin (1-i) may be composed of the amino acid sequence represented by SEQ ID NO: 4.
 第2の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、グリシン残基の含有量が低減されたアミノ酸配列を有する。第2の改変フィブロインは、天然由来のフィブロインと比較して、少なくともREP中の1又は複数のグリシン残基が別のアミノ酸残基に置換されたことに相当するアミノ酸配列を有するものということができる。 The second modified fibroin has an amino acid sequence whose domain sequence has a reduced content of glycine residues compared to naturally occurring fibroin. It can be said that the second modified fibroin has an amino acid sequence corresponding to at least one or more glycine residues in REP substituted with another amino acid residue as compared with naturally occurring fibroin. .
 第2の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、REP中のGGX及びGPGXX(但し、Gはグリシン残基、Pはプロリン残基、Xはグリシン以外のアミノ酸残基を示す。)から選ばれる少なくとも一つのモチーフ配列において、少なくとも1又は複数の当該モチーフ配列中の1つのグリシン残基が別のアミノ酸残基に置換されたことに相当するアミノ酸配列を有するものであってもよい。 The second modified fibroin has a domain sequence of GGX and GPGXX in REP (where G is a glycine residue, P is a proline residue, and X is an amino acid residue other than glycine) as compared to naturally occurring fibroin. In which at least one glycine residue in at least one or more of the motif sequences is substituted with another amino acid residue. May be.
 第2の改変フィブロインは、上述のグリシン残基が別のアミノ酸残基に置換されたモチーフ配列の割合が、全モチーフ配列に対して、10%以上であってもよい。 In the second modified fibroin, the ratio of the motif sequence in which the above glycine residue is replaced with another amino acid residue may be 10% or more with respect to the entire motif sequence.
 第2の改変フィブロインは、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、上記ドメイン配列から、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を除いた配列中の全REPに含まれるXGX(但し、Xはグリシン以外のアミノ酸残基を示す。)からなるアミノ酸配列の総アミノ酸残基数をzとし、上記ドメイン配列から、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を除いた配列中の総アミノ酸残基数をwとしたときに、z/wが30%以上、40%以上、50%以上又は50.9%以上であるアミノ酸配列を有するものであってもよい。(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数は83%以上であってよいが、86%以上であることが好ましく、90%以上であることがより好ましく、95%以上であることが更に好ましく、100%であること(アラニン残基のみで構成されることを意味する)が更により好ましい。 The second modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , and is located on the most C-terminal side from the domain sequence (A) from the n motif to the domain sequence. The total number of amino acid residues in the amino acid sequence consisting of XGX (where X represents an amino acid residue other than glycine) contained in all REPs in the sequence excluding the sequence up to the C-terminal of (A) where the total number of amino acid residues in the sequence excluding the sequence from the n motif located at the most C-terminal side to the C-terminal of the domain sequence is w, z / w is 30% or more, It may have an amino acid sequence that is 40% or more, 50% or more, or 50.9% or more. (A) The number of alanine residues relative to the total number of amino acid residues in the n motif may be 83% or more, preferably 86% or more, more preferably 90% or more, and 95% or more. More preferably, it is 100% (meaning that it is composed only of alanine residues).
 第2の改変フィブロインは、GGXモチーフの1つのグリシン残基を別のアミノ酸残基に置換することにより、XGXからなるアミノ酸配列の含有割合を高めたものであることが好ましい。第2の改変フィブロインは、ドメイン配列中のGGXからなるアミノ酸配列の含有割合が30%以下であることが好ましく、20%以下であることがより好ましく、10%以下であることが更に好ましく、6%以下であることが更により好ましく、4%以下であることが更によりまた好ましく、2%以下であることが特に好ましい。ドメイン配列中のGGXからなるアミノ酸配列の含有割合は、下記XGXからなるアミノ酸配列の含有割合(z/w)の算出方法と同様の方法で算出することができる。 The second modified fibroin is preferably one in which the content ratio of the amino acid sequence consisting of XGX is increased by substituting one glycine residue of the GGX motif with another amino acid residue. In the second modified fibroin, the content ratio of the amino acid sequence consisting of GGX in the domain sequence is preferably 30% or less, more preferably 20% or less, still more preferably 10% or less, % Or less is even more preferable, 4% or less is even more preferable, and 2% or less is particularly preferable. The content ratio of the amino acid sequence consisting of GGX in the domain sequence can be calculated by the same method as the method for calculating the content ratio (z / w) of the amino acid sequence consisting of XGX below.
 z/wの算出方法を更に詳細に説明する。まず、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むフィブロイン(改変フィブロイン又は天然由来のフィブロイン)において、ドメイン配列から、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列を除いた配列に含まれる全てのREPから、XGXからなるアミノ酸配列を抽出する。XGXを構成するアミノ酸残基の総数がzである。例えば、XGXからなるアミノ酸配列が50個抽出された場合(重複はなし)、zは50×3=150である。また、例えば、XGXGXからなるアミノ酸配列の場合のように2つのXGXに含まれるX(中央のX)が存在する場合は、重複分を控除して計算する(XGXGXの場合は5アミノ酸残基である)。wは、ドメイン配列から、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列を除いた配列に含まれる総アミノ酸残基数である。例えば、図1に示したドメイン配列の場合、wは4+50+4+100+4+10+4+20+4+30=230である(最もC末端側に位置する(A)モチーフは除いている。)。次に、zをwで除すことによって、z/w(%)を算出することができる。 The method for calculating z / w will be described in more detail. First, in a fibroin (modified fibroin or naturally-occurring fibroin) containing a domain sequence represented by Formula 1: [(A) n motif-REP] m , (A) n located closest to the C-terminal side from the domain sequence An amino acid sequence consisting of XGX is extracted from all REPs included in the sequence excluding the sequence from the motif to the C-terminal of the domain sequence. The total number of amino acid residues constituting XGX is z. For example, when 50 amino acid sequences consisting of XGX are extracted (no duplication), z is 50 × 3 = 150. Also, for example, when there is an X (center X) included in two XGXs as in the case of an amino acid sequence consisting of XGXGX, the calculation is performed by subtracting the overlap (in the case of XGXGX, it is 5 amino acid residues). is there). w is the total number of amino acid residues contained in the sequence excluding the sequence from the domain sequence to the most C-terminal (A) n motif to the C-terminus of the domain sequence. For example, in the case of the domain sequence shown in FIG. 1, w is 4 + 50 + 4 + 100 + 4 + 10 + 4 + 20 + 4 + 30 = 230 (excluding the (A) n motif located closest to the C-terminal side). Next, z / w (%) can be calculated by dividing z by w.
 ここで、天然由来のフィブロインにおけるz/wについて説明する。まず、上述のように、NCBI GenBankにアミノ酸配列情報が登録されているフィブロインを例示した方法により確認したところ、663種類のフィブロイン(このうち、クモ類由来のフィブロインは415種類)が抽出された。抽出された全てのフィブロインのうち、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、フィブロイン中のGGXからなるアミノ酸配列の含有割合が6%以下である天然由来のフィブロインのアミノ酸配列から、上述の算出方法により、z/wを算出した。その結果を図2に示す。図2の横軸はz/w(%)を示し、縦軸は頻度を示す。図2から明らかなとおり、天然由来のフィブロインにおけるz/wは、いずれも50.9%未満である(最も高いもので、50.86%)。 Here, z / w in naturally derived fibroin will be described. First, as described above, when a fibroin whose amino acid sequence information is registered in NCBI GenBank was confirmed by a method exemplified, 663 types of fibroin (of which 415 types were derived from spiders) were extracted. Of all the extracted fibroin, it is derived from the natural origin including the domain sequence represented by Formula 1: [(A) n motif-REP] m , and the content ratio of the amino acid sequence consisting of GGX in fibroin is 6% or less Z / w was calculated from the amino acid sequence of the fibroin by the calculation method described above. The result is shown in FIG. The horizontal axis in FIG. 2 indicates z / w (%), and the vertical axis indicates frequency. As is clear from FIG. 2, z / w in naturally derived fibroin is less than 50.9% (the highest is 50.86%).
 第2の改変フィブロインにおいて、z/wは、50.9%以上であることが好ましく、56.1%以上であることがより好ましく、58.7%以上であることが更に好ましく、70%以上であることが更により好ましく、80%以上であることが更によりまた好ましい。z/wの上限に特に制限はないが、例えば、95%以下であってもよい。 In the second modified fibroin, z / w is preferably 50.9% or more, more preferably 56.1% or more, further preferably 58.7% or more, and 70% or more. It is still more preferable that it is 80% or more. Although there is no restriction | limiting in particular in the upper limit of z / w, For example, 95% or less may be sufficient.
 第2の改変フィブロインは、例えば、クローニングした天然由来のフィブロインの遺伝子配列から、グリシン残基をコードする塩基配列の少なくとも一部を置換して別のアミノ酸残基をコードするように改変することにより得ることができる。このとき、改変するグリシン残基として、GGXモチーフ及びGPGXXモチーフにおける1つのグリシン残基を選択してもよいし、またz/wが50.9%以上になるように置換してもよい。また、例えば、天然由来のフィブロインのアミノ酸配列から上記態様を満たすアミノ酸配列を設計し、設計したアミノ酸配列をコードする核酸を化学合成することにより得ることもできる。いずれの場合においても、天然由来のフィブロインのアミノ酸配列からREP中のグリシン残基を別のアミノ酸残基に置換したことに相当する改変に加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列の改変を行ってもよい。 The second modified fibroin is obtained by, for example, modifying a cloned natural fibroin gene sequence so as to encode another amino acid residue by substituting at least a part of a base sequence encoding a glycine residue. Obtainable. At this time, one glycine residue in GGX motif and GPGXX motif may be selected as a glycine residue to be modified, or substitution may be performed so that z / w is 50.9% or more. In addition, for example, an amino acid sequence satisfying the above-described aspect can be designed from the amino acid sequence of naturally derived fibroin, and a nucleic acid encoding the designed amino acid sequence can be obtained by chemical synthesis. In any case, in addition to the modification corresponding to the substitution of the glycine residue in REP with another amino acid residue from the amino acid sequence of naturally occurring fibroin, one or more amino acid residues are further substituted or deleted. The amino acid sequence corresponding to the insertion and / or addition may be modified.
 上記の別のアミノ酸残基としては、グリシン残基以外のアミノ酸残基であれば特に制限はないが、バリン(V)残基、ロイシン(L)残基、イソロイシン(I)残基、メチオニン(M)残基、プロリン(P)残基、フェニルアラニン(F)残基及びトリプトファン(W)残基等の疎水性アミノ酸残基、グルタミン(Q)残基、アスパラギン(N)残基、セリン(S)残基、リシン(K)残基及びグルタミン酸(E)残基等の親水性アミノ酸残基が好ましく、バリン(V)残基、ロイシン(L)残基、イソロイシン(I)残基、フェニルアラニン(F)残基及びグルタミン(Q)残基がより好ましく、グルタミン(Q)残基が更に好ましい。 The other amino acid residue is not particularly limited as long as it is an amino acid residue other than a glycine residue, but a valine (V) residue, a leucine (L) residue, an isoleucine (I) residue, M) hydrophobic amino acid residues such as proline (P) residue, phenylalanine (F) residue and tryptophan (W) residue, glutamine (Q) residue, asparagine (N) residue, serine (S ) Residues, hydrophilic amino acid residues such as lysine (K) residues and glutamic acid (E) residues are preferred, and valine (V) residues, leucine (L) residues, isoleucine (I) residues, F) residue and glutamine (Q) residue are more preferred, and glutamine (Q) residue is still more preferred.
 第2の改変フィブロインのより具体的な例として、(2-i)配列番号6(Met-PRT380)、配列番号7(Met-PRT410)、配列番号8(Met-PRT525)若しくは配列番号9(Met-PRT799)で示されるアミノ酸配列、又は(2-ii)配列番号6、配列番号7、配列番号8若しくは配列番号9で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。 More specific examples of the second modified fibroin include (2-i) SEQ ID NO: 6 (Met-PRT380), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525) or SEQ ID NO: 9 (Met -PRT799), or (2-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, Mention may be made of modified fibroin.
 (2-i)の改変フィブロインについて説明する。配列番号6で示されるアミノ酸配列は、天然由来のフィブロインに相当する配列番号10(Met-PRT313)で示されるアミノ酸配列のREP中の全てのGGXをGQXに置換したものである。配列番号7で示されるアミノ酸配列は、配列番号6で示されるアミノ酸配列から、N末端側からC末端側に向かって2つおきに(A)モチーフを欠失させ、更にC末端配列の手前に[(A)モチーフ-REP]を1つ挿入したものである。配列番号8で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列の各(A)モチーフのC末端側に2つのアラニン残基を挿入し、更に一部のグルタミン(Q)残基をセリン(S)残基に置換し、配列番号7の分子量とほぼ同じとなるようにC末端側の一部のアミノ酸を欠失させたものである。配列番号9で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列中に存在する20個のドメイン配列の領域(但し、当該領域のC末端側の数アミノ酸残基が置換されている。)を4回繰り返した配列のC末端に所定のヒンジ配列とHisタグ配列が付加されたものである。 The modified fibroin (2-i) will be described. The amino acid sequence represented by SEQ ID NO: 6 is obtained by substituting GQX for all GGX in the REP of the amino acid sequence represented by SEQ ID NO: 10 (Met-PRT313) corresponding to naturally occurring fibroin. The amino acid sequence represented by SEQ ID NO: 7 is the amino acid sequence represented by SEQ ID NO: 6, wherein every two (A) n motifs are deleted from the N-terminal side to the C-terminal side, and further before the C-terminal sequence. One [(A) n motif-REP] is inserted into the. The amino acid sequence represented by SEQ ID NO: 8 has two alanine residues inserted at the C-terminal side of each (A) n motif of the amino acid sequence represented by SEQ ID NO: 7, and a part of glutamine (Q) residues. Substituted with a serine (S) residue and a part of the amino acid at the C-terminal side was deleted so as to be almost the same as the molecular weight of SEQ ID NO: 7. The amino acid sequence represented by SEQ ID NO: 9 is a region of 20 domain sequences present in the amino acid sequence represented by SEQ ID NO: 7 (however, several amino acid residues on the C-terminal side of the region are substituted). Is obtained by adding a predetermined hinge sequence and a His tag sequence to the C-terminus of the sequence repeated four times.
 配列番号10で示されるアミノ酸配列(天然由来のフィブロインに相当)におけるz/wの値は、46.8%である。配列番号6で示されるアミノ酸配列、配列番号7で示されるアミノ酸配列、配列番号8で示されるアミノ酸配列、及び配列番号9で示されるアミノ酸配列におけるz/wの値は、それぞれ58.7%、70.1%、66.1%及び70.0%である。また、配列番号10、配列番号6、配列番号7、配列番号8及び配列番号9で示されるアミノ酸配列のギザ比率(後述する)1:1.8~11.3におけるx/yの値は、それぞれ15.0%、15.0%、93.4%、92.7%及び89.8%である。 The value of z / w in the amino acid sequence represented by SEQ ID NO: 10 (corresponding to naturally occurring fibroin) is 46.8%. The z / w values of the amino acid sequence shown by SEQ ID NO: 6, the amino acid sequence shown by SEQ ID NO: 7, the amino acid sequence shown by SEQ ID NO: 8, and the amino acid sequence shown by SEQ ID NO: 9 are 58.7%, 70.1%, 66.1% and 70.0%. In addition, the value of x / y at the ratio of the amino acid sequences shown in SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 (described later) 1: 1.8 to 11.3 is: 15.0%, 15.0%, 93.4%, 92.7% and 89.8%, respectively.
 (2-i)の改変フィブロインは、配列番号6、配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列からなるものであってもよい。 The modified fibroin (2-i) may be composed of the amino acid sequence represented by SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
 (2-ii)の改変フィブロインは、配列番号6、配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(2-ii)の改変フィブロインもまた、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin (2-ii) includes an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9. The modified fibroin of (2-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m . The sequence identity is preferably 95% or more.
 (2-ii)の改変フィブロインは、配列番号6、配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列と90%以上の配列同一性を有し、かつREP中に含まれるXGX(但し、Xはグリシン以外のアミノ酸残基を示す。)からなるアミノ酸配列の総アミノ酸残基数をzとし、上記ドメイン配列中のREPの総アミノ酸残基数をwとしたときに、z/wが50.9%以上であることが好ましい。 The modified fibroin of (2-ii) has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and is contained in REP (XGX ( Where X is an amino acid residue other than glycine.) Z / w where z is the total number of amino acid residues of the amino acid sequence consisting of z and w is the total number of amino acid residues of REP in the domain sequence. Is preferably 50.9% or more.
 第2の改変フィブロインは、N末端及びC末端のいずれか一方又は両方にタグ配列を含んでいてもよい。これにより、改変フィブロインの単離、固定化、検出及び可視化等が可能となる。 The second modified fibroin may contain a tag sequence at one or both of the N-terminal and C-terminal. This makes it possible to isolate, immobilize, detect and visualize the modified fibroin.
 タグ配列として、例えば、他の分子との特異的親和性(結合性、アフィニティ)を利用したアフィニティタグを挙げることができる。アフィニティタグの具体例として、ヒスチジンタグ(Hisタグ)を挙げることができる。Hisタグは、ヒスチジン残基が4から10個程度並んだ短いペプチドで、ニッケル等の金属イオンと特異的に結合する性質があるため、金属キレートクロマトグラフィー(chelating metal chromatography)による改変フィブロインの単離に利用することができる。タグ配列の具体例として、例えば、配列番号11で示されるアミノ酸配列(Hisタグ配列及びヒンジ配列を含むアミノ酸配列)が挙げられる。 Examples of tag sequences include affinity tags that use specific affinity (binding property, affinity) with other molecules. Specific examples of the affinity tag include a histidine tag (His tag). The His tag is a short peptide with about 4 to 10 histidine residues, and has the property of binding specifically to metal ions such as nickel. Therefore, the isolation of modified fibroin by metal chelating chromatography (chelating metal chromatography) Can be used. Specific examples of the tag sequence include the amino acid sequence represented by SEQ ID NO: 11 (amino acid sequence including His tag sequence and hinge sequence).
 また、グルタチオンに特異的に結合するグルタチオン-S-トランスフェラーゼ(GST)、マルトースに特異的に結合するマルトース結合タンパク質(MBP)等のタグ配列を利用することもできる。 Tag sequences such as glutathione-S-transferase (GST) that specifically binds to glutathione and maltose-binding protein (MBP) that specifically binds to maltose can also be used.
 さらに、抗原抗体反応を利用した「エピトープタグ」を利用することもできる。抗原性を示すペプチド(エピトープ)をタグ配列として付加することにより、当該エピトープに対する抗体を結合させることができる。エピトープタグとして、HA(インフルエンザウイルスのヘマグルチニンのペプチド配列)タグ、mycタグ、FLAGタグ等を挙げることができる。エピトープタグを利用することにより、高い特異性で容易に改変フィブロインを精製することができる。 Furthermore, an “epitope tag” using an antigen-antibody reaction can also be used. By adding a peptide (epitope) exhibiting antigenicity as a tag sequence, an antibody against the epitope can be bound. As the epitope tag, HA (peptide sequence of hemagglutinin of influenza virus) tag, myc tag, FLAG tag and the like can be mentioned. By using the epitope tag, the modified fibroin can be easily purified with high specificity.
 さらにタグ配列を特定のプロテアーゼで切り離せるようにしたものも使用することができる。当該タグ配列を介して吸着したタンパク質をプロテアーゼ処理することにより、タグ配列を切り離した改変フィブロインを回収することもできる。 Furthermore, a tag sequence that can be separated with a specific protease can also be used. By treating the protein adsorbed via the tag sequence with protease, the modified fibroin from which the tag sequence has been separated can also be recovered.
 タグ配列を含む改変フィブロインのより具体的な例として、(2-iii)配列番号12(PRT380)、配列番号13(PRT410)、配列番号14(PRT525)若しくは配列番号15(PRT799)で示されるアミノ酸配列、又は(2-iv)配列番号12、配列番号13、配列番号14若しくは配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。 As more specific examples of modified fibroin containing a tag sequence, (2-iii) the amino acid represented by SEQ ID NO: 12 (PRT380), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799) Examples include (2-iv) modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in (2-iv) SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. .
 配列番号16(PRT313)、配列番号12、配列番号13、配列番号14及び配列番号15で示されるアミノ酸配列は、それぞれ配列番号10、配列番号6、配列番号7、配列番号8及び配列番号9で示されるアミノ酸配列のN末端に配列番号11で示されるアミノ酸配列(Hisタグ配列及びヒンジ配列を含む)を付加したものである。 The amino acid sequences represented by SEQ ID NO: 16 (PRT313), SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 are SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively. The amino acid sequence shown in SEQ ID NO: 11 (including His tag sequence and hinge sequence) is added to the N-terminus of the amino acid sequence shown.
 (2-iii)の改変フィブロインは、配列番号12、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列からなるものであってもよい。 (2-iii) The modified fibroin may be composed of the amino acid sequence represented by SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
 (2-iv)の改変フィブロインは、配列番号12、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(2-iv)の改変フィブロインもまた、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin (2-iv) includes an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. The modified fibroin of (2-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m . The sequence identity is preferably 95% or more.
 (2-iv)の改変フィブロインは、配列番号12、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有し、かつREP中に含まれるXGX(但し、Xはグリシン以外のアミノ酸残基を示す。)からなるアミノ酸配列の総アミノ酸残基数をzとし、上記ドメイン配列中のREPの総アミノ酸残基数をwとしたときに、z/wが50.9%以上であることが好ましい。 The modified fibroin (2-iv) has an XGX (which has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 and is contained in REP ( Where X is an amino acid residue other than glycine.) Z / w where z is the total number of amino acid residues of the amino acid sequence consisting of z and w is the total number of amino acid residues of REP in the domain sequence. Is preferably 50.9% or more.
 第2の改変フィブロインは、組換えタンパク質生産系において生産されたタンパク質を宿主の外部に放出するための分泌シグナルを含んでいてもよい。分泌シグナルの配列は、宿主の種類に応じて適宜設定することができる。 The second modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host. The sequence of the secretion signal can be appropriately set according to the type of host.
 第3の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、(A)モチーフの含有量が低減されたアミノ酸配列を有する。第3の改変フィブロインのドメイン配列は、天然由来のフィブロインと比較して、少なくとも1又は複数の(A)モチーフが欠失したことに相当するアミノ酸配列を有するものということができる。 The third modified fibroin has an amino acid sequence in which the domain sequence has a reduced content of (A) n motif compared to naturally occurring fibroin. It can be said that the domain sequence of the third modified fibroin has an amino acid sequence corresponding to the deletion of at least one or more (A) n motifs, as compared to naturally occurring fibroin.
 第3の改変フィブロインは、天然由来のフィブロインから(A)モチーフを10~40%欠失させたことに相当するアミノ酸配列を有するものであってもよい。 The third modified fibroin may have an amino acid sequence corresponding to 10% to 40% deletion of the (A) n motif from naturally occurring fibroin.
 第3の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、少なくともN末端側からC末端側に向かって1~3つの(A)モチーフ毎に1つの(A)モチーフが欠失したことに相当するアミノ酸配列を有するものであってもよい。 The third modification fibroin its domain sequence, compared to the naturally occurring fibroin, at least from the N-terminal side toward the C-terminal one to three (A) n motif every one (A) n motif May have an amino acid sequence corresponding to deletion of.
 第3の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、少なくともN末端側からC末端側に向かって2つ連続した(A)モチーフの欠失、及び1つの(A)モチーフの欠失がこの順に繰り返されたことに相当するアミノ酸配列を有するものであってもよい。 The third modified fibroin has a domain sequence that is at least two consecutive from the N-terminal side to the C-terminal side compared to the naturally occurring fibroin (A) deletion of the n motif, and one (A ) It may have an amino acid sequence corresponding to the deletion of the n motif repeated in this order.
 第3の改変フィブロインは、そのドメイン配列が、少なくともN末端側からC末端側に向かって2つおきに(A)モチーフが欠失したことに相当するアミノ酸配列を有するものであってもよい。 The third modified fibroin may have an amino acid sequence whose domain sequence corresponds to that at least every two (A) n motifs are deleted from the N-terminal side to the C-terminal side. .
 第3の改変フィブロインは、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、N末端側からC末端側に向かって、隣合う2つの[(A)モチーフ-REP]ユニットのREPのアミノ酸残基数を順次比較して、アミノ酸残基数が少ないREPのアミノ酸残基数を1としたとき、他方のREPのアミノ酸残基数の比が1.8~11.3となる隣合う2つの[(A)モチーフ-REP]ユニットのアミノ酸残基数を足し合わせた合計値の最大値をxとし、ドメイン配列の総アミノ酸残基数をyとしたときに、x/yが20%以上、30%以上、40%以上又は50%以上であるアミノ酸配列を有するものであってもよい。(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数は83%以上であってよいが、86%以上であることが好ましく、90%以上であることがより好ましく、95%以上であることが更に好ましく、100%であること(アラニン残基のみで構成されることを意味する)が更により好ましい。 The third modified fibroin includes a domain sequence represented by Formula 1: [(A) n motif-REP] m , and two adjacent [(A) n motifs from the N-terminal side toward the C-terminal side. -REP] When the number of amino acid residues in the REP of the unit is sequentially compared, and the number of amino acid residues in the REP with a small number of amino acid residues is 1, the ratio of the number of amino acid residues in the other REP is 1.8 to When the maximum total value of the total number of amino acid residues of two adjacent [(A) n motif-REP] units that becomes 11.3 is x and the total number of amino acid residues in the domain sequence is y In addition, it may have an amino acid sequence in which x / y is 20% or more, 30% or more, 40% or more, or 50% or more. (A) The number of alanine residues relative to the total number of amino acid residues in the n motif may be 83% or more, preferably 86% or more, more preferably 90% or more, and 95% or more. More preferably, it is 100% (meaning that it is composed only of alanine residues).
 x/yの算出方法を図1を参照しながら更に詳細に説明する。図1には、改変フィブロインからN末端配列及びC末端配列を除いたドメイン配列を示す。当該ドメイン配列は、N末端側(左側)から(A)モチーフ-第1のREP(50アミノ酸残基)-(A)モチーフ-第2のREP(100アミノ酸残基)-(A)モチーフ-第3のREP(10アミノ酸残基)-(A)モチーフ-第4のREP(20アミノ酸残基)-(A)モチーフ-第5のREP(30アミノ酸残基)-(A)モチーフという配列を有する。 The method for calculating x / y will be described in more detail with reference to FIG. FIG. 1 shows a domain sequence obtained by removing the N-terminal sequence and the C-terminal sequence from the modified fibroin. The domain sequence is from the N-terminal side (left side): (A) n motif-first REP (50 amino acid residues)-(A) n motif-second REP (100 amino acid residues)-(A) n Motif-third REP (10 amino acid residues)-(A) n motif-fourth REP (20 amino acid residues)-(A) n motif-fifth REP (30 amino acid residues)-(A) It has a sequence called n motif.
 隣合う2つの[(A)モチーフ-REP]ユニットは、重複がないように、N末端側からC末端側に向かって、順次選択する。このとき、選択されない[(A)モチーフ-REP]ユニットが存在してもよい。図1には、パターン1(第1のREPと第2のREPの比較、及び第3のREPと第4のREPの比較)、パターン2(第1のREPと第2のREPの比較、及び第4のREPと第5のREPの比較)、パターン3(第2のREPと第3のREPの比較、及び第4のREPと第5のREPの比較)、パターン4(第1のREPと第2のREPの比較)を示した。なお、これ以外にも選択方法は存在する。 Two adjacent [(A) n motif-REP] units are sequentially selected from the N-terminal side to the C-terminal side so as not to overlap. At this time, an unselected [(A) n motif-REP] unit may exist. FIG. 1 includes pattern 1 (comparison between the first REP and the second REP, and comparison between the third REP and the fourth REP), pattern 2 (comparison between the first REP and the second REP, and 4th REP and 5th REP), pattern 3 (2nd REP and 3rd REP comparison, 4th REP and 5th REP comparison), pattern 4 (first REP and Comparison of the second REP). There are other selection methods.
 次に各パターンについて、選択した隣合う2つの[(A)モチーフ-REP]ユニット中の各REPのアミノ酸残基数を比較する。比較は、よりアミノ酸残基数の少ない方を1としたときの、他方のアミノ酸残基数の比を求めることによって行う。例えば、第1のREP(50アミノ酸残基)と第2のREP(100アミノ酸残基)の比較の場合、よりアミノ酸残基数の少ない第1のREPを1としたとき、第2のREPのアミノ酸残基数の比は、100/50=2である。同様に、第4のREP(20アミノ酸残基)と第5のREP(30アミノ酸残基)の比較の場合、よりアミノ酸残基数の少ない第4のREPを1としたとき、第5のREPのアミノ酸残基数の比は、30/20=1.5である。 Next, for each pattern, the number of amino acid residues of each REP in the two adjacent [(A) n motif-REP] units selected is compared. The comparison is performed by determining the ratio of the number of amino acid residues on the other side when the smaller number of amino acid residues is 1. For example, in the comparison of the first REP (50 amino acid residues) and the second REP (100 amino acid residues), when the first REP having a smaller number of amino acid residues is 1, the second REP The ratio of the number of amino acid residues is 100/50 = 2. Similarly, in the comparison of the fourth REP (20 amino acid residues) and the fifth REP (30 amino acid residues), when the fourth REP having a smaller number of amino acid residues is 1, the fifth REP The ratio of the number of amino acid residues is 30/20 = 1.5.
 図1中、よりアミノ酸残基数の少ない方を1としたときに、他方のアミノ酸残基数の比が1.8~11.3となる[(A)モチーフ-REP]ユニットの組を実線で示した。本明細書中、この比をギザ比率と呼ぶ。よりアミノ酸残基数の少ない方を1としたときに、他方のアミノ酸残基数の比が1.8未満又は11.3超となる[(A)モチーフ-REP]ユニットの組は破線で示した。 In FIG. 1, when the smaller number of amino acid residues is 1, the ratio of the number of other amino acid residues is 1.8 to 11.3 [(A) n motif-REP] unit pairs Shown in solid line. In the present specification, this ratio is referred to as a jagged ratio. When the smaller number of amino acid residues is 1, the ratio of the number of other amino acid residues is less than 1.8 or more than 11.3. [(A) n motif-REP] unit pairs are indicated by broken lines. Indicated.
 各パターンにおいて、実線で示した隣合う2つの[(A)モチーフ-REP]ユニットの全てのアミノ酸残基数を足し合わせる(REPのみではなく、(A)モチーフのアミノ酸残基数もである。)。そして、足し合わせた合計値を比較して、当該合計値が最大となるパターンの合計値(合計値の最大値)をxとする。図1に示した例では、パターン1の合計値が最大である。 In each pattern, the number of all amino acid residues of two adjacent [(A) n motif-REP] units indicated by solid lines is added (not only REP but also (A) the number of amino acid residues of the n motif. is there.). Then, the total value added is compared, and the total value (maximum value of the total value) of the pattern having the maximum total value is set as x. In the example shown in FIG. 1, the total value of pattern 1 is the maximum.
 次に、xをドメイン配列の総アミノ酸残基数yで除すことによって、x/y(%)を算出することができる。 Next, x / y (%) can be calculated by dividing x by the total number of amino acid residues y of the domain sequence.
 第3の改変フィブロインにおいて、x/yは、50%以上であることが好ましく、60%以上であることがより好ましく、65%以上であることが更に好ましく、70%以上であることが更により好ましく、75%以上であることが更によりまた好ましく、80%以上であることが特に好ましい。x/yの上限に特に制限はなく、例えば、100%以下であってよい。ギザ比率が1:1.9~11.3の場合には、x/yは89.6%以上であることが好ましく、ギザ比率が1:1.8~3.4の場合には、x/yは77.1%以上であることが好ましく、ギザ比率が1:1.9~8.4の場合には、x/yは75.9%以上であることが好ましく、ギザ比率が1:1.9~4.1の場合には、x/yは64.2%以上であることが好ましい。 In the third modified fibroin, x / y is preferably 50% or more, more preferably 60% or more, still more preferably 65% or more, and even more preferably 70% or more. Preferably, it is still more preferably 75% or more, and particularly preferably 80% or more. There is no restriction | limiting in particular in the upper limit of x / y, For example, you may be 100% or less. When the jagged ratio is 1: 1.9 to 11.3, x / y is preferably 89.6% or more, and when the jagged ratio is 1: 1.8 to 3.4, x / y / Y is preferably 77.1% or more, and when the jagged ratio is 1: 1.9 to 8.4, x / y is preferably 75.9% or more, and the jagged ratio is 1 In the case of 1.9 to 4.1, x / y is preferably 64.2% or more.
 第3の改変フィブロインが、ドメイン配列中に複数存在する(A)モチーフの少なくとも7つがアラニン残基のみで構成される改変フィブロインである場合、x/yは、46.4%以上であることが好ましく、50%以上であることがより好ましく、55%以上であることが更に好ましく、60%以上であることが更により好ましく、70%以上であることが更によりまた好ましく、80%以上であることが特に好ましい。x/yの上限に特に制限はなく、100%以下であればよい。 A plurality of third modified fibroins are present in the domain sequence (A) When at least 7 of the n motifs are modified fibroins composed of only alanine residues, x / y is 46.4% or more It is preferably 50% or more, more preferably 55% or more, still more preferably 60% or more, still more preferably 70% or more, and more preferably 80% or more. It is particularly preferred. There is no restriction | limiting in particular in the upper limit of x / y, and what is necessary is just 100% or less.
 ここで、天然由来のフィブロインにおけるx/yについて説明する。まず、上述のように、NCBI GenBankにアミノ酸配列情報が登録されているフィブロインを例示した方法により確認したところ、663種類のフィブロイン(このうち、クモ類由来のフィブロインは415種類)が抽出された。抽出された全てのフィブロインのうち、式1:[(A)モチーフ-REP]で表されるドメイン配列で構成される天然由来のフィブロインのアミノ酸配列から、上述の算出方法により、x/yを算出した。ギザ比率が1:1.9~4.1の場合の結果を図3に示す。 Here, x / y in naturally derived fibroin will be described. First, as described above, when a fibroin whose amino acid sequence information is registered in NCBI GenBank was confirmed by a method exemplified, 663 types of fibroin (of which 415 types were derived from spiders) were extracted. Of all the extracted fibroin, x / y is calculated from the amino acid sequence of naturally derived fibroin composed of the domain sequence represented by Formula 1: [(A) n motif-REP] m by the above-described calculation method. Was calculated. FIG. 3 shows the results when the jagged ratio is 1: 1.9 to 4.1.
 図3の横軸はx/y(%)を示し、縦軸は頻度を示す。図3から明らかなとおり、天然由来のフィブロインにおけるx/yは、いずれも64.2%未満である(最も高いもので、64.14%)。 3, the horizontal axis indicates x / y (%), and the vertical axis indicates frequency. As is clear from FIG. 3, x / y in naturally derived fibroin is less than 64.2% (the highest, 64.14%).
 第3の改変フィブロインは、例えば、クローニングした天然由来のフィブロインの遺伝子配列から、x/yが64.2%以上になるように(A)モチーフをコードする配列の1又は複数を欠失させることにより得ることができる。また、例えば、天然由来のフィブロインのアミノ酸配列から、x/yが64.2%以上になるように1又は複数の(A)モチーフが欠失したことに相当するアミノ酸配列を設計し、設計したアミノ酸配列をコードする核酸を化学合成することにより得ることもできる。いずれの場合においても、天然由来のフィブロインのアミノ酸配列から(A)モチーフが欠失したことに相当する改変に加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列の改変を行ってもよい。 In the third modified fibroin, for example, one or a plurality of sequences encoding the n motif is deleted so that x / y is 64.2% or more from the cloned gene sequence of naturally occurring fibroin. Can be obtained. In addition, for example, an amino acid sequence corresponding to the deletion of one or more (A) n motifs is designed so that x / y is 64.2% or more from the amino acid sequence of naturally occurring fibroin. It can also be obtained by chemically synthesizing a nucleic acid encoding the amino acid sequence. In any case, in addition to the modification corresponding to the deletion of the (A) n motif from the amino acid sequence of naturally occurring fibroin, one or more amino acid residues are further substituted, deleted, inserted and / or added. The amino acid sequence corresponding to this may be modified.
 第3の改変フィブロインのより具体的な例として、(3-i)配列番号17(Met-PRT399)、配列番号7(Met-PRT410)、配列番号8(Met-PRT525)若しくは配列番号9(Met-PRT799)で示されるアミノ酸配列、又は(3-ii)配列番号17、配列番号7、配列番号8若しくは配列番号9で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。 More specific examples of the third modified fibroin include (3-i) SEQ ID NO: 17 (Met-PRT399), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), or SEQ ID NO: 9 (Met -PRT799), or (3-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, Mention may be made of modified fibroin.
 (3-i)の改変フィブロインについて説明する。配列番号17で示されるアミノ酸配列は、天然由来のフィブロインに相当する配列番号10(Met-PRT313)で示されるアミノ酸配列から、N末端側からC末端側に向かって2つおきに(A)モチーフを欠失させ、更にC末端配列の手前に[(A)モチーフ-REP]を1つ挿入したものである。配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列は、第2の改変フィブロインで説明したとおりである。 The modified fibroin (3-i) will be described. The amino acid sequence represented by SEQ ID NO: 17 is derived from the amino acid sequence represented by SEQ ID NO: 10 (Met-PRT313) corresponding to naturally-occurring fibroin from the N-terminal side to the C-terminal side every two (A) n The motif is deleted, and one [(A) n motif-REP] is inserted before the C-terminal sequence. The amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 is as described in the second modified fibroin.
 配列番号10で示されるアミノ酸配列(天然由来のフィブロインに相当)のギザ比率1:1.8~11.3におけるx/yの値は15.0%である。配列番号17で示されるアミノ酸配列、及び配列番号7で示されるアミノ酸配列におけるx/yの値は、いずれも93.4%である。配列番号8で示されるアミノ酸配列におけるx/yの値は、92.7%である。配列番号9で示されるアミノ酸配列におけるx/yの値は、89.8%である。配列番号10、配列番号17、配列番号7、配列番号8及び配列番号9で示されるアミノ酸配列におけるz/wの値は、それぞれ46.8%、56.2%、70.1%、66.1%及び70.0%である。 The value of x / y in the amino acid sequence represented by SEQ ID NO: 10 (corresponding to naturally-occurring fibroin) at a jagged ratio of 1: 1.8 to 11.3 is 15.0%. The value of x / y in the amino acid sequence shown by SEQ ID NO: 17 and the amino acid sequence shown by SEQ ID NO: 7 are both 93.4%. The value of x / y in the amino acid sequence represented by SEQ ID NO: 8 is 92.7%. The value of x / y in the amino acid sequence represented by SEQ ID NO: 9 is 89.8%. The z / w values in the amino acid sequences shown in SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 are 46.8%, 56.2%, 70.1% and 66. respectively. 1% and 70.0%.
 (3-i)の改変フィブロインは、配列番号17、配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列からなるものであってもよい。 The modified fibroin (3-i) may consist of the amino acid sequence represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9.
 (3-ii)の改変フィブロインは、配列番号17、配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(3-ii)の改変フィブロインもまた、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin (3-ii) includes an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9. The modified fibroin of (3-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m . The sequence identity is preferably 95% or more.
 (3-ii)の改変フィブロインは、配列番号17、配列番号7、配列番号8又は配列番号9で示されるアミノ酸配列と90%以上の配列同一性を有し、かつN末端側からC末端側に向かって、隣合う2つの[(A)モチーフ-REP]ユニットのREPのアミノ酸残基数を順次比較して、アミノ酸残基数が少ないREPのアミノ酸残基数を1としたとき、他方のREPのアミノ酸残基数の比が1.8~11.3(ギザ比率が1:1.8~11.3)となる隣合う2つの[(A)モチーフ-REP]ユニットのアミノ酸残基数を足し合わせた合計値の最大値をxとし、ドメイン配列の総アミノ酸残基数をyとしたときに、x/yが64.2%以上であることが好ましい。 The modified fibroin of (3-ii) has 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, and from the N-terminal side to the C-terminal side When the number of amino acid residues of REP of two adjacent [(A) n motif-REP] units is sequentially compared, and the number of amino acid residues of REP having a small number of amino acid residues is 1, the other The amino acid residues of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of REP of 1.8 to 11.3 (giza ratio is 1: 1.8 to 11.3) It is preferable that x / y is 64.2% or more, where x is the maximum total value of the total number of bases and y is the total number of amino acid residues in the domain sequence.
 第3の改変フィブロインは、N末端及びC末端のいずれか一方又は両方に上述したタグ配列を含んでいてもよい。 The third modified fibroin may contain the tag sequence described above at one or both of the N-terminal and C-terminal.
 タグ配列を含む改変フィブロインのより具体的な例として、(3-iii)配列番号18(PRT399)、配列番号13(PRT410)、配列番号14(PRT525)若しくは配列番号15(PRT799)で示されるアミノ酸配列、又は(3-iv)配列番号18、配列番号13、配列番号14若しくは配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。 As more specific examples of modified fibroin containing a tag sequence, (3-iii) amino acids represented by SEQ ID NO: 18 (PRT399), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799) And a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the sequence or (3-iv) the amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. .
 配列番号18、配列番号13、配列番号14及び配列番号15で示されるアミノ酸配列は、それぞれ配列番号17、配列番号7、配列番号8及び配列番号9で示されるアミノ酸配列のN末端に配列番号11で示されるアミノ酸配列(Hisタグ配列及びヒンジ配列を含む)を付加したものである。 The amino acid sequences represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 are SEQ ID NO: 11 at the N-terminus of the amino acid sequences represented by SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively. Are added to the amino acid sequence (including His tag sequence and hinge sequence).
 (3-iii)の改変フィブロインは、配列番号18、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列からなるものであってもよい。 (3-iii) The modified fibroin may be composed of the amino acid sequence represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.
 (3-iv)の改変フィブロインは、配列番号18、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(3-iv)の改変フィブロインもまた、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin (3-iv) comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. The modified fibroin of (3-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m . The sequence identity is preferably 95% or more.
 (3-iv)の改変フィブロインは、配列番号18、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有し、かつN末端側からC末端側に向かって、隣合う2つの[(A)モチーフ-REP]ユニットのREPのアミノ酸残基数を順次比較して、アミノ酸残基数が少ないREPのアミノ酸残基数を1としたとき、他方のREPのアミノ酸残基数の比が1.8~11.3となる隣合う2つの[(A)モチーフ-REP]ユニットのアミノ酸残基数を足し合わせた合計値の最大値をxとし、ドメイン配列の総アミノ酸残基数をyとしたときに、x/yが64.2%以上であることが好ましい。 The modified fibroin (3-iv) has a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, and from the N-terminal side to the C-terminal side. When the number of amino acid residues of REP of two adjacent [(A) n motif-REP] units is sequentially compared, and the number of amino acid residues of REP having a small number of amino acid residues is 1, the other X is the maximum total value of the total number of amino acid residues of two adjacent [(A) n motif-REP] units with a ratio of the number of amino acid residues of REP of 1.8 to 11.3. When the total number of amino acid residues of the domain sequence is y, x / y is preferably 64.2% or more.
 第3の改変フィブロインは、組換えタンパク質生産系において生産されたタンパク質を宿主の外部に放出するための分泌シグナルを含んでいてもよい。分泌シグナルの配列は、宿主の種類に応じて適宜設定することができる。 The third modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host. The sequence of the secretion signal can be appropriately set according to the type of host.
 第4の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、(A)モチーフの含有量が低減されたことに加え、グリシン残基の含有量が低減されたアミノ酸配列を有するものである。第4の改変フィブロインのドメイン配列は、天然由来のフィブロインと比較して、少なくとも1又は複数の(A)モチーフが欠失したことに加え、更に少なくともREP中の1又は複数のグリシン残基が別のアミノ酸残基に置換されたことに相当するアミノ酸配列を有するものということができる。すなわち、第4の改変フィブロインは、上述した第2の改変フィブロインと、第3の改変フィブロインの特徴を併せ持つ改変フィブロインである。具体的な態様等は、第2の改変フィブロイン、及び第3の改変フィブロインで説明したとおりである。 The fourth modified fibroin has an amino acid sequence whose domain sequence has a reduced glycine residue content in addition to (A) a reduced content of the n motif compared to naturally occurring fibroin. It is what you have. The domain sequence of the fourth modified fibroin has at least one or more (A) n motifs deleted as compared to naturally occurring fibroin, and at least one or more glycine residues in the REP. It can be said to have an amino acid sequence corresponding to the substitution with another amino acid residue. That is, the fourth modified fibroin is a modified fibroin having the characteristics of the second modified fibroin described above and the third modified fibroin. Specific embodiments and the like are as described in the second modified fibroin and the third modified fibroin.
 第4の改変フィブロインのより具体的な例として、(4-i)配列番号7(Met-PRT410)、配列番号8(Met-PRT525)、配列番号9(Met-PRT799)、配列番号13(PRT410)、配列番号14(PRT525)若しくは配列番号15(PRT799)で示されるアミノ酸配列、又は(4-ii)配列番号7、配列番号8、配列番号9、配列番号13、配列番号14若しくは配列番号15で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。配列番号7、配列番号8、配列番号9、配列番号13、配列番号14又は配列番号15で示されるアミノ酸配列を含む改変フィブロインの具体的な態様は上述のとおりである。 As more specific examples of the fourth modified fibroin, (4-i) SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), SEQ ID NO: 9 (Met-PRT799), SEQ ID NO: 13 (PRT410) ), SEQ ID NO: 14 (PRT525) or SEQ ID NO: 15 (PRT799), or (4-ii) SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 And a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by Specific embodiments of the modified fibroin comprising the amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 are as described above.
 第5の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のアミノ酸残基が疎水性指標の大きいアミノ酸残基に置換されたこと、及び/又はREP中に1又は複数の疎水性指標の大きいアミノ酸残基が挿入されたことに相当する、局所的に疎水性指標の大きい領域を含むアミノ酸配列を有するものであってよい。 The fifth modified fibroin has a domain sequence in which one or more amino acid residues in REP are replaced with amino acid residues having a higher hydrophobicity index and / or REP compared to naturally occurring fibroin. It may have an amino acid sequence including a region having a large hydrophobicity index corresponding to the insertion of one or more amino acid residues having a large hydrophobicity index.
 局所的に疎水性指標の大きい領域は、連続する2~4アミノ酸残基で構成されていることが好ましい。 The region where the hydrophobic index is locally large is preferably composed of 2 to 4 amino acid residues.
 上述の疎水性指標の大きいアミノ酸残基は、イソロイシン(I)、バリン(V)、ロイシン(L)、フェニルアラニン(F)、システイン(C)、メチオニン(M)及びアラニン(A)から選ばれるアミノ酸残基であることがより好ましい。 The amino acid residue having a large hydrophobicity index is an amino acid selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A). More preferably, it is a residue.
 第5の改変フィブロインは、天然由来のフィブロインと比較して、REP中の1又は複数のアミノ酸残基が疎水性指標の大きいアミノ酸残基に置換されたこと、及び/又はREP中に1又は複数の疎水性指標の大きいアミノ酸残基が挿入されたことに相当する改変に加え、更に、天然由来のフィブロインと比較して、1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列の改変があってもよい。 The fifth modified fibroin has one or more amino acid residues in REP substituted with amino acid residues having a higher hydrophobicity index and / or one or more in REP compared to naturally occurring fibroin. In addition to the modification corresponding to the insertion of an amino acid residue having a large hydrophobicity index, further, substitution, deletion, insertion and / or addition of one or more amino acid residues as compared with naturally occurring fibroin There may be amino acid sequence modifications corresponding to the above.
 第5の改変フィブロインは、例えば、クローニングした天然由来のフィブロインの遺伝子配列からREP中の1又は複数の親水性アミノ酸残基(例えば、疎水性指標がマイナスであるアミノ酸残基)を疎水性アミノ酸残基(例えば、疎水性指標がプラスであるアミノ酸残基)に置換すること、及び/又はREP中に1又は複数の疎水性アミノ酸残基を挿入することにより得ることができる。また、例えば、天然由来のフィブロインのアミノ酸配列からREP中の1又は複数の親水性アミノ酸残基を疎水性アミノ酸残基に置換したこと、及び/又はREP中に1又は複数の疎水性アミノ酸残基を挿入したことに相当するアミノ酸配列を設計し、設計したアミノ酸配列をコードする核酸を化学合成することにより得ることもできる。いずれの場合においても、天然由来のフィブロインのアミノ酸配列からREP中の1又は複数の親水性アミノ酸残基を疎水性アミノ酸残基に置換したこと、及び/又はREP中に1又は複数の疎水性アミノ酸残基を挿入したことに相当する改変に加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列の改変を行ってもよい。 For example, the fifth modified fibroin is obtained by removing one or more hydrophilic amino acid residues (for example, amino acid residues having a negative hydrophobicity index) in the REP from the cloned natural fibroin gene sequence. It can be obtained by substituting a group (for example, an amino acid residue having a positive hydrophobicity index) and / or inserting one or more hydrophobic amino acid residues in REP. In addition, for example, one or more hydrophilic amino acid residues in REP are substituted with hydrophobic amino acid residues from the amino acid sequence of naturally occurring fibroin, and / or one or more hydrophobic amino acid residues in REP It can also be obtained by designing an amino acid sequence corresponding to insertion of, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence. In any case, one or more hydrophilic amino acid residues in REP have been replaced with hydrophobic amino acid residues from the amino acid sequence of naturally occurring fibroin and / or one or more hydrophobic amino acids in REP In addition to the modification corresponding to the insertion of a residue, the amino acid sequence corresponding to the substitution, deletion, insertion and / or addition of one or more amino acid residues may be further modified.
 第5の改変フィブロインは、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を上記ドメイン配列から除いた配列に含まれる全てのREPにおいて、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域に含まれるアミノ酸残基の総数をpとし、最もC末端側に位置する(A)モチーフから上記ドメイン配列のC末端までの配列を上記ドメイン配列から除いた配列に含まれるアミノ酸残基の総数をqとしたときに、p/qが6.2%以上であるアミノ酸配列を有してもよい。 The fifth modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m , and is located on the most C-terminal side (A) from the n motif to the C terminus of the domain sequence. In all REPs included in the sequence excluding the sequence from the domain sequence, p is the total number of amino acid residues included in the region where the average value of the hydrophobicity index of four consecutive amino acid residues is 2.6 or more, (A) When the total number of amino acid residues contained in the sequence excluding the sequence from the n motif to the C terminus of the domain sequence, which is located at the most C-terminal side, from the domain sequence is q, p / q is 6 It may have an amino acid sequence that is 2% or more.
 アミノ酸残基の疎水性指標については、公知の指標(Hydropathy index:Kyte J,&Doolittle R(1982)“A simple method for displaying the hydropathic character of a protein”,J.Mol.Biol.,157,pp.105-132)を使用する。具体的には、各アミノ酸の疎水性指標(ハイドロパシー・インデックス、以下「HI」とも記す。)は、下記表1に示すとおりである。 As for the hydrophobicity index of amino acid residues, a known index (Hydropathy index: Kyte J, & Doolittle R (1982) “A simple method for displaying the hydropathic character of bio.p. 7”. 105-132). Specifically, the hydrophobicity index (hydropathic index, hereinafter also referred to as “HI”) of each amino acid is as shown in Table 1 below.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
 p/qの算出方法を更に詳細に説明する。算出には、式1:[(A)モチーフ-REP]で表されるドメイン配列から、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列を除いた配列(以下、「配列A」とする)を用いる。まず、配列Aに含まれる全てのREPにおいて、連続する4アミノ酸残基の疎水性指標の平均値を算出する。疎水性指標の平均値は、連続する4アミノ酸残基に含まれる各アミノ酸残基のHIの総和を4(アミノ酸残基数)で除して求める。疎水性指標の平均値は、全ての連続する4アミノ酸残基について求める(各アミノ酸残基は、1~4回平均値の算出に用いられる。)。次いで、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域を特定する。あるアミノ酸残基が、複数の「疎水性指標の平均値が2.6以上となる連続する4アミノ酸残基」に該当する場合であっても、領域中には1アミノ酸残基として含まれることになる。そして、当該領域に含まれるアミノ酸残基の総数がpである。また、配列Aに含まれるアミノ酸残基の総数がqである。 The method for calculating p / q will be described in more detail. For the calculation, a sequence obtained by removing the sequence from the domain sequence represented by Formula 1: [(A) n motif-REP] m to the most C-terminal side from the domain (A) n motif to the C terminus of the domain sequence. (Hereinafter referred to as “array A”). First, in all REPs included in the sequence A, the average value of the hydrophobicity index of four consecutive amino acid residues is calculated. The average value of the hydrophobicity index is obtained by dividing the total HI of each amino acid residue contained in the four consecutive amino acid residues by 4 (number of amino acid residues). The average value of the hydrophobicity index is obtained for all four consecutive amino acid residues (each amino acid residue is used for calculating the average value 1 to 4 times). Next, a region where the average value of the hydrophobicity index of four consecutive amino acid residues is 2.6 or more is specified. Even if a certain amino acid residue corresponds to a plurality of “four consecutive amino acid residues whose average value of hydrophobicity index is 2.6 or more”, it should be included as one amino acid residue in the region. become. The total number of amino acid residues contained in the region is p. The total number of amino acid residues contained in sequence A is q.
 例えば、「疎水性指標の平均値が2.6以上となる連続する4アミノ酸残基」が20カ所抽出された場合(重複はなし)、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域には、連続する4アミノ酸残基(重複はなし)が20含まれることになり、pは20×4=80である。また、例えば、2つの「疎水性指標の平均値が2.6以上となる連続する4アミノ酸残基」が1アミノ酸残基だけ重複して存在する場合、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域には、7アミノ酸残基含まれることになる(p=2×4-1=7。「-1」は重複分の控除である。)。例えば、図4に示したドメイン配列の場合、「疎水性指標の平均値が2.6以上となる連続する4アミノ酸残基」が重複せずに7つ存在するため、pは7×4=28となる。また、例えば、図4に示したドメイン配列の場合、qは4+50+4+40+4+10+4+20+4+30=170である(C末端側の最後に存在する(A)モチーフは含めない)。次に、pをqで除すことによって、p/q(%)を算出することができる。図4の場合28/170=16.47%となる。 For example, when 20 “four consecutive amino acid residues with an average value of hydrophobicity index of 2.6 or more” are extracted (no overlap), the average value of the hydrophobicity index of four consecutive amino acid residues is 2 The region of .6 or more contains 20 consecutive 4 amino acid residues (no overlap), and p is 20 × 4 = 80. In addition, for example, when two “four consecutive amino acid residues having an average value of hydrophobicity index of 2.6 or more” overlap by one amino acid residue, the hydrophobicity index of four consecutive amino acid residues In the region where the average value of is 2.6 or more, 7 amino acid residues are included (p = 2 × 4-1 = 7, where “−1” is a deduction of duplicates). For example, in the case of the domain sequence shown in FIG. 4, there are seven “4 consecutive amino acid residues with an average value of hydrophobicity index of 2.6 or more” without duplication, and therefore p is 7 × 4 = 28. For example, in the case of the domain sequence shown in FIG. 4, q is 4 + 50 + 4 + 40 + 4 + 10 + 4 + 20 + 4 + 30 = 170 (the (A) n motif present at the end on the C-terminal side is not included). Next, p / q (%) can be calculated by dividing p by q. In the case of FIG. 4, 28/170 = 16.47%.
 第5の改変フィブロインにおいて、p/qは、6.2%以上であることが好ましく、7%以上であることがより好ましく、10%以上であることが更に好ましく、20%以上であることが更により好ましく、30%以上であることが更によりまた好ましい。p/qの上限は、特に制限されないが、例えば、45%以下であってもよい。 In the fifth modified fibroin, p / q is preferably 6.2% or more, more preferably 7% or more, further preferably 10% or more, and preferably 20% or more. Even more preferably, it is still more preferably 30% or more. The upper limit of p / q is not particularly limited, but may be 45% or less, for example.
 第5の改変フィブロインは、例えば、クローニングした天然由来のフィブロインのアミノ酸配列を、上記のp/qの条件を満たすように、REP中の1又は複数の親水性アミノ酸残基(例えば、疎水性指標がマイナスであるアミノ酸残基)を疎水性アミノ酸残基(例えば、疎水性指標がプラスであるアミノ酸残基)に置換すること、及び/又はREP中に1又は複数の疎水性アミノ酸残基を挿入することにより、局所的に疎水性指標の大きい領域を含むアミノ酸配列に改変することにより得ることができる。また、例えば、天然由来のフィブロインのアミノ酸配列から上記のp/qの条件を満たすアミノ酸配列を設計し、設計したアミノ酸配列をコードする核酸を化学合成することにより得ることもできる。いずれの場合においても、天然由来のフィブロインと比較して、REP中の1又は複数のアミノ酸残基が疎水性指標の大きいアミノ酸残基に置換されたこと、及び/又はREP中に1又は複数の疎水性指標の大きいアミノ酸残基が挿入されたことに相当する改変に加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当する改変を行ってもよい。 The fifth modified fibroin is, for example, one or a plurality of hydrophilic amino acid residues (for example, a hydrophobicity index) in the REP so that the amino acid sequence of the naturally-derived fibroin thus cloned satisfies the above p / q condition. Is replaced with a hydrophobic amino acid residue (for example, an amino acid residue with a positive hydrophobicity index) and / or one or more hydrophobic amino acid residues are inserted in the REP By doing so, it can be obtained by locally modifying the amino acid sequence to include a region having a large hydrophobicity index. Alternatively, for example, an amino acid sequence satisfying the above p / q conditions can be designed from the amino acid sequence of naturally derived fibroin, and a nucleic acid encoding the designed amino acid sequence can be obtained by chemical synthesis. In any case, compared to naturally occurring fibroin, one or more amino acid residues in REP were replaced with amino acid residues having a higher hydrophobicity index and / or one or more amino acid residues in REP. In addition to modifications corresponding to insertion of amino acid residues having a large hydrophobicity index, modifications corresponding to substitution, deletion, insertion and / or addition of one or more amino acid residues may be performed. .
 疎水性指標の大きいアミノ酸残基としては、特に制限はないが、イソロイシン(I)、バリン(V)、ロイシン(L)、フェニルアラニン(F)、システイン(C)、メチオニン(M)及びアラニン(A)が好ましく、バリン(V)、ロイシン(L)及びイソロイシン(I)がより好ましい。 The amino acid residue having a large hydrophobicity index is not particularly limited, but isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A ) Are preferred, and valine (V), leucine (L) and isoleucine (I) are more preferred.
 第5の改変フィブロインのより具体的な例として、(5-i)配列番号19(Met-PRT720)、配列番号20(Met-PRT665)若しくは配列番号21(Met-PRT666)で示されるアミノ酸配列、又は(5-ii)配列番号19、配列番号20若しくは配列番号21で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。 As a more specific example of the fifth modified fibroin, (5-i) the amino acid sequence represented by SEQ ID NO: 19 (Met-PRT720), SEQ ID NO: 20 (Met-PRT665) or SEQ ID NO: 21 (Met-PRT666), Or (5-ii) a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
 (5-i)の改変フィブロインについて説明する。配列番号19で示されるアミノ酸配列は、配列番号7(Met-PRT410)で示されるアミノ酸配列に対し、C末端側の端末のドメイン配列を除いて、REP一つ置きにそれぞれ3アミノ酸残基からなるアミノ酸配列(VLI)を2カ所挿入し、更に一部のグルタミン(Q)残基をセリン(S)残基に置換し、かつC末端側の一部のアミノ酸を欠失させたものである。配列番号20で示されるアミノ酸配列は、配列番号8(Met-PRT525)で示されるアミノ酸配列に対し、REP一つ置きにそれぞれ3アミノ酸残基からなるアミノ酸配列(VLI)を1カ所挿入したものである。配列番号21で示されるアミノ酸配列は、配列番号8で示されるアミノ酸配列に対し、REP一つ置きにそれぞれ3アミノ酸残基からなるアミノ酸配列(VLI)を2カ所挿入したものである。 (5) The modified fibroin (5-i) will be described. The amino acid sequence represented by SEQ ID NO: 19 consists of 3 amino acid residues for every other REP with respect to the amino acid sequence represented by SEQ ID NO: 7 (Met-PRT410), excluding the domain sequence of the terminal on the C-terminal side. An amino acid sequence (VLI) is inserted at two positions, a part of glutamine (Q) residues is substituted with a serine (S) residue, and a part of amino acids on the C-terminal side is deleted. The amino acid sequence represented by SEQ ID NO: 20 is an amino acid sequence represented by SEQ ID NO: 8 (Met-PRT525) with one amino acid sequence (VLI) consisting of 3 amino acid residues inserted every other REP. is there. The amino acid sequence shown in SEQ ID NO: 21 is obtained by inserting two amino acid sequences (VLI) each consisting of 3 amino acid residues into the amino acid sequence shown in SEQ ID NO: 8 every other REP.
 (5-i)の改変フィブロインは、配列番号19、配列番号20又は配列番号21で示されるアミノ酸配列からなるものであってもよい。 The modified fibroin (5-i) may be composed of the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.
 (5-ii)の改変フィブロインは、配列番号19、配列番号20又は配列番号21で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(5-ii)の改変フィブロインもまた、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin (5-ii) comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21. The modified fibroin of (5-ii) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m . The sequence identity is preferably 95% or more.
 (5-ii)の改変フィブロインは、配列番号19、配列番号20又は配列番号21で示されるアミノ酸配列と90%以上の配列同一性を有し、かつ最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列に含まれる全てのREPにおいて、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域に含まれるアミノ酸残基の総数をpとし、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列に含まれるアミノ酸残基の総数をqとしたときに、p/qが6.2%以上であることが好ましい。 The modified fibroin of (5-ii) has a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21, and is located on the most C-terminal side (A) n In all REPs included in the sequence excluding the sequence from the motif to the C-terminal of the domain sequence, the amino acids included in the region where the average value of the hydrophobicity index of 4 consecutive amino acid residues is 2.6 or more P is the total number of residues, and (A) When the total number of amino acid residues contained in the sequence excluding the sequence from the n motif to the C terminus of the domain sequence from the domain sequence is q , P / q is preferably 6.2% or more.
 第5の改変フィブロインは、N末端及びC末端のいずれか一方又は両方にタグ配列を含んでいてもよい。 The fifth modified fibroin may contain a tag sequence at one or both of the N-terminal and C-terminal.
 タグ配列を含む改変フィブロインのより具体的な例として、(5-iii)配列番号22(PRT720)、配列番号23(PRT665)若しくは配列番号24(PRT666)で示されるアミノ酸配列、又は(5-iv)配列番号22、配列番号23若しくは配列番号24で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む、改変フィブロインを挙げることができる。 More specific examples of the modified fibroin containing the tag sequence include (5-iii) the amino acid sequence represented by SEQ ID NO: 22 (PRT720), SEQ ID NO: 23 (PRT665) or SEQ ID NO: 24 (PRT666), or (5-iv And a modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24.
 配列番号22、配列番号23及び配列番号24で示されるアミノ酸配列は、それぞれ配列番号19、配列番号20及び配列番号21で示されるアミノ酸配列のN末端に配列番号11で示されるアミノ酸配列(Hisタグ配列及びヒンジ配列を含む)を付加したものである。 The amino acid sequences represented by SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24 are the amino acid sequences represented by SEQ ID NO: 11 (His tag) at the N-terminus of the amino acid sequences represented by SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21, respectively. Including a sequence and a hinge sequence).
 (5-iii)の改変フィブロインは、配列番号22、配列番号23又は配列番号24で示されるアミノ酸配列からなるものであってもよい。 (5-iii) The modified fibroin may be composed of the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.
 (5-iv)の改変フィブロインは、配列番号22、配列番号23又は配列番号24で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(5-iv)の改変フィブロインもまた、式1:[(A)モチーフ-REP]で表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin (5-iv) comprises an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24. The modified fibroin of (5-iv) is also a protein containing a domain sequence represented by Formula 1: [(A) n motif-REP] m . The sequence identity is preferably 95% or more.
 (5-iv)の改変フィブロインは、配列番号22、配列番号23又は配列番号24で示されるアミノ酸配列と90%以上の配列同一性を有し、かつ最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列に含まれる全てのREPにおいて、連続する4アミノ酸残基の疎水性指標の平均値が2.6以上となる領域に含まれるアミノ酸残基の総数をpとし、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列に含まれるアミノ酸残基の総数をqとしたときに、p/qが6.2%以上であることが好ましい。 The modified fibroin of (5-iv) has a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 22, SEQ ID NO: 23 or SEQ ID NO: 24, and is located on the most C-terminal side (A) n In all REPs included in the sequence excluding the sequence from the motif to the C-terminal of the domain sequence, the amino acids included in the region where the average value of the hydrophobicity index of 4 consecutive amino acid residues is 2.6 or more P is the total number of residues, and (A) When the total number of amino acid residues contained in the sequence excluding the sequence from the n motif to the C terminus of the domain sequence from the domain sequence is q , P / q is preferably 6.2% or more.
 第5の改変フィブロインは、組換えタンパク質生産系において生産されたタンパク質を宿主の外部に放出するための分泌シグナルを含んでいてもよい。分泌シグナルの配列は、宿主の種類に応じて適宜設定することができる。 The fifth modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host. The sequence of the secretion signal can be appropriately set according to the type of host.
 第6の改変フィブロインは、天然由来のフィブロインと比較して、グルタミン残基の含有量が低減されたアミノ酸配列を有する。 The sixth modified fibroin has an amino acid sequence in which the content of glutamine residues is reduced compared to naturally occurring fibroin.
 第6の改変フィブロインは、REPのアミノ酸配列中に、GGXモチーフ及びGPGXXモチーフから選ばれる少なくとも一つのモチーフが含まれていることが好ましい。 The sixth modified fibroin preferably contains at least one motif selected from GGX motif and GPGXX motif in the amino acid sequence of REP.
 第6の改変フィブロインが、REP中にGPGXXモチーフを含む場合、GPGXXモチーフ含有率は、通常1%以上であり、5%以上であってもよく、10%以上であるのが好ましい。GPGXXモチーフ含有率の上限に特に制限はなく、50%以下であってよく、30%以下であってもよい。 When the sixth modified fibroin contains a GPGXX motif in REP, the content ratio of the GPGXX motif is usually 1% or more, may be 5% or more, and is preferably 10% or more. There is no restriction | limiting in particular in the upper limit of GPGXX motif content rate, 50% or less may be sufficient and 30% or less may be sufficient.
 本明細書において、「GPGXXモチーフ含有率」は、以下の方法により算出される値である。
 式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むフィブロイン(改変フィブロイン又は天然由来のフィブロイン)において、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列に含まれる全てのREPにおいて、その領域に含まれるGPGXXモチーフの個数の総数を3倍した数(即ち、GPGXXモチーフ中のG及びPの総数に相当)をsとし、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除き、更に(A)モチーフを除いた全REPのアミノ酸残基の総数をtとしたときに、GPGXXモチーフ含有率はs/tとして算出される。
In the present specification, the “GPGXX motif content” is a value calculated by the following method.
Formula 1: [(A) n motif-REP] m , or Formula 2: [(A) n motif-REP] m- (A) fibroin (modified fibroin or naturally derived) containing a domain sequence represented by the n motif In fibroin), the number of GPGXX motifs contained in the region in all REPs contained in the sequence excluding the sequence from the domain sequence (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence. The number obtained by multiplying the total number by three (ie, corresponding to the total number of G and P in the GPGXX motif) is s, and is located at the most C-terminal side. (A) The sequence from the n motif to the C-terminal of the domain sequence is determined from the domain sequence. (A) The content ratio of the GPGXX motif is calculated as s / t, where t is the total number of amino acid residues of all REPs excluding the n motif. It is.
 GPGXXモチーフ含有率の算出において、「最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列」を対象としているのは、「最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列」(REPに相当する配列)には、フィブロインに特徴的な配列と相関性の低い配列が含まれることがあり、mが小さい場合(つまり、ドメイン配列が短い場合)、GPGXXモチーフ含有率の算出結果に影響するので、この影響を排除するためである。なお、REPのC末端に「GPGXXモチーフ」が位置する場合、「XX」が例えば「AA」の場合であっても、「GPGXXモチーフ」として扱う。 In the calculation of the content ratio of the GPGXX motif, “A sequence located at the most C-terminal side (A) excluding the sequence from the n motif to the C-terminal of the domain sequence from the domain sequence” (A) The sequence from the n motif to the C terminus of the domain sequence ”(sequence corresponding to REP) may include a sequence that is not highly correlated with the sequence characteristic of fibroin, and m is small In this case (that is, when the domain sequence is short), the calculation result of the content ratio of the GPGXX motif is affected, so this influence is excluded. When the “GPGXX motif” is located at the C-terminus of REP, even if “XX” is, for example, “AA”, it is treated as “GPGXX motif”.
 図5は、改変フィブロインのドメイン配列を示す模式図である。図5を参照しながらGPGXXモチーフ含有率の算出方法を具体的に説明する。まず、図5に示した改変フィブロインのドメイン配列(「[(A)モチーフ-REP]-(A)モチーフ」タイプである。)では、全てのREPが「最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列」(図5中、「領域A」で示した配列。)に含まれているため、sを算出するためのGPGXXモチーフの個数は7であり、sは7×3=21となる。同様に、全てのREPが「最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列」(図5中、「領域A」で示した配列。)に含まれているため、当該配列から更に(A)モチーフを除いた全REPのアミノ酸残基の総数tは50+40+10+20+30=150である。次に、sをtで除すことによって、s/t(%)を算出することができ、図5の改変フィブロインの場合21/150=14.0%となる。 FIG. 5 is a schematic diagram showing the domain sequence of the modified fibroin. The calculation method of the content ratio of GPGXX motif will be specifically described with reference to FIG. First, in the domain sequence of the modified fibroin shown in FIG. 5 (“[(A) n motif-REP] m- (A) n motif” type), all REPs are “most C-terminally located”. (A) Since it is included in the “sequence excluding the sequence from the n motif to the C terminal of the domain sequence from the domain sequence” (the sequence indicated by “region A” in FIG. 5), The number of GPGXX motifs is 7, and s is 7 × 3 = 21. Similarly, all REPs are “a sequence located at the most C-terminal side (A) The sequence from the n motif to the C-terminal of the domain sequence is excluded from the domain sequence” (the sequence indicated by “region A” in FIG. )), The total number t of amino acid residues of all REPs excluding (A) the n motif from the sequence is 50 + 40 + 10 + 20 + 30 = 150. Next, s / t (%) can be calculated by dividing s by t. In the case of the modified fibroin in FIG. 5, 21/150 = 14.0%.
 第6の改変フィブロインは、グルタミン残基含有率が9%以下であることが好ましく、7%以下であることがより好ましく、4%以下であることが更に好ましく、0%であることが特に好ましい。 The sixth modified fibroin preferably has a glutamine residue content of 9% or less, more preferably 7% or less, still more preferably 4% or less, and particularly preferably 0%. .
 本明細書において、「グルタミン残基含有率」は、以下の方法により算出される値である。
 式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むフィブロイン(改変フィブロイン又は天然由来のフィブロイン)において、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列(図5の「領域A」に相当する配列。)に含まれる全てのREPにおいて、その領域に含まれるグルタミン残基の総数をuとし、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除き、更に(A)モチーフを除いた全REPのアミノ酸残基の総数をtとしたときに、グルタミン残基含有率はu/tとして算出される。グルタミン残基含有率の算出において、「最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列」を対象としている理由は、上述した理由と同様である。
In the present specification, the “glutamine residue content” is a value calculated by the following method.
Formula 1: [(A) n motif-REP] m , or Formula 2: [(A) n motif-REP] m- (A) fibroin (modified fibroin or naturally derived) containing a domain sequence represented by the n motif In fibroin), (A) the sequence from the n- motif to the C-terminal of the domain sequence located on the most C-terminal side (sequence corresponding to “region A” in FIG. 5) is included. In the REP, the total number of glutamine residues contained in the region is u, the sequence from the (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence is excluded from the domain sequence, and (A) n The glutamine residue content is calculated as u / t, where t is the total number of amino acid residues in all REPs excluding the motif. In the calculation of the glutamine residue content rate, the reason why "A sequence located at the most C-terminal side (A) excluding the sequence from the n motif to the C-terminus of the domain sequence from the domain sequence" is the reason described above. It is the same.
 第6の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のグルタミン残基を欠失したこと、又は他のアミノ酸残基に置換したことに相当するアミノ酸配列を有するものであってよい。 The sixth modified fibroin corresponds to its domain sequence having one or more glutamine residues in REP deleted or replaced with other amino acid residues compared to naturally occurring fibroin. It may have an amino acid sequence.
 「他のアミノ酸残基」は、グルタミン残基以外のアミノ酸残基であればよいが、グルタミン残基よりも疎水性指標の大きいアミノ酸残基であることが好ましい。アミノ酸残基の疎水性指標は表1に示すとおりである。 The “other amino acid residue” may be an amino acid residue other than a glutamine residue, but is preferably an amino acid residue having a larger hydrophobicity index than the glutamine residue. Table 1 shows the hydrophobicity index of amino acid residues.
 表1に示すとおり、グルタミン残基よりも疎水性指標の大きいアミノ酸残基としては、イソロイシン(I)、バリン(V)、ロイシン(L)、フェニルアラニン(F)、システイン(C)、メチオニン(M)アラニン(A)、グリシン(G)、スレオニン(T)、セリン(S)、トリプトファン(W)、チロシン(Y)、プロリン(P)及びヒスチジン(H)から選ばれるアミノ酸残基を挙げることができる。これらの中でも、イソロイシン(I)、バリン(V)、ロイシン(L)、フェニルアラニン(F)、システイン(C)、メチオニン(M)及びアラニン(A)から選ばれるアミノ酸残基であることがより好ましく、イソロイシン(I)、バリン(V)、ロイシン(L)及びフェニルアラニン(F)から選ばれるアミノ酸残基であることが更に好ましい。 As shown in Table 1, amino acid residues having a larger hydrophobicity index than glutamine residues include isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M ) Amino acid residues selected from alanine (A), glycine (G), threonine (T), serine (S), tryptophan (W), tyrosine (Y), proline (P) and histidine (H). it can. Among these, an amino acid residue selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) and alanine (A) is more preferable. More preferably, it is an amino acid residue selected from isoleucine (I), valine (V), leucine (L) and phenylalanine (F).
 第6の改変フィブロインは、REPの疎水性度が、-0.8以上であることが好ましく、-0.7以上であることがより好ましく、0以上であることが更に好ましく、0.3以上であることが更により好ましく、0.4以上であることが特に好ましい。REPの疎水性度の上限に特に制限はなく、1.0以下であってよく、0.7以下であってもよい。 In the sixth modified fibroin, the hydrophobicity of REP is preferably −0.8 or more, more preferably −0.7 or more, still more preferably 0 or more, and 0.3 or more. It is still more preferable that it is and it is especially preferable that it is 0.4 or more. There is no restriction | limiting in particular in the upper limit of the hydrophobicity of REP, It may be 1.0 or less and may be 0.7 or less.
 本明細書において、「REPの疎水性度」は、以下の方法により算出される値である。
 式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むフィブロイン(改変フィブロイン又は天然由来のフィブロイン)において、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列(図5の「領域A」に相当する配列。)に含まれる全てのREPにおいて、その領域の各アミノ酸残基の疎水性指標の総和をvとし、最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除き、更に(A)モチーフを除いた全REPのアミノ酸残基の総数をtとしたときに、REPの疎水性度はv/tとして算出される。REPの疎水性度の算出において、「最もC末端側に位置する(A)モチーフからドメイン配列のC末端までの配列をドメイン配列から除いた配列」を対象としている理由は、上述した理由と同様である。
In the present specification, the “hydrophobicity of REP” is a value calculated by the following method.
Formula 1: [(A) n motif-REP] m , or Formula 2: [(A) n motif-REP] m- (A) fibroin (modified fibroin or naturally derived) containing a domain sequence represented by the n motif In fibroin), (A) the sequence from the n- motif to the C-terminal of the domain sequence located on the most C-terminal side (sequence corresponding to “region A” in FIG. 5) is included. In the REP, the sum of the hydrophobicity index of each amino acid residue in the region is represented by v, and the sequence from the (A) n motif located at the most C-terminal side to the C-terminus of the domain sequence is excluded from the domain sequence, and ( A) The hydrophobicity of REP is calculated as v / t, where t is the total number of amino acid residues of all REPs excluding the n motif. In the calculation of the hydrophobicity of REP, the reason why “A sequence located at the most C-terminal side (A) excluding the sequence from the n motif to the C-terminal of the domain sequence from the domain sequence” is the reason described above. It is the same.
 第6の改変フィブロインは、そのドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のグルタミン残基を欠失したこと、及び/又はREP中の1又は複数のグルタミン残基を他のアミノ酸残基に置換したことに相当する改変に加え、更に1又は複数のアミノ酸残基を置換、欠失、挿入及び/又は付加したことに相当するアミノ酸配列の改変があってもよい。 The sixth modified fibroin has its domain sequence deleted one or more glutamine residues in REP and / or one or more glutamine residues in REP compared to naturally occurring fibroin. In addition to modifications corresponding to substitution of other amino acid residues, there may also be amino acid sequence modifications corresponding to substitution, deletion, insertion and / or addition of one or more amino acid residues. .
 第6の改変フィブロインは、例えば、クローニングした天然由来のフィブロインの遺伝子配列からREP中の1又は複数のグルタミン残基を欠失させること、及び/又はREP中の1又は複数のグルタミン残基を他のアミノ酸残基に置換することにより得ることができる。また、例えば、天然由来のフィブロインのアミノ酸配列からREP中の1又は複数のグルタミン残基を欠失したこと、及び/又はREP中の1又は複数のグルタミン残基を他のアミノ酸残基に置換したことに相当するアミノ酸配列を設計し、設計したアミノ酸配列をコードする核酸を化学合成することにより得ることもできる。 The sixth modified fibroin is, for example, deleting one or more glutamine residues in REP from the cloned gene sequence of naturally occurring fibroin and / or other one or more glutamine residues in REP. It can obtain by substituting to the amino acid residue. In addition, for example, one or more glutamine residues in REP are deleted from the amino acid sequence of naturally occurring fibroin, and / or one or more glutamine residues in REP are replaced with other amino acid residues. In particular, it can also be obtained by designing a corresponding amino acid sequence and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
 第6の改変フィブロインのより具体的な例として、(6-i)配列番号25(Met-PRT888)、配列番号26(Met-PRT965)、配列番号27(Met-PRT889)、配列番号28(Met-PRT916)、配列番号29(Met-PRT918)、配列番号30(Met-PRT699)、配列番号31(Met-PRT698)若しくは配列番号32(Met-PRT966)で示されるアミノ酸配列を含む改変フィブロイン、又は(6-ii)配列番号25、配列番号26、配列番号27、配列番号28、配列番号29、配列番号30、配列番号31若しくは配列番号32で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む改変フィブロインを挙げることができる。 More specific examples of the sixth modified fibroin include (6-i) SEQ ID NO: 25 (Met-PRT888), SEQ ID NO: 26 (Met-PRT965), SEQ ID NO: 27 (Met-PRT889), SEQ ID NO: 28 (Met -PRT916), a modified fibroin comprising the amino acid sequence shown in SEQ ID NO: 29 (Met-PRT918), SEQ ID NO: 30 (Met-PRT699), SEQ ID NO: 31 (Met-PRT698) or SEQ ID NO: 32 (Met-PRT966), or (6-ii) 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32 Mention may be made of modified fibroin comprising an amino acid sequence having.
 (6-i)の改変フィブロインについて説明する。配列番号25で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列(Met-PRT410)中のQQを全てVLに置換したものである。配列番号26で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列中のQQを全てTSに置換し、かつ残りのQをAに置換したものである。配列番号27で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列中のQQを全てVLに置換し、かつ残りのQをIに置換したものである。配列番号28で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列中のQQを全てVIに置換し、かつ残りのQをLに置換したものである。配列番号29で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列中のQQを全てVFに置換し、かつ残りのQをIに置換したものである。 The (6-i) modified fibroin will be described. The amino acid sequence represented by SEQ ID NO: 25 is obtained by substituting VL for QQ in the amino acid sequence represented by SEQ ID NO: 7 (Met-PRT410). The amino acid sequence represented by SEQ ID NO: 26 is obtained by substituting all QQs in the amino acid sequence represented by SEQ ID NO: 7 with TS and replacing the remaining Q with A. The amino acid sequence represented by SEQ ID NO: 27 is obtained by substituting all QQs in the amino acid sequence represented by SEQ ID NO: 7 with VL and replacing the remaining Q with I. The amino acid sequence represented by SEQ ID NO: 28 is obtained by replacing all QQs in the amino acid sequence represented by SEQ ID NO: 7 with VI and replacing the remaining Q with L. The amino acid sequence represented by SEQ ID NO: 29 is one in which all QQs in the amino acid sequence represented by SEQ ID NO: 7 are substituted with VF, and the remaining Q is substituted with I.
 配列番号30で示されるアミノ酸配列は、配列番号8で示されるアミノ酸配列(Met-PRT525)中のQQを全てVLに置換したものである。配列番号31で示されるアミノ酸配列は、配列番号8で示されるアミノ酸配列中のQQを全てVLに置換し、かつ残りのQをIに置換したものである。 The amino acid sequence represented by SEQ ID NO: 30 is obtained by substituting VL for all QQs in the amino acid sequence represented by SEQ ID NO: 8 (Met-PRT525). The amino acid sequence shown in SEQ ID NO: 31 is obtained by substituting all QQs in the amino acid sequence shown in SEQ ID NO: 8 with VL and replacing the remaining Q with I.
 配列番号32で示されるアミノ酸配列は、配列番号7で示されるアミノ酸配列(Met-PRT410)中に存在する20個のドメイン配列の領域を2回繰り返した配列中のQQを全てVFに置換し、かつ残りのQをIに置換したものである。 In the amino acid sequence represented by SEQ ID NO: 32, QQ in the sequence in which the region of 20 domain sequences present in the amino acid sequence represented by SEQ ID NO: 7 (Met-PRT410) is repeated twice is substituted with VF, And the remaining Q is replaced with I.
 配列番号25、配列番号26、配列番号27、配列番号28、配列番号29、配列番号30、配列番号31及び配列番号32で示されるアミノ酸配列は、いずれもグルタミン残基含有率は9%以下である(表2)。 The amino acid sequences represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32 all have a glutamine residue content of 9% or less. Yes (Table 2).
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
 (6-i)の改変フィブロインは、配列番号25、配列番号26、配列番号27、配列番号28、配列番号29、配列番号30、配列番号31又は配列番号32で示されるアミノ酸配列からなるものであってもよい。 The modified fibroin (6-i) comprises the amino acid sequence represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32. There may be.
 (6-ii)の改変フィブロインは、配列番号25、配列番号26、配列番号27、配列番号28、配列番号29、配列番号30、配列番号31又は配列番号32で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(6-ii)の改変フィブロインもまた、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin of (6-ii) is 90% or more of the amino acid sequence represented by SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or SEQ ID NO: 32 An amino acid sequence having the following sequence identity is included. The modified fibroin of (6-ii) is also represented by the formula 1: [(A) n motif-REP] m or the formula 2: [(A) n motif-REP] m- (A) n motif. A protein containing a sequence. The sequence identity is preferably 95% or more.
 (6-ii)の改変フィブロインは、グルタミン残基含有率が9%以下であることが好ましい。また、(6-ii)の改変フィブロインは、GPGXXモチーフ含有率が10%以上であることが好ましい。 The modified fibroin (6-ii) preferably has a glutamine residue content of 9% or less. The modified fibroin (6-ii) preferably has a GPGXX motif content of 10% or more.
 第6の改変フィブロインは、N末端及びC末端のいずれか一方又は両方にタグ配列を含んでいてもよい。これにより、改変フィブロインの単離、固定化、検出及び可視化等が可能となる。 The sixth modified fibroin may contain a tag sequence at one or both of the N-terminal and C-terminal. This makes it possible to isolate, immobilize, detect and visualize the modified fibroin.
 タグ配列を含む改変フィブロインのより具体的な例として、(6-iii)配列番号33(PRT888)、配列番号34(PRT965)、配列番号35(PRT889)、配列番号36(PRT916)、配列番号37(PRT918)、配列番号38(PRT699)、配列番号39(PRT698)若しくは配列番号40(PRT966)で示されるアミノ酸配列を含む改変フィブロイン、又は(6-iv)配列番号33、配列番号34、配列番号35、配列番号36、配列番号37、配列番号38、配列番号39若しくは配列番号40で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含む改変フィブロインを挙げることができる。 As more specific examples of modified fibroin containing a tag sequence, (6-iii) SEQ ID NO: 33 (PRT888), SEQ ID NO: 34 (PRT965), SEQ ID NO: 35 (PRT889), SEQ ID NO: 36 (PRT916), SEQ ID NO: 37 (PRT918), SEQ ID NO: 38 (PRT699), SEQ ID NO: 39 (PRT698) or modified fibroin comprising the amino acid sequence shown by SEQ ID NO: 40 (PRT966), or (6-iv) SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, modified fibroin comprising an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 or SEQ ID NO: 40.
 配列番号33、配列番号34、配列番号35、配列番号36、配列番号37、配列番号38、配列番号39及び配列番号40で示されるアミノ酸配列は、それぞれ配列番号25、配列番号26、配列番号27、配列番号28、配列番号29、配列番号30、配列番号31及び配列番号32で示されるアミノ酸配列のN末端に配列番号11で示されるアミノ酸配列(Hisタグ配列及びヒンジ配列を含む)を付加したものである。N末端にタグ配列を付加しただけであるため、グルタミン残基含有率に変化はなく、配列番号33、配列番号34、配列番号35、配列番号36、配列番号37、配列番号38、配列番号39及び配列番号40で示されるアミノ酸配列は、いずれもグルタミン残基含有率が9%以下である(表3)。 The amino acid sequences represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40 are SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, respectively. The amino acid sequence represented by SEQ ID NO: 11 (including His tag sequence and hinge sequence) was added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 and SEQ ID NO: 32. Is. Since only the tag sequence was added to the N-terminus, there was no change in glutamine residue content, and SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39. And the amino acid sequence represented by SEQ ID NO: 40 has a glutamine residue content of 9% or less (Table 3).
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
 (6-iii)の改変フィブロインは、配列番号33、配列番号34、配列番号35、配列番号36、配列番号37、配列番号38、配列番号39又は配列番号40で示されるアミノ酸配列からなるものであってもよい。 The modified fibroin (6-iii) comprises the amino acid sequence represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40. There may be.
 (6-iv)の改変フィブロインは、配列番号33、配列番号34、配列番号35、配列番号36、配列番号37、配列番号38、配列番号39又は配列番号40で示されるアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列を含むものである。(6-iv)の改変フィブロインもまた、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含むタンパク質である。上記配列同一性は、95%以上であることが好ましい。 The modified fibroin of (6-iv) has 90% or more of the amino acid sequence represented by SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 or SEQ ID NO: 40 An amino acid sequence having the following sequence identity is included. The modified fibroin of (6-iv) is also a domain represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif. A protein containing a sequence. The sequence identity is preferably 95% or more.
 (6-iv)の改変フィブロインは、グルタミン残基含有率が9%以下であることが好ましい。また、(6-iv)の改変フィブロインは、GPGXXモチーフ含有率が10%以上であることが好ましい。 The modified fibroin (6-iv) preferably has a glutamine residue content of 9% or less. The modified fibroin (6-iv) preferably has a GPGXX motif content of 10% or more.
 第6の改変フィブロインは、組換えタンパク質生産系において生産されたタンパク質を宿主の外部に放出するための分泌シグナルを含んでいてもよい。分泌シグナルの配列は、宿主の種類に応じて適宜設定することができる。 The sixth modified fibroin may contain a secretion signal for releasing the protein produced in the recombinant protein production system to the outside of the host. The sequence of the secretion signal can be appropriately set according to the type of host.
 改変フィブロインは、第1の改変フィブロイン、第2の改変フィブロイン、第3の改変フィブロイン、第4の改変フィブロイン、第5の改変フィブロイン、及び第6の改変フィブロインが有する特徴のうち、少なくとも2つ以上の特徴を併せ持つ改変フィブロインであってもよい。 The modified fibroin has at least two or more of the characteristics of the first modified fibroin, the second modified fibroin, the third modified fibroin, the fourth modified fibroin, the fifth modified fibroin, and the sixth modified fibroin. It may be a modified fibroin having the following characteristics.
 本実施形態に係る改変フィブロインの限界酸素指数(LOI)値は、18以上、20以上、22以上、24以上、26以上、28以上、29以上、又は30以上であってもよい。本明細書において、LOI値は、「消防危50号(平成7年5月31日付け)」に記載の「粉粒状又は融点の低い合成樹脂の試験方法」に準拠して測定される値である。 The limit oxygen index (LOI) value of the modified fibroin according to this embodiment may be 18 or more, 20 or more, 22 or more, 24 or more, 26 or more, 28 or more, 29 or more, or 30 or more. In this specification, the LOI value is a value measured in accordance with “Test method for powdered or low melting point synthetic resin” described in “Fire Safety No. 50 (May 31, 1995)”. is there.
 本実施形態に係る改変フィブロインの下記式Aに従って求められる最高吸湿発熱度は、0.025℃/g超であってよい。
 式A:最高吸湿発熱度={(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移したときの試料温度の最高値)-(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移すときの試料温度)}(℃)/試料重量(g)
 なお、式A中、低湿度環境は、温度20℃及び相対湿度40%の環境を意味し、高湿度環境は、温度20℃及び相対湿度90%の環境を意味する。
The maximum hygroscopic exotherm calculated | required according to the following formula A of the modified fibroin which concerns on this embodiment may be more than 0.025 degreeC / g.
Formula A: Maximum moisture absorption exotherm = {(maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) − (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment)} (° C.) / Sample weight (g)
In the formula A, a low humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 40%, and a high humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 90%.
 本実施形態に係る改変フィブロインの最高吸湿発熱度は、0.026℃/g以上、0.027℃/g以上、0.028℃/g以上、0.029℃/g以上、0.030℃/g以上、0.035℃/g以上、又は0.040℃/g以上であってもよい。最高吸湿発熱度の上限に特に制限はないが、通常、0.060℃/g以下である。 The maximum moisture absorption exotherm of the modified fibroin according to this embodiment is 0.026 ° C./g or more, 0.027 ° C./g or more, 0.028 ° C./g or more, 0.029 ° C./g or more, 0.030 ° C. / G or more, 0.035 ° C./g or more, or 0.040 ° C./g or more. Although there is no restriction | limiting in particular in the upper limit of the maximum moisture absorption heat generation degree, Usually, it is 0.060 degrees C / g or less.
 本実施形態に係る改変フィブロインは、下記式Bに従って求められる保温性指数が0.20以上であってよい。
 式B:保温性指数=保温率(%)/試料の目付け(g/m
 ここで、本明細書において、保温率は、サーモラボII型試験機(30cm/秒の有風下)を用いたドライコンタクト法で測定した保温率を意味し、後述する参考例に記載の方法により測定される値である。
The modified fibroin according to the present embodiment may have a heat retention index determined according to the following formula B of 0.20 or more.
Formula B: Thermal insulation index = Heat retention ratio (%) / Sample weight (g / m 2 )
Here, in this specification, the heat retention rate means a heat retention rate measured by a dry contact method using a Thermolab II type tester (under wind of 30 cm / second), and is measured by a method described in a reference example described later. Is the value to be
 本実施形態に係る改変フィブロインの保温性指数は、0.22以上であってよく、0.24以上であってよく、0.26以上であってよく、0.28以上であってよく、0.30以上であってよく、0.32以上であってよい。保温性指数の上限に特に制限はないが、例えば、0.60以下、又は0.40以下であってよい。 The heat retention index of the modified fibroin according to this embodiment may be 0.22 or more, may be 0.24 or more, may be 0.26 or more, may be 0.28 or more, and may be 0. .30 or more and 0.32 or more. Although there is no restriction | limiting in particular in the upper limit of a heat retention index | exponent, For example, it may be 0.60 or less or 0.40 or less.
<改変フィブロインの製造方法>
 上記いずれの実施形態に係る改変フィブロインも、例えば、当該改変フィブロインをコードする核酸配列と、当該核酸配列に作動可能に連結された1又は複数の調節配列とを有する発現ベクターで形質転換された宿主により、当該核酸を発現させることにより生産することができる。
<Method for producing modified fibroin>
The modified fibroin according to any of the above embodiments is, for example, a host transformed with an expression vector having a nucleic acid sequence encoding the modified fibroin and one or more regulatory sequences operably linked to the nucleic acid sequence. Can be produced by expressing the nucleic acid.
 改変フィブロインをコードする核酸の製造方法は、特に制限されない。例えば、天然のフィブロインをコードする遺伝子を利用して、ポリメラーゼ連鎖反応(PCR)などで増幅しクローニングし、遺伝子工学的手法により改変する方法、又は、化学的に合成する方法によって、当該核酸を製造することができる。核酸の化学的な合成方法も特に制限されず、例えば、NCBIのウェブデータベースなどより入手したフィブロインのアミノ酸配列情報をもとに、AKTA oligopilot plus 10/100(GEヘルスケア・ジャパン株式会社)などで自動合成したオリゴヌクレオチドをPCRなどで連結する方法によって遺伝子を化学的に合成することができる。この際に、改変フィブロインの精製及び/又は確認を容易にするため、上記のアミノ酸配列のN末端に開始コドン及びHis10タグからなるアミノ酸配列を付加したアミノ酸配列からなる改変フィブロインをコードする核酸を合成してもよい。 The method for producing the nucleic acid encoding the modified fibroin is not particularly limited. For example, using the gene encoding natural fibroin, the nucleic acid is produced by a method such as amplification by polymerase chain reaction (PCR), cloning, modification by genetic engineering techniques, or chemical synthesis. can do. The method for chemically synthesizing nucleic acids is not particularly limited. For example, based on the amino acid sequence information of fibroin obtained from the NCBI web database, etc., AKTA oligopilot plus 10/100 (GE Healthcare Japan Co., Ltd.) A gene can be chemically synthesized by a method of linking oligonucleotides that are synthesized automatically by PCR or the like. At this time, in order to facilitate purification and / or confirmation of the modified fibroin, a nucleic acid encoding the modified fibroin consisting of an amino acid sequence in which an amino acid sequence consisting of a start codon and a His10 tag is added to the N terminus of the above amino acid sequence is synthesized. May be.
 調節配列は、宿主における改変フィブロインの発現を制御する配列(例えば、プロモーター、エンハンサー、リボソーム結合配列、転写終結配列等)であり、宿主の種類に応じて適宜選択することができる。プロモーターとして、宿主細胞中で機能し、改変フィブロインを発現誘導可能な誘導性プロモーターを用いてもよい。誘導性プロモーターは、誘導物質(発現誘導剤)の存在、リプレッサー分子の非存在、又は温度、浸透圧若しくはpH値の上昇若しくは低下等の物理的要因により、転写を制御できるプロモーターである。 Regulatory sequences are sequences that control the expression of modified fibroin in the host (for example, promoters, enhancers, ribosome binding sequences, transcription termination sequences, etc.), and can be appropriately selected depending on the type of host. As the promoter, an inducible promoter that functions in the host cell and can induce expression of the modified fibroin may be used. An inducible promoter is a promoter that can control transcription by the presence of an inducer (expression inducer), absence of a repressor molecule, or physical factors such as an increase or decrease in temperature, osmotic pressure or pH value.
 発現ベクターの種類は、プラスミドベクター、ウイルスベクター、コスミドベクター、フォスミドベクター、人工染色体ベクター等、宿主の種類に応じて適宜選択することができる。発現ベクターとしては、宿主細胞において自立複製が可能、又は宿主の染色体中への組込みが可能で、改変フィブロインをコードする核酸を転写できる位置にプロモーターを含有しているものが好適に用いられる。 The type of expression vector can be appropriately selected according to the type of host, such as a plasmid vector, virus vector, cosmid vector, fosmid vector, artificial chromosome vector, and the like. As the expression vector, a vector that can replicate autonomously in a host cell or can be integrated into a host chromosome and contains a promoter at a position where a nucleic acid encoding a modified fibroin can be transcribed is preferably used.
 宿主として、原核生物、並びに酵母、糸状真菌、昆虫細胞、動物細胞及び植物細胞等の真核生物のいずれも好適に用いることができる。 As the host, any of prokaryotes and eukaryotes such as yeast, filamentous fungi, insect cells, animal cells and plant cells can be preferably used.
 原核生物の宿主の好ましい例として、エシェリヒア属、ブレビバチルス属、セラチア属、バチルス属、ミクロバクテリウム属、ブレビバクテリウム属、コリネバクテリウム属及びシュードモナス属等に属する細菌を挙げることができる。エシェリヒア属に属する微生物として、例えば、エシェリヒア・コリ等を挙げることができる。ブレビバチルス属に属する微生物として、例えば、ブレビバチルス・アグリ等を挙げることができる。セラチア属に属する微生物として、例えば、セラチア・リクエファシエンス等を挙げることができる。バチルス属に属する微生物として、例えば、バチルス・サチラス等を挙げることができる。ミクロバクテリウム属に属する微生物として、例えば、ミクロバクテリウム・アンモニアフィラム等を挙げることができる。ブレビバクテリウム属に属する微生物として、例えば、ブレビバクテリウム・ディバリカタム等を挙げることができる。コリネバクテリウム属に属する微生物として、例えば、コリネバクテリウム・アンモニアゲネス等を挙げることができる。シュードモナス(Pseudomonas)属に属する微生物として、例えば、シュードモナス・プチダ等を挙げることができる。 Preferred examples of prokaryotic hosts include bacteria belonging to the genus Escherichia, Brevibacillus, Serratia, Bacillus, Microbacterium, Brevibacterium, Corynebacterium, Pseudomonas and the like. Examples of microorganisms belonging to the genus Escherichia include Escherichia coli. Examples of microorganisms belonging to the genus Brevibacillus include Brevibacillus agri and the like. Examples of microorganisms belonging to the genus Serratia include Serratia liqufaciens and the like. Examples of microorganisms belonging to the genus Bacillus include Bacillus subtilis. Examples of microorganisms belonging to the genus Microbacterium include microbacterium / ammonia film. Examples of microorganisms belonging to the genus Brevibacterium include Brevibacterium divaricatam. Examples of microorganisms belonging to the genus Corynebacterium include Corynebacterium ammoniagenes. Examples of microorganisms belonging to the genus Pseudomonas include Pseudomonas putida.
 原核生物を宿主とする場合、改変フィブロインをコードする核酸を導入するベクターとしては、例えば、pBTrp2(ベーリンガーマンハイム社製)、pGEX(Pharmacia社製)、pUC18、pBluescriptII、pSupex、pET22b、pCold、pUB110、pNCO2(特開2002-238569号公報)等を挙げることができる。 When a prokaryotic host is used, vectors for introducing a nucleic acid encoding a modified fibroin include, for example, pBTrp2 (manufactured by Boehringer Mannheim), pGEX (manufactured by Pharmacia), pUC18, pBluescriptII, pSupex, pET22b, pCold, pUB110, pNCO2 (Japanese Patent Laid-Open No. 2002-238696) and the like can be mentioned.
 真核生物の宿主としては、例えば、酵母及び糸状真菌(カビ等)を挙げることができる。酵母としては、例えば、サッカロマイセス属、ピキア属、シゾサッカロマイセス属等に属する酵母を挙げることができる。糸状真菌としては、例えば、アスペルギルス属、ペニシリウム属、トリコデルマ(Trichoderma)属等に属する糸状真菌を挙げることができる。 Examples of eukaryotic hosts include yeast and filamentous fungi (molds, etc.). Examples of the yeast include yeasts belonging to the genus Saccharomyces, Pichia, Schizosaccharomyces and the like. Examples of the filamentous fungi include filamentous fungi belonging to the genus Aspergillus, the genus Penicillium, the genus Trichoderma and the like.
 真核生物を宿主とする場合、改変フィブロインをコードする核酸を導入するベクターとしては、例えば、YEp13(ATCC37115)、YEp24(ATCC37051)等を挙げることができる。上記宿主細胞への発現ベクターの導入方法としては、上記宿主細胞へDNAを導入する方法であればいずれも用いることができる。例えば、カルシウムイオンを用いる方法〔Proc. Natl. Acad. Sci. USA,69,2110(1972)〕、エレクトロポレーション法、スフェロプラスト法、プロトプラスト法、酢酸リチウム法、コンピテント法等を挙げることができる。 When a eukaryote is used as a host, examples of a vector into which a nucleic acid encoding a modified fibroin is introduced include YEp13 (ATCC37115) and YEp24 (ATCC37051). As a method for introducing the expression vector into the host cell, any method can be used as long as it is a method for introducing DNA into the host cell. For example, a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], electroporation method, spheroplast method, protoplast method, lithium acetate method, competent method, and the like.
 発現ベクターで形質転換された宿主による核酸の発現方法としては、直接発現のほか、モレキュラー・クローニング第2版に記載されている方法等に準じて、分泌生産、融合タンパク質発現等を行うことができる。 As a method for expressing a nucleic acid by a host transformed with an expression vector, in addition to direct expression, secretory production, fusion protein expression, etc. can be performed according to the method described in Molecular Cloning 2nd edition, etc. .
 改変フィブロインは、例えば、発現ベクターで形質転換された宿主を培養培地中で培養し、培養培地中に当該改変フィブロインを生成及び蓄積させ、該培養培地から採取することにより製造することができる。宿主を培養培地中で培養する方法は、宿主の培養に通常用いられる方法に従って行うことができる。 The modified fibroin can be produced, for example, by culturing a host transformed with an expression vector in a culture medium, generating and accumulating the modified fibroin in the culture medium, and collecting from the culture medium. The method for culturing a host in a culture medium can be performed according to a method usually used for culturing a host.
 宿主が、大腸菌等の原核生物又は酵母等の真核生物である場合、培養培地として、宿主が資化し得る炭素源、窒素源及び無機塩類等を含有し、宿主の培養を効率的に行える培地であれば天然培地及び合成培地のいずれを用いてもよい。 When the host is a prokaryotic organism such as Escherichia coli or a eukaryotic organism such as yeast, the culture medium contains a carbon source, nitrogen source, inorganic salts, etc. that can be assimilated by the host, and can efficiently culture the host. If so, either a natural medium or a synthetic medium may be used.
 炭素源としては、上記形質転換微生物が資化し得るものであればよく、例えば、グルコース、フラクトース、スクロース、及びこれらを含有する糖蜜、デンプン及びデンプン加水分解物等の炭水化物、酢酸及びプロピオン酸等の有機酸、並びにエタノール及びプロパノール等のアルコール類を用いることができる。窒素源としては、例えば、アンモニア、塩化アンモニウム、硫酸アンモニウム、酢酸アンモニウム及びリン酸アンモニウム等の無機酸又は有機酸のアンモニウム塩、その他の含窒素化合物、並びにペプトン、肉エキス、酵母エキス、コーンスチープリカー、カゼイン加水分解物、大豆粕及び大豆粕加水分解物、各種発酵菌体及びその消化物を用いることができる。無機塩類としては、例えば、リン酸第一カリウム、リン酸第二カリウム、リン酸マグネシウム、硫酸マグネシウム、塩化ナトリウム、硫酸第一鉄、硫酸マンガン、硫酸銅及び炭酸カルシウムを用いることができる。 Any carbon source may be used as long as it can be assimilated by the above-mentioned transformed microorganism. Examples thereof include glucose, fructose, sucrose, and carbohydrates such as molasses, starch and starch hydrolyzate, acetic acid and propionic acid, etc. Organic acids and alcohols such as ethanol and propanol can be used. Examples of the nitrogen source include ammonium salts of inorganic acids or organic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, and ammonium phosphate, other nitrogen-containing compounds, and peptone, meat extract, yeast extract, corn steep liquor, Casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented cells and digested products thereof can be used. As inorganic salts, for example, monopotassium phosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate and calcium carbonate can be used.
 大腸菌等の原核生物又は酵母等の真核生物の培養は、例えば、振盪培養又は深部通気攪拌培養等の好気的条件下で行うことができる。培養温度は、例えば、15~40℃である。培養時間は、通常16時間~7日間である。培養中の培養培地のpHは3.0~9.0に保持することが好ましい。培養培地のpHの調整は、無機酸、有機酸、アルカリ溶液、尿素、炭酸カルシウム及びアンモニア等を用いて行うことができる。 Cultivation of prokaryotes such as E. coli or eukaryotes such as yeast can be performed under aerobic conditions such as shaking culture or deep aeration and agitation culture. The culture temperature is, for example, 15 to 40 ° C. The culture time is usually 16 hours to 7 days. The pH of the culture medium during the culture is preferably maintained at 3.0 to 9.0. The pH of the culture medium can be adjusted using an inorganic acid, an organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like.
 また、培養中、必要に応じて、アンピシリン及びテトラサイクリン等の抗生物質を培養培地に添加してもよい。プロモーターとして誘導性のプロモーターを用いた発現ベクターで形質転換した微生物を培養するときには、必要に応じてインデューサーを培地に添加してもよい。例えば、lacプロモーターを用いた発現ベクターで形質転換した微生物を培養するときにはイソプロピル-β-D-チオガラクトピラノシド等を、trpプロモーターを用いた発現ベクターで形質転換した微生物を培養するときにはインドールアクリル酸等を培地に添加してもよい。 Moreover, during the culture, antibiotics such as ampicillin and tetracycline may be added to the culture medium as necessary. When culturing a microorganism transformed with an expression vector using an inducible promoter as a promoter, an inducer may be added to the medium as necessary. For example, isopropyl-β-D-thiogalactopyranoside is used when cultivating a microorganism transformed with an expression vector using the lac promoter, and indole acrylic is used when culturing a microorganism transformed with an expression vector using the trp promoter. An acid or the like may be added to the medium.
 発現させた改変フィブロインの単離及び精製は通常用いられている方法で行うことができる。例えば、当該改変フィブロインが、細胞内に溶解状態で発現した場合には、培養終了後、宿主細胞を遠心分離により回収し、水系緩衝液に懸濁した後、超音波破砕機、フレンチプレス、マントンガウリンホモゲナイザー及びダイノミル等により宿主細胞を破砕し、無細胞抽出液を得る。該無細胞抽出液を遠心分離することにより得られる上清から、タンパク質の単離精製に通常用いられている方法、すなわち、溶媒抽出法、硫安等による塩析法、脱塩法、有機溶媒による沈殿法、ジエチルアミノエチル(DEAE)-セファロース、DIAION HPA-75(三菱化成社製)等のレジンを用いた陰イオン交換クロマトグラフィー法、S-Sepharose FF(Pharmacia社製)等のレジンを用いた陽イオン交換クロマトグラフィー法、ブチルセファロース、フェニルセファロース等のレジンを用いた疎水性クロマトグラフィー法、分子篩を用いたゲルろ過法、アフィニティークロマトグラフィー法、クロマトフォーカシング法、等電点電気泳動等の電気泳動法等の方法を単独又は組み合わせて使用し、精製標品を得ることができる。 Isolation and purification of the expressed modified fibroin can be performed by a commonly used method. For example, when the modified fibroin is expressed in a dissolved state in the cells, the host cells are recovered by centrifugation after culturing, suspended in an aqueous buffer, and then subjected to an ultrasonic crusher, a French press, a manton. The host cells are disrupted with a Gaurin homogenizer, dynomill, etc. to obtain a cell-free extract. From the supernatant obtained by centrifuging the cell-free extract, a method usually used for protein isolation and purification, that is, a solvent extraction method, a salting-out method using ammonium sulfate, a desalting method, an organic solvent, etc. Precipitation method, anion exchange chromatography method using a resin such as diethylaminoethyl (DEAE) -Sepharose, DIAION HPA-75 (manufactured by Mitsubishi Kasei), and a positive using a resin such as S-Sepharose FF (manufactured by Pharmacia) Electrophoretic methods such as ion exchange chromatography, hydrophobic chromatography using resins such as butyl sepharose and phenyl sepharose, gel filtration using molecular sieve, affinity chromatography, chromatofocusing, isoelectric focusing Using methods such as these alone or in combination, purification It is possible to obtain the goods.
 また、改変フィブロインが細胞内に不溶体を形成して発現した場合は、同様に宿主細胞を回収後、破砕し、遠心分離を行うことにより、沈殿画分として改変フィブロインの不溶体を回収する。回収した改変フィブロインの不溶体はタンパク質変性剤で可溶化することができる。該操作の後、上記と同様の単離精製法により改変フィブロインの精製標品を得ることができる。当該改変フィブロインが細胞外に分泌された場合には、培養上清から当該改変フィブロインを回収することができる。すなわち、培養物を遠心分離等の手法により処理することにより培養上清を取得し、その培養上清から、上記と同様の単離精製法を用いることにより、精製標品を得ることができる。 In addition, when the modified fibroin is expressed by forming an insoluble substance in the cell, the host cell is similarly collected, crushed, and centrifuged to collect the modified fibroin insoluble substance as a precipitate fraction. The recovered insoluble form of modified fibroin can be solubilized with a protein denaturant. After the operation, a purified preparation of modified fibroin can be obtained by the same isolation and purification method as described above. When the modified fibroin is secreted extracellularly, the modified fibroin can be recovered from the culture supernatant. That is, a culture supernatant is obtained by treating the culture with a technique such as centrifugation, and a purified preparation can be obtained from the culture supernatant by using the same isolation and purification method as described above.
<人造フィブロイン繊維>
 本実施形態に係る人造フィブロイン繊維は、上述した改変フィブロインを紡糸したものであり、上述した改変フィブロインを主成分として含む。
<Artificial fibroin fiber>
The artificial fibroin fiber according to this embodiment is obtained by spinning the above-described modified fibroin and contains the above-described modified fibroin as a main component.
 本実施形態に係る人造フィブロイン繊維は、LOI値が、18以上であってよく、20以上であってもよく、22以上であってもよく、24以上であってもよく、26以上であってもよく、28以上であってもよく、29以上であってもよく、30以上であってもよい。 The artificial fibroin fiber according to this embodiment may have a LOI value of 18 or more, 20 or more, 22 or more, 24 or more, or 26 or more. 28 or more, 29 or more, or 30 or more.
 本実施形態に係る人造フィブロイン繊維は、下記式Aに従って求められる最高吸湿発熱度が0.025℃/g超であってよい。
 式A:最高吸湿発熱度={(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移したときの試料温度の最高値)-(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移すときの試料温度)}(℃)/試料重量(g)
 なお、式A中、低湿度環境は、温度20℃及び相対湿度40%の環境を意味し、高湿度環境は、温度20℃及び相対湿度90%の環境を意味する。
The artificial fibroin fiber according to the present embodiment may have a maximum moisture absorption exotherm calculated according to the following formula A of more than 0.025 ° C./g.
Formula A: Maximum moisture absorption exotherm = {(maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) − (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment)} (° C.) / Sample weight (g)
In the formula A, a low humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 40%, and a high humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 90%.
 本実施形態に係る人造フィブロイン繊維は、最高吸湿発熱度が0.026℃/g以上であってもよく、0.027℃/g以上であってもよく、0.028℃/g以上であってもよく、0.029℃/g以上であってもよく、0.030℃/g以上であってもよく、0.035℃/g以上であってもよく、0.040℃/g以上であってもよい。最高吸湿発熱度の上限に特に制限はないが、通常、0.060℃/g以下である。 The artificial fibroin fiber according to this embodiment may have a maximum heat absorption exotherm of 0.026 ° C./g or more, 0.027 ° C./g or more, and 0.028 ° C./g or more. Or 0.029 ° C./g or more, 0.030 ° C./g or more, 0.035 ° C./g or more, or 0.040 ° C./g or more. It may be. Although there is no restriction | limiting in particular in the upper limit of the maximum moisture absorption heat generation degree, Usually, it is 0.060 degrees C / g or less.
 本実施形態に係る人造フィブロイン繊維は、下記式Bに従って求められる保温性指数が0.20以上であってよい。
 式B:保温性指数=保温率(%)/試料の目付け(g/m
The artificial fibroin fiber according to the present embodiment may have a heat retention index determined according to the following formula B of 0.20 or more.
Formula B: Thermal insulation index = Heat retention ratio (%) / Sample weight (g / m 2 )
 本実施形態に係る人造フィブロイン繊維の保温性指数は、0.22以上であってよく、0.24以上であってよく、0.26以上であってよく、0.28以上であってよく、0.30以上であってよく、0.32以上であってよい。保温性指数の上限に特に制限はないが、例えば、0.60以下、又は0.40以下であってよい。 The heat retention index of the artificial fibroin fiber according to this embodiment may be 0.22 or more, may be 0.24 or more, may be 0.26 or more, may be 0.28 or more, It may be 0.30 or more, and may be 0.32 or more. Although there is no restriction | limiting in particular in the upper limit of a heat retention index | exponent, For example, it may be 0.60 or less or 0.40 or less.
<人造フィブロイン繊維の製造方法>
 本実施形態に係る人造フィブロイン繊維は、公知の紡糸方法によって製造することができる。すなわち、例えば、改変フィブロインを主成分として含む人造フィブロイン繊維を製造する際には、まず、上述した方法に準じて製造した改変フィブロインをジメチルスルホキシド(DMSO)、N,N-ジメチルホルムアミド(DMF)、ギ酸、又はヘキサフルオロイソプロパノール(HFIP)等の溶媒に、必要に応じて溶解促進剤としての無機塩と共に添加し、溶解してドープ液を作製する。次いで、このドープ液を用いて、湿式紡糸、乾式紡糸、乾湿式紡糸又は溶融紡糸等の公知の紡糸方法により紡糸して、目的とする人造フィブロイン繊維を得ることができる。好ましい紡糸方法としては、湿式紡糸又は乾湿式紡糸を挙げることができる。
<Manufacturing method of artificial fibroin fiber>
The artificial fibroin fiber according to the present embodiment can be produced by a known spinning method. That is, for example, when producing an artificial fibroin fiber containing a modified fibroin as a main component, first, the modified fibroin produced according to the above-described method is converted into dimethyl sulfoxide (DMSO), N, N-dimethylformamide (DMF), A dope solution is prepared by adding to a solvent such as formic acid or hexafluoroisopropanol (HFIP) together with an inorganic salt as a dissolution accelerator, if necessary, and dissolving. Next, the target artificial fibroin fiber can be obtained by spinning using this dope solution by a known spinning method such as wet spinning, dry spinning, dry wet spinning or melt spinning. Preferred spinning methods include wet spinning or dry wet spinning.
 図6は、人造フィブロイン繊維を製造するための紡糸装置の一例を概略的に示す説明図である。図6に示す紡糸装置10は、乾湿式紡糸用の紡糸装置の一例であり、押出し装置1と、未延伸糸製造装置2と、湿熱延伸装置3と、乾燥装置4とを有している。 FIG. 6 is an explanatory view schematically showing an example of a spinning device for producing artificial fibroin fibers. A spinning device 10 illustrated in FIG. 6 is an example of a spinning device for dry and wet spinning, and includes an extrusion device 1, an undrawn yarn production device 2, a wet heat drawing device 3, and a drying device 4.
 紡糸装置10を使用した紡糸方法を説明する。まず、貯槽7に貯蔵されたドープ液6が、ギアポンプ8により口金9から押し出される。ラボスケールにおいては、ドープ液をシリンダーに充填し、シリンジポンプを用いてノズルから押し出してもよい。次いで、押し出されたドープ液6は、エアギャップ19を経て、凝固液槽20の凝固液11内に供給され、溶媒が除去されて、改変フィブロインが凝固し、繊維状凝固体が形成される。次いで、繊維状凝固体が、延伸浴槽21内の温水12中に供給されて、延伸される。延伸倍率は供給ニップローラ13と引き取りニップローラ14との速度比によって決まる。その後、延伸された繊維状凝固体が、乾燥装置4に供給され、糸道22内で乾燥されて、人造フィブロイン繊維が、巻糸体5として得られる。18a~18gは糸ガイドである。 A spinning method using the spinning device 10 will be described. First, the dope solution 6 stored in the storage tank 7 is pushed out from the base 9 by the gear pump 8. In the lab scale, the dope solution may be filled into a cylinder and extruded from a nozzle using a syringe pump. Next, the extruded dope liquid 6 is supplied into the coagulating liquid 11 in the coagulating liquid tank 20 through the air gap 19, the solvent is removed, the modified fibroin is coagulated, and a fibrous coagulated body is formed. Next, the fibrous solidified body is supplied into the hot water 12 in the drawing bath 21 and drawn. The draw ratio is determined by the speed ratio between the supply nip roller 13 and the take-up nip roller 14. Thereafter, the stretched fibrous solidified body is supplied to the drying device 4 and dried in the yarn path 22, and an artificial fibroin fiber is obtained as the wound thread body 5. Reference numerals 18a to 18g denote thread guides.
 凝固液11としては、脱溶媒できる溶媒であればよく、例えば、メタノール、エタノール及び2-プロパノール等の炭素数1~5の低級アルコール、並びにアセトン等を挙げることができる。凝固液11は、適宜水を含んでいてもよい。凝固液11の温度は、0~30℃であることが好ましい。口金9として、直径0.1~0.6mmのノズルを有するシリンジポンプを使用する場合、押出し速度は1ホール当たり、0.2~6.0ml/時間が好ましく、1.4~4.0ml/時間であることがより好ましい。凝固したタンパク質が凝固液11中を通過する距離(実質的には、糸ガイド18aから糸ガイド18bまでの距離)は、脱溶媒が効率的に行える長さがあればよく、例えば、200~500mmである。未延伸糸の引き取り速度は、例えば、1~20m/分であってよく、1~3m/分であることが好ましい。凝固液11中での滞留時間は、例えば、0.01~3分であってよく、0.05~0.15分であることが好ましい。また、凝固液11中で延伸(前延伸)をしてもよい。凝固液槽20は多段設けてもよく、また延伸は必要に応じて、各段、又は特定の段で行ってもよい。 The coagulation liquid 11 may be any solvent that can be desolvated, and examples thereof include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol and 2-propanol, and acetone. The coagulation liquid 11 may appropriately contain water. The temperature of the coagulation liquid 11 is preferably 0 to 30 ° C. When a syringe pump having a nozzle having a diameter of 0.1 to 0.6 mm is used as the base 9, the extrusion speed is preferably 0.2 to 6.0 ml / hour per hole, and 1.4 to 4.0 ml / hour More preferably it is time. The distance that the coagulated protein passes through the coagulation liquid 11 (substantially, the distance from the yarn guide 18a to the yarn guide 18b) may be a length that allows efficient desolvation, for example, 200 to 500 mm. It is. The take-up speed of the undrawn yarn may be, for example, 1 to 20 m / min, and preferably 1 to 3 m / min. The residence time in the coagulating liquid 11 may be, for example, 0.01 to 3 minutes, and preferably 0.05 to 0.15 minutes. Further, stretching (pre-stretching) may be performed in the coagulating liquid 11. The coagulating liquid tank 20 may be provided in multiple stages, and the stretching may be performed in each stage or a specific stage as necessary.
 なお、人造フィブロイン繊維を得る際に実施される延伸は、例えば、上記した凝固液槽20内で行う前延伸、及び延伸浴槽21内で行う湿熱延伸の他、乾熱延伸も採用される。 In addition, as the stretching performed when obtaining the artificial fibroin fiber, for example, dry stretching is also adopted in addition to the pre-stretching performed in the coagulating liquid tank 20 and the wet heat stretching performed in the stretching bath 21.
 湿熱延伸は、温水中、温水に有機溶剤等を加えた溶液中、又はスチーム加熱中で行うことができる。温度としては、例えば、50~90℃であってよく、75~85℃が好ましい。湿熱延伸では、未延伸糸(又は前延伸糸)を、例えば、1~10倍延伸することができ、2~8倍延伸することが好ましい。 Wet heat stretching can be performed in warm water, in a solution obtained by adding an organic solvent or the like to warm water, or in steam heating. The temperature may be, for example, 50 to 90 ° C., and preferably 75 to 85 ° C. In wet heat drawing, undrawn yarn (or predrawn yarn) can be drawn, for example, 1 to 10 times, and preferably 2 to 8 times.
 乾熱延伸は、電気管状炉、乾熱板等を使用して行うことができる。温度としては、例えば、140℃~270℃であってよく、160℃~230℃が好ましい。乾熱延伸では、未延伸糸(又は前延伸糸)を、例えば、0.5~8倍延伸することができ、1~4倍延伸することが好ましい。 Dry heat stretching can be performed using an electric tubular furnace, a dry heat plate, or the like. The temperature may be, for example, 140 ° C. to 270 ° C., and preferably 160 ° C. to 230 ° C. In dry heat drawing, an undrawn yarn (or predrawn yarn) can be drawn, for example, 0.5 to 8 times, and preferably 1 to 4 times.
 湿熱延伸及び乾熱延伸はそれぞれ単独で行ってもよく、またこれらを多段で、又は組み合わせて行ってもよい。すなわち、一段目延伸を湿熱延伸で行い、二段目延伸を乾熱延伸で行う、又は一段目延伸を湿熱延伸行い、二段目延伸を湿熱延伸行い、更に三段目延伸を乾熱延伸で行う等、湿熱延伸及び乾熱延伸を適宜組み合わせて行うことができる。 Wet heat stretching and dry heat stretching may be performed independently, or may be performed in multiple stages or in combination. That is, the first stage stretching is performed by wet heat stretching, the second stage stretching is performed by dry heat stretching, or the first stage stretching is performed by wet heat stretching, the second stage stretching is performed by wet heat stretching, and the third stage stretching is performed by dry heat stretching. For example, wet heat stretching and dry heat stretching can be appropriately combined.
 最終的な延伸倍率は、その下限値が、未延伸糸(又は前延伸糸)に対して、好ましくは、1倍超、2倍以上、3倍以上、4倍以上、5倍以上、6倍以上、7倍以上、8倍以上、9倍以上のうちのいずれかであり、上限値が、好ましくは40倍以下、30倍以下、20倍以下、15倍以下、14倍以下、13倍以下、12倍以下、11倍以下、10倍以下である。人造フィブロイン繊維が2倍以上の延伸倍率で紡糸された繊維であると、人造フィブロイン繊維を水に接触させて湿潤状態にした際の収縮率は、より高くなる。 The final draw ratio of the lower limit of the undrawn yarn (or predrawn yarn) is preferably more than 1 time, 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times. Above, 7 times or more, 8 times or more, 9 times or more, and upper limit is preferably 40 times or less, 30 times or less, 20 times or less, 15 times or less, 14 times or less, 13 times or less 12 times or less, 11 times or less, and 10 times or less. When the artificial fibroin fiber is a fiber spun at a draw ratio of 2 times or more, the shrinkage rate when the artificial fibroin fiber is brought into a wet state by being brought into contact with water becomes higher.
<高収縮人造フィブロイン繊維>
 本実施形態に係る高収縮人造フィブロイン繊維は、上述した人造フィブロイン繊維が収縮されてなるものである。上述した人造フィブロイン繊維は、水に接触させて湿潤状態にすることにより充分に収縮し、また従来知られている合成繊維よりも穏やかな条件下で充分に高い収縮率で収縮することができる。
<High shrinkage artificial fibroin fiber>
The high shrinkage artificial fibroin fiber according to the present embodiment is obtained by shrinking the above-described artificial fibroin fiber. The above-mentioned artificial fibroin fiber is sufficiently shrunk by being brought into a wet state by being brought into contact with water, and can be shrunk at a sufficiently high shrinkage rate under milder conditions than conventionally known synthetic fibers.
 したがって、本実施形態に係る高収縮人造フィブロイン繊維では、下記式で定義される収縮率が2%以上となる。
 収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
Therefore, in the high shrinkage artificial fibroin fiber according to the present embodiment, the shrinkage rate defined by the following formula is 2% or more.
Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
 本実施形態に係る高収縮人造フィブロイン繊維の収縮率は、2.5%以上、3%以上、3.5%以上、4%以上、4.5%以上、5%以上、5.5%以上、又は6%以上であってよい。収縮率の上限は特に限定されないが、80%以下、60%以下、40%以下、20%以下、10%以下、7%以下、6%以下、5%以下、4%以下、又は3%以下であってよい。 The shrinkage rate of the high shrinkage artificial fibroin fiber according to the present embodiment is 2.5% or more, 3% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more, 5.5% or more. Or 6% or more. The upper limit of the shrinkage rate is not particularly limited, but 80% or less, 60% or less, 40% or less, 20% or less, 10% or less, 7% or less, 6% or less, 5% or less, 4% or less, or 3% or less It may be.
 本実施形態に係る高収縮人造フィブロイン繊維は、LOI値が、18以上であってよく、20以上であってもよく、22以上であってもよく、24以上であってもよく、26以上であってもよく、28以上であってもよく、29以上であってもよく、30以上であってもよい。 The high shrinkage artificial fibroin fiber according to this embodiment may have a LOI value of 18 or more, 20 or more, 22 or more, 24 or more, or 26 or more. It may be 28 or more, 29 or more, or 30 or more.
 本実施形態に係る高収縮人造フィブロイン繊維は、下記式Aに従って求められる最高吸湿発熱度が0.025℃/g超であってよい。
 式A:最高吸湿発熱度={(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移したときの試料温度の最高値)-(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移すときの試料温度)}(℃)/試料重量(g)
 なお、式A中、低湿度環境は、温度20℃及び相対湿度40%の環境を意味し、高湿度環境は、温度20℃及び相対湿度90%の環境を意味する。
The high-shrinkage artificial fibroin fiber according to this embodiment may have a maximum moisture absorption exotherm calculated according to the following formula A of more than 0.025 ° C./g.
Formula A: Maximum moisture absorption exotherm = {(maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) − (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment)} (° C.) / Sample weight (g)
In the formula A, a low humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 40%, and a high humidity environment means an environment having a temperature of 20 ° C. and a relative humidity of 90%.
 本実施形態に係る高収縮人造フィブロイン繊維は、最高吸湿発熱度が0.026℃/g以上であってもよく、0.027℃/g以上であってもよく、0.028℃/g以上であってもよく、0.029℃/g以上であってもよく、0.030℃/g以上であってもよく、0.035℃/g以上であってもよく、0.040℃/g以上であってもよい。最高吸湿発熱度の上限に特に制限はないが、通常、0.060℃/g以下である。 The high-shrinkage artificial fibroin fiber according to this embodiment may have a maximum moisture absorption exotherm of 0.026 ° C./g or more, 0.027 ° C./g or more, or 0.028 ° C./g or more. May be 0.029 ° C / g or more, 0.030 ° C / g or more, 0.035 ° C / g or more, and 0.040 ° C / g. It may be g or more. Although there is no restriction | limiting in particular in the upper limit of the maximum moisture absorption heat generation degree, Usually, it is 0.060 degrees C / g or less.
 本実施形態に係る高収縮人造フィブロイン繊維は、下記式Bに従って求められる保温性指数が0.20以上であってよい。
 式B:保温性指数=保温率(%)/試料の目付け(g/m
The heat-shrinkability index calculated | required according to the following formula B may be 0.20 or more as for the high shrinkage artificial fibroin fiber which concerns on this embodiment.
Formula B: Thermal insulation index = Heat retention ratio (%) / Sample weight (g / m 2 )
 本実施形態に係る高収縮人造フィブロイン繊維の保温性指数は、0.22以上であってよく、0.24以上であってよく、0.26以上であってよく、0.28以上であってよく、0.30以上であってよく、0.32以上であってよい。保温性指数の上限に特に制限はないが、例えば、0.60以下、又は0.40以下であってよい。 The heat retention index of the high shrinkage artificial fibroin fiber according to the present embodiment may be 0.22 or more, may be 0.24 or more, may be 0.26 or more, and may be 0.28 or more. It may be 0.30 or more and may be 0.32 or more. Although there is no restriction | limiting in particular in the upper limit of a heat retention index | exponent, For example, it may be 0.60 or less or 0.40 or less.
<高収縮人造フィブロイン繊維の製造方法>
 本実施形態に係る高収縮人造フィブロイン繊維の製造方法は、改変フィブロインを含む人造フィブロイン繊維を、沸点未満の水と接触させて、収縮させる工程(以下、「収縮工程」ともいう。)を備える。
<Method for producing high shrinkage artificial fibroin fiber>
The method for producing high-shrinkage artificial fibroin fibers according to the present embodiment includes a step (hereinafter, also referred to as “shrinking step”) in which the artificial fibroin fibers containing the modified fibroin are brought into contact with water having a boiling point below.
 収縮工程では、人造フィブロイン繊維を沸点未満の水と接触させ(以下、「接触ステップ」ともいう。)て、人造フィブロイン繊維を湿潤状態にする。湿潤状態とは、人造フィブロイン繊維の少なくとも一部が水で濡れた状態を意味する。これにより、外力によらずに人造フィブロイン繊維を収縮させて、高収縮人造フィブロイン繊維を得ることができる。接触ステップでの人造フィブロイン繊維の外力によらない収縮は、例えば、以下の理由により生ずると考えられる。すなわち、一つの理由は、人造フィブロインの二次構造や三次構造に起因すると考えられ、また別の一つの理由は、例えば、製造工程での延伸等によって残留応力を有する人造フィブロイン繊維において、水が繊維間又は繊維内へ浸入することにより、残留応力が緩和されることで生ずると考えられる。したがって、収縮工程での人造フィブロイン繊維の収縮率は、例えば、上記した人造フィブロイン繊維の製造過程での延伸倍率の大きさに応じて任意にコントロールすることもできると考えられる。 In the shrinking step, the artificial fibroin fiber is brought into a wet state by bringing the artificial fibroin fiber into contact with water having a boiling point (hereinafter also referred to as “contact step”). The wet state means a state in which at least a part of the artificial fibroin fiber is wet with water. Thereby, an artificial fibroin fiber can be shrunk | reduced irrespective of external force, and a highly shrinkable artificial fibroin fiber can be obtained. It is considered that the contraction of the artificial fibroin fiber in the contacting step due to the external force is caused by the following reason, for example. That is, one reason is considered to be due to the secondary structure or tertiary structure of the artificial fibroin, and another reason is that, for example, in the artificial fibroin fiber having a residual stress due to stretching in the manufacturing process, water is It is considered that the residual stress is relaxed by entering between the fibers or in the fibers. Therefore, it is considered that the shrinkage ratio of the artificial fibroin fiber in the shrinking process can be arbitrarily controlled according to the size of the draw ratio in the manufacturing process of the artificial fibroin fiber described above, for example.
 接触ステップで人造フィブロイン繊維に接触させる水の温度は、沸点未満であってよい。これにより、取扱い性及び収縮工程の作業性等が向上する。また、収縮時間を充分に短縮するという観点からは、水の温度の下限値が、10℃以上であることが好ましく、40℃以上であることがより好ましく、70℃以上であることが更に好ましい。水の温度の上限値は90℃以下であることが好ましい。 The temperature of the water contacted with the artificial fibroin fiber in the contact step may be less than the boiling point. Thereby, the handleability and the workability of the shrinking process are improved. Further, from the viewpoint of sufficiently shortening the shrinkage time, the lower limit value of the water temperature is preferably 10 ° C or higher, more preferably 40 ° C or higher, and further preferably 70 ° C or higher. . The upper limit of the water temperature is preferably 90 ° C. or lower.
 接触ステップにおいて、水を人造フィブロイン繊維に接触させる方法は、特に限定されない。当該方法として、例えば、人造フィブロイン繊維を水中に浸漬する方法、人造フィブロイン繊維に対して水を常温で又は加温したスチーム等の状態で噴霧する方法、及び人造フィブロイン繊維を水蒸気が充満した高湿度環境下に暴露する方法等が挙げられる。これらの方法の中でも、接触ステップにおいては、収縮時間の短縮化が効果的に図れるとともに、加工設備の簡素化等が実現できることから、人造フィブロイン繊維を水中に浸漬する方法が好ましい。 In the contacting step, the method for bringing water into contact with the artificial fibroin fiber is not particularly limited. Examples of the method include, for example, a method of immersing the artificial fibroin fiber in water, a method of spraying water on the artificial fibroin fiber at room temperature or in a heated steam state, and the high humidity where the artificial fibroin fiber is filled with water vapor. Examples include exposure to the environment. Among these methods, the method of immersing artificial fibroin fiber in water is preferable in the contact step because the shrinkage time can be effectively shortened and the processing equipment can be simplified.
 接触ステップにおいて、人造フィブロイン繊維を弛緩させた状態で水に接触させると、人造フィブロイン繊維が、単に収縮するだけでなく、波打つように縮れてしまうことがある。このような縮れの発生を防止するために、例えば、人造フィブロイン繊維を繊維軸方向に緊張させ(引っ張り)ながら沸点未満の水と接触させるなど、人造フィブロイン繊維を弛緩させない状態で接触ステップを実施してもよい。 In the contact step, when the artificial fibroin fiber is brought into contact with water in a relaxed state, the artificial fibroin fiber may not only contract but also shrink like a wave. In order to prevent the occurrence of such shrinkage, for example, the contact step is performed in a state where the artificial fibroin fiber is not relaxed, for example, the artificial fibroin fiber is brought into contact with water below the boiling point while being tensioned (pulled) in the fiber axis direction. May be.
 収縮工程の後に、湿潤状態の高収縮人造フィブロイン繊維を乾燥させてもよい(以下、「乾燥工程」ともいう。)。 After the shrinking step, the wet highly shrinkable artificial fibroin fiber may be dried (hereinafter also referred to as “drying step”).
 乾燥工程は、収縮工程を経た高収縮人造フィブロイン繊維を乾燥する工程である。乾燥は、例えば、自然乾燥でもよく、乾燥設備を使用して強制的に乾燥させてもよい。乾燥設備としては、接触型又は非接触型の公知の乾燥設備がいずれも使用可能である。また、乾燥温度も、例えば、高収縮人造フィブロイン繊維に含まれるタンパク質が分解したり、高収縮人造フィブロイン繊維が熱的損傷を受けたりする温度よりも低い温度であれば何ら限定されるものではないが、一般には、20~150℃の範囲内の温度であり、50~100℃の範囲内の温度であることが好ましい。温度がこの範囲にあることにより、高収縮人造フィブロイン繊維の熱的損傷、又は高収縮人造フィブロイン繊維に含まれるタンパク質の分解が生ずることなく、高収縮人造フィブロイン繊維が、より迅速且つ効率的に乾燥される。乾燥時間は、乾燥温度等に応じて適宜に設定され、例えば、過乾燥による高収縮人造フィブロイン繊維の品質及び物性等への影響が可及的に排除され得る時間等が採用される。 The drying step is a step of drying the high shrinkage artificial fibroin fiber that has undergone the shrinkage step. Drying may be, for example, natural drying or forced drying using a drying facility. As the drying equipment, any known drying equipment of contact type or non-contact type can be used. The drying temperature is not limited as long as it is lower than the temperature at which, for example, the protein contained in the high-shrinkage artificial fibroin fiber is decomposed or the high-shrinkage artificial fibroin fiber is thermally damaged. However, in general, the temperature is in the range of 20 to 150 ° C., and the temperature is preferably in the range of 50 to 100 ° C. The temperature in this range allows the high shrinkage artificial fibroin fiber to dry more quickly and efficiently without thermal damage of the high shrinkage artificial fibroin fiber or degradation of the protein contained in the high shrinkage artificial fibroin fiber. Is done. The drying time is appropriately set according to the drying temperature or the like, and for example, a time that can eliminate as much as possible the influence on the quality and physical properties of the high shrinkage artificial fibroin fiber due to overdrying is adopted.
 本実施形態に係る高収縮人造フィブロイン繊維の製造方法では、収縮工程を経ることで、収縮率が2%以上である高収縮人造フィブロイン繊維を得ることができる。 In the method for producing a high-shrinkage artificial fibroin fiber according to the present embodiment, a high-shrinkage artificial fibroin fiber having a shrinkage rate of 2% or more can be obtained through the shrinking step.
 図7は、高収縮人造フィブロイン繊維を製造するための製造装置の一例を概略的に示す説明図である。図7に示す製造装置40は、人造フィブロイン繊維を送り出すフィードローラ42と、高収縮人造フィブロイン繊維38を巻き取るワインダー44と、収縮工程を実施するウォーターバス46と、乾燥工程を実施する乾燥機48と、を有して構成されている。 FIG. 7 is an explanatory view schematically showing an example of a production apparatus for producing high-shrinkage artificial fibroin fibers. The manufacturing apparatus 40 shown in FIG. 7 includes a feed roller 42 that feeds out artificial fibroin fibers, a winder 44 that winds up the highly shrinkable artificial fibroin fibers 38, a water bath 46 that performs a shrinking process, and a dryer 48 that performs a drying process. And is configured.
 より詳細には、フィードローラ42は、人造フィブロイン繊維36の巻回物が装着可能とされており、図示しない電動モータ等の回転によって、人造フィブロイン繊維36の巻回物から人造フィブロイン繊維36を連続的且つ自動的に送り出し得るようになっている。ワインダー44は、フィードローラ42から送り出された後、接触ステップと乾燥ステップを経て収縮された人造フィブロイン繊維36(高収縮人造フィブロイン繊維38)を、図示しない電動モータの回転によって連続的且つ自動的に巻き取り得るようになっている。なお、ここでは、フィードローラ42による人造フィブロイン繊維36の送出し速度と、ワインダー44による高収縮人造フィブロイン繊維38の巻取り速度とが、互いに独立して制御可能とされている。 More specifically, the feed roller 42 can be attached with a wound product of the artificial fibroin fiber 36, and the artificial fibroin fiber 36 is continuously formed from the wound product of the artificial fibroin fiber 36 by rotation of an electric motor (not shown). Can be delivered automatically and automatically. The winder 44 continuously and automatically turns the artificial fibroin fiber 36 (high-shrinking artificial fibroin fiber 38), which is fed from the feed roller 42 and then contracted through the contact step and the drying step, by the rotation of an electric motor (not shown). It can be wound up. Here, the feeding speed of the artificial fibroin fiber 36 by the feed roller 42 and the winding speed of the highly shrinkable artificial fibroin fiber 38 by the winder 44 can be controlled independently of each other.
 ウォーターバス46と乾燥機48は、フィードローラ42とワインダー44との間に、人造フィブロイン繊維36の送り方向の上流側と下流側にそれぞれ並んで配置されている。なお、図7に示す製造装置40は、フィードローラ42からワインダー44に向かって走行する収縮前及び後の人造フィブロイン繊維36を中継するリレーローラ50及び52を有している。 The water bath 46 and the dryer 48 are arranged side by side between the feed roller 42 and the winder 44 on the upstream side and the downstream side in the feeding direction of the artificial fibroin fiber 36. 7 includes relay rollers 50 and 52 that relay the artificial fibroin fiber 36 before and after contraction, which travels from the feed roller 42 toward the winder 44.
 ウォーターバス46はヒータ54を有し、このヒータ54にて加温された湯47が、ウォーターバス46内に収容されている。また、ウォーターバス46内には、テンションローラ56が、湯47中に浸漬された状態で設置されている。これにより、フィードローラ42から送り出された人造フィブロイン繊維36が、ウォーターバス46内を、テンションローラ56に巻き掛けられた状態で湯47中に浸漬されつつ、ワインダー44側に向かって走行するようになっている。なお、人造フィブロイン繊維36の湯47中への浸漬時間は、人造フィブロイン繊維36の走行速度に応じて適宜にコントロールされる。 The water bath 46 has a heater 54, and hot water 47 heated by the heater 54 is accommodated in the water bath 46. A tension roller 56 is installed in the water bath 46 so as to be immersed in the hot water 47. As a result, the artificial fibroin fiber 36 fed out from the feed roller 42 travels toward the winder 44 while being immersed in the hot water 47 while being wound around the tension roller 56 in the water bath 46. It has become. The immersion time of the artificial fibroin fiber 36 in the hot water 47 is appropriately controlled according to the traveling speed of the artificial fibroin fiber 36.
 乾燥機48は、一対のホットローラ58を有している。一対のホットローラ58は、ウォーターバス46内から離脱してワインダー44側に向かって走行する人造フィブロイン繊維36が巻き掛け可能とされている。これにより、ウォーターバス46内で湯47に浸漬された人造フィブロイン繊維36が、乾燥機48内で一対のホットローラ58にて加熱され、乾燥させられた後、ワインダー44に向かって更に送り出されるようになっている。 The dryer 48 has a pair of hot rollers 58. The pair of hot rollers 58 can be wound around the artificial fibroin fiber 36 that moves away from the water bath 46 and travels toward the winder 44 side. As a result, the artificial fibroin fiber 36 immersed in the hot water 47 in the water bath 46 is heated by the pair of hot rollers 58 in the dryer 48 and dried, and then sent out further toward the winder 44. It has become.
 このような構造を有する製造装置40を用いて、高収縮人造フィブロイン繊維38を製造する際には、先ず、例えば、図6に示された紡糸装置10を用いて紡糸された人造フィブロイン繊維36の巻回物をフィードローラ42に装着する。次に、フィードローラ42から人造フィブロイン繊維36を連続的に送り出して、ウォーターバス46内で湯47に浸漬させる。このとき、例えば、ワインダー44の巻き取り速度をフィードローラ42の送り出し速度よりも遅くしておく。これにより、人造フィブロイン繊維36が、フィードローラ42とワインダー44との間で弛緩しないように緊張された状態で、湯47との接触により収縮するため、縮れの発生を防止することができる。湯47との接触により人造フィブロイン繊維36は収縮し、高収縮人造フィブロイン繊維38が得られる。 When manufacturing the high shrinkage artificial fibroin fiber 38 using the manufacturing apparatus 40 having such a structure, first, for example, the artificial fibroin fiber 36 spun using the spinning apparatus 10 shown in FIG. 6 is used. The wound material is attached to the feed roller 42. Next, the artificial fibroin fiber 36 is continuously fed from the feed roller 42 and immersed in hot water 47 in the water bath 46. At this time, for example, the winding speed of the winder 44 is set slower than the feeding speed of the feed roller 42. Thereby, since the artificial fibroin fiber 36 is contracted by contact with the hot water 47 in a state where the artificial fibroin fiber 36 is tensioned so as not to relax between the feed roller 42 and the winder 44, occurrence of crimping can be prevented. By contact with hot water 47, the artificial fibroin fiber 36 contracts, and a highly contracted artificial fibroin fiber 38 is obtained.
 次に、高収縮人造フィブロイン繊維38を、乾燥機48の一対のホットローラ58により加熱する。これにより、高収縮人造フィブロイン繊維38を乾燥させることができる。このとき、フィードローラ42の送出し速度とワインダー44の巻取り速度との比率をコントロールすることで、高収縮人造フィブロイン繊維38を更に収縮させることもできるし、長さを変化させないこともできる。そして、得られた高収縮人造フィブロイン繊維38をワインダー44にて巻き取って、高収縮人造フィブロイン繊維38の巻回物を得る。 Next, the high shrinkage artificial fibroin fiber 38 is heated by the pair of hot rollers 58 of the dryer 48. Thereby, the high shrinkage artificial fibroin fiber 38 can be dried. At this time, by controlling the ratio between the feed speed of the feed roller 42 and the winding speed of the winder 44, the high-shrinkage artificial fibroin fiber 38 can be further shrunk, and the length can be kept unchanged. The obtained high-shrinkage artificial fibroin fiber 38 is wound up by a winder 44 to obtain a wound product of the high-shrinkage artificial fibroin fiber 38.
 なお、一対のホットローラ58に代えて、図8に示されるような乾熱板64等、単なる熱源のみからなる乾燥設備を用いて高収縮人造フィブロイン繊維38を乾燥させてもよい。この場合にも、フィードローラ42の送出し速度とワインダー44の巻取り速度との互いの相対速度を、乾燥設備として一対のホットローラ58を使用する場合と同様に調節することにより、高収縮人造フィブロイン繊維38を更に収縮させることもできるし、長さを変化させないこともできる。ここでは、乾燥手段が乾熱板64にて構成されることとなる。また、乾燥機48は必須ではない。 Note that, instead of the pair of hot rollers 58, the high-shrinkage artificial fibroin fiber 38 may be dried using a drying facility consisting of only a heat source such as a dry heat plate 64 as shown in FIG. Also in this case, by adjusting the relative speed of the feed speed of the feed roller 42 and the winding speed of the winder 44 in the same manner as in the case of using a pair of hot rollers 58 as a drying facility, a high shrinkage artificial structure is achieved. The fibroin fiber 38 can be further shrunk or the length can be kept unchanged. Here, the drying means is constituted by the dry heat plate 64. Further, the dryer 48 is not essential.
 上述のように、製造装置40を用いることによって、目的とする高収縮人造フィブロイン繊維38を自動的且つ連続的に、しかも極めて容易に製造することができる。 As described above, by using the manufacturing apparatus 40, the target high-shrinkage artificial fibroin fiber 38 can be manufactured automatically, continuously, and extremely easily.
 図8は、高収縮人造フィブロイン繊維を製造するための製造装置の別の例を概略的に示す説明図である。図8(a)は、当該製造装置に備わる、収縮工程を実施する加工装置を示し、図8(b)は、当該製造装置に備わる、乾燥工程を実施する乾燥装置を示す。図8に示される製造装置は、人造フィブロイン繊維36に対する収縮工程を実施する加工装置60と、得られた高収縮人造フィブロイン繊維38を乾燥させる乾燥装置62とを有し、それらが互いに独立した構造とされている。 FIG. 8 is an explanatory view schematically showing another example of a production apparatus for producing high-shrinkage artificial fibroin fibers. FIG. 8A shows a processing apparatus that performs the shrinking process included in the manufacturing apparatus, and FIG. 8B shows a drying apparatus that performs the drying process included in the manufacturing apparatus. The manufacturing apparatus shown in FIG. 8 has a processing device 60 that performs a shrinking process on the artificial fibroin fiber 36 and a drying device 62 that dries the resulting high-shrinkage artificial fibroin fiber 38, and these are independent of each other. It is said that.
 より具体的には、図8(a)に示す加工装置60は、図7に示された製造装置40から乾燥機48を省略して、フィードローラ42とウォーターバス46とワインダー44とを、人造フィブロイン繊維36の走行方向の上流から下流側に向かって順に並べて配置してなる構造を有している。このような加工装置60は、フィードローラ42から送り出された人造フィブロイン繊維36を、ウォーターバス46内の湯47中に浸漬させて、収縮させるようになっている。そして、収縮により得られた高収縮人造フィブロイン繊維38をワインダー44にて巻き取るように構成されている。 More specifically, the processing device 60 shown in FIG. 8A omits the dryer 48 from the manufacturing device 40 shown in FIG. 7 and replaces the feed roller 42, the water bath 46, and the winder 44 with an artificial. It has a structure in which the fibroin fibers 36 are arranged in order from the upstream side to the downstream side in the traveling direction. In such a processing device 60, the artificial fibroin fiber 36 fed from the feed roller 42 is immersed in hot water 47 in the water bath 46 and contracted. The high-shrinkage artificial fibroin fiber 38 obtained by shrinkage is wound up by a winder 44.
 図8(b)に示す乾燥装置62は、フィードローラ42及びワインダー44と、乾熱板64とを有している。乾熱板64は、フィードローラ42とワインダー44との間に、乾熱面66が、高収縮人造フィブロイン繊維38に接触し、且つその走行方向に沿って伸びるように配置されている。この乾燥装置62では、前述したように、例えば、フィードローラ42の送出し速度とワインダー44の巻取り速度との比率をコントロールすることで、高収縮人造フィブロイン繊維38を更に収縮させることもできるし、長さを変化させないこともできる。 8B includes a feed roller 42 and a winder 44, and a dry heat plate 64. The dry heat plate 64 is disposed between the feed roller 42 and the winder 44 so that the dry heat surface 66 is in contact with the high-shrinkage artificial fibroin fiber 38 and extends in the running direction. In the drying device 62, as described above, the high-shrinkage artificial fibroin fiber 38 can be further shrunk by controlling the ratio of the feed speed of the feed roller 42 and the wind-up speed of the winder 44, for example. , You can not change the length.
 このような構造を有する製造装置を用いることによって、人造フィブロイン繊維36を加工装置60により収縮させて目的とする高収縮人造フィブロイン繊維38を得た後、乾燥装置62にて高収縮人造フィブロイン繊維38を乾燥させることができる。 By using the manufacturing apparatus having such a structure, the artificial fibroin fiber 36 is contracted by the processing apparatus 60 to obtain the desired high-shrinking artificial fibroin fiber 38, and then the high-shrinking artificial fibroin fiber 38 is obtained by the drying apparatus 62. Can be dried.
 なお、図8(a)に示された加工装置60からフィードローラ42とワインダー44とを省略して、ウォーターバス46のみで加工装置を構成してもよい。このような加工装置を有する製造装置を用いる場合には、例えば、高収縮人造フィブロイン繊維が、いわゆるバッチ式で製造されることとなる。また、図8(b)に示す乾燥装置62は必須ではない。 Note that the processing apparatus 60 may be configured with only the water bath 46 by omitting the feed roller 42 and the winder 44 from the processing apparatus 60 shown in FIG. In the case of using a manufacturing apparatus having such a processing apparatus, for example, high-shrinkage artificial fibroin fibers are manufactured in a so-called batch type. Moreover, the drying apparatus 62 shown in FIG.8 (b) is not essential.
<高収縮人造フィブロイン繊維の用途>
 本発明に係る高収縮人造フィブロイン繊維は、高い収縮率で収縮されているため、肌触り性及び柔軟性に優れており、例えば、衣料及び寝具等に使用される繊維として好適である。
<Use of high shrinkage artificial fibroin fiber>
Since the high-shrinkage artificial fibroin fiber according to the present invention is shrunk at a high shrinkage rate, it is excellent in touch and flexibility, and is suitable as a fiber used for, for example, clothing and bedding.
〔人造フィブロイン繊維の収縮方法〕
 以上説明した本発明の高収縮人造フィブロイン繊維の製造方法は、改変フィブロインを含む人造フィブロイン繊維を、沸点未満の水と接触させて、収縮させる工程を備え、下記式で定義される収縮率が2%以上である、人造フィブロイン繊維の収縮方法と捉えることもできる。
 収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
[Shrinking method of artificial fibroin fiber]
The manufacturing method of the high shrinkage artificial fibroin fiber of the present invention described above includes a step of shrinking an artificial fibroin fiber containing modified fibroin by bringing it into contact with water having a boiling point below, and the shrinkage rate defined by the following formula is 2 %, It can also be regarded as a shrinkage method of artificial fibroin fiber.
Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
 以下、実施例等に基づいて本発明をより具体的に説明する。ただし、本発明は以下の実施例に限定されるものではない。 Hereinafter, the present invention will be described more specifically based on examples and the like. However, the present invention is not limited to the following examples.
〔試験例1:高収縮人造フィブロイン繊維の評価〕
(1)改変フィブロイン(人造フィブロイン)の製造
(改変フィブロインをコードする核酸の合成、及び発現ベクターの構築)
 配列番号18で示されるアミノ酸配列を有する改変フィブロイン(PRT399)、配列番号12で示されるアミノ酸配列を有する改変フィブロイン(PRT380)、配列番号13で示されるアミノ酸配列を有する改変フィブロイン(PRT410)、及び配列番号15で示されるアミノ酸配列を有する改変フィブロイン(PRT799)を設計した。
[Test Example 1: Evaluation of high shrinkage artificial fibroin fiber]
(1) Production of modified fibroin (artificial fibroin) (synthesis of nucleic acid encoding modified fibroin and construction of expression vector)
Modified fibroin having the amino acid sequence represented by SEQ ID NO: 18 (PRT399), modified fibroin having the amino acid sequence represented by SEQ ID NO: 12 (PRT380), modified fibroin having the amino acid sequence represented by SEQ ID NO: 13 (PRT410), and sequence A modified fibroin (PRT799) having the amino acid sequence shown by number 15 was designed.
 設計した4種類の改変フィブロインをコードする核酸をそれぞれ合成した。当該核酸には、5’末端にNdeIサイト、終止コドン下流にEcoRIサイトを付加した。これら4種類の核酸をクローニングベクター(pUC118)にクローニングした。その後、同核酸をNdeI及びEcoRIで制限酵素処理して切り出した後、タンパク質発現ベクターpET-22b(+)に組換えて発現ベクターを得た。 The nucleic acids encoding the four types of designed modified fibroin were synthesized respectively. The nucleic acid was added with an NdeI site at the 5 'end and an EcoRI site downstream of the stop codon. These four types of nucleic acids were cloned into a cloning vector (pUC118). Thereafter, the nucleic acid was cleaved by restriction enzyme treatment with NdeI and EcoRI, and then recombined with the protein expression vector pET-22b (+) to obtain an expression vector.
(改変フィブロインの発現)
 得られたpET-22b(+)発現ベクターで、大腸菌BLR(DE3)を形質転換した。当該形質転換大腸菌を、アンピシリンを含む2mLのLB培地で15時間培養した。当該培養液を、アンピシリンを含む100mLのシード培養用培地(表4)にOD600が0.005となるように添加した。培養液温度を30℃に保ち、OD600が5になるまでフラスコ培養を行い(約15時間)、シード培養液を得た。
(Expression of modified fibroin)
Escherichia coli BLR (DE3) was transformed with the obtained pET-22b (+) expression vector. The transformed Escherichia coli was cultured in 2 mL of LB medium containing ampicillin for 15 hours. The culture solution was added to 100 mL of a seed culture medium (Table 4) containing ampicillin so that the OD 600 was 0.005. The culture temperature was kept at 30 ° C., and flask culture was performed until the OD 600 reached 5 (about 15 hours) to obtain a seed culture solution.
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
 当該シード培養液を500mLの生産培地(表5)を添加したジャーファーメンターにOD600が0.05となるように添加した。培養液温度を37℃に保ち、pH6.9で一定に制御して培養した。また培養液中の溶存酸素濃度を、溶存酸素飽和濃度の20%に維持した。 The seed culture was added to a jar fermenter to which 500 mL of production medium (Table 5) was added so that the OD 600 was 0.05. The culture solution temperature was maintained at 37 ° C., and the culture was performed at a constant pH of 6.9. The dissolved oxygen concentration in the culture solution was maintained at 20% of the dissolved oxygen saturation concentration.
Figure JPOXMLDOC01-appb-T000005
Figure JPOXMLDOC01-appb-T000005
 生産培地中のグルコースが完全に消費された直後に、フィード液(グルコース455g/1L、Yeast Extract 120g/1L)を1mL/分の速度で添加した。培養液温度を37℃に保ち、pH6.9で一定に制御して培養した。培養液中の溶存酸素濃度を、溶存酸素飽和濃度の20%に維持しながら、20時間培養を行った。その後、1Mのイソプロピル-β-チオガラクトピラノシド(IPTG)を培養液に対して終濃度1mMになるよう添加し、目的とする改変フィブロインを発現誘導させた。IPTG添加後20時間経過した時点で、培養液を遠心分離し、菌体を回収した。IPTG添加前とIPTG添加後の培養液から調製した菌体を用いてSDS-PAGEを行い、IPTG添加に依存した目的とする改変フィブロインのサイズに相当するバンドの出現により、目的とする改変フィブロインの発現を確認した。 Immediately after the glucose in the production medium was completely consumed, a feed solution (glucose 455 g / 1 L, Yeast Extract 120 g / 1 L) was added at a rate of 1 mL / min. The culture solution temperature was maintained at 37 ° C., and the culture was performed at a constant pH of 6.9. The culture was performed for 20 hours while maintaining the dissolved oxygen concentration in the culture solution at 20% of the dissolved oxygen saturation concentration. Thereafter, 1M isopropyl-β-thiogalactopyranoside (IPTG) was added to the culture solution to a final concentration of 1 mM to induce expression of the target modified fibroin. At the time when 20 hours passed after the addition of IPTG, the culture solution was centrifuged, and the cells were collected. SDS-PAGE was performed using cells prepared from the culture solution before and after IPTG addition, and the appearance of a band corresponding to the size of the target modified fibroin depending on the addition of IPTG Expression was confirmed.
(改変フィブロインの精製)
 IPTGを添加してから2時間後に回収した菌体を20mM Tris-HCl buffer(pH7.4)で洗浄した。洗浄後の菌体を約1mMのPMSFを含む20mM Tris-HCl緩衝液(pH7.4)に懸濁させ、高圧ホモジナイザー(GEA Niro Soavi社)で細胞を破砕した。破砕した細胞を遠心分離し、沈殿物を得た。得られた沈殿物を、高純度になるまで20mM Tris-HCl緩衝液(pH7.4)で洗浄した。洗浄後の沈殿物を100mg/mLの濃度になるように8M グアニジン緩衝液(8M グアニジン塩酸塩、10mM リン酸二水素ナトリウム、20mM NaCl、1mM Tris-HCl、pH7.0)で懸濁し、60℃で30分間、スターラーで撹拌し、溶解させた。溶解後、透析チューブ(三光純薬株式会社製のセルロースチューブ36/32)を用いて水で透析を行った。透析後に得られた白色の凝集タンパク質を遠心分離により回収した。回収した凝集タンパク質から凍結乾燥機で水分を除き、目的とする改変フィブロインの凍結乾燥粉末を得た。
(Purification of modified fibroin)
The cells recovered 2 hours after the addition of IPTG were washed with 20 mM Tris-HCl buffer (pH 7.4). The washed cells were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing about 1 mM PMSF, and the cells were disrupted with a high-pressure homogenizer (GEA Niro Soavi). The disrupted cells were centrifuged to obtain a precipitate. The resulting precipitate was washed with 20 mM Tris-HCl buffer (pH 7.4) until high purity. The washed precipitate was suspended in 8M guanidine buffer (8M guanidine hydrochloride, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, 1 mM Tris-HCl, pH 7.0) to a concentration of 100 mg / mL, and 60 ° C. And stirred for 30 minutes with a stirrer to dissolve. After dissolution, dialysis was performed with water using a dialysis tube (cellulose tube 36/32 manufactured by Sanko Junyaku Co., Ltd.). White aggregated protein obtained after dialysis was collected by centrifugation. Water was removed from the recovered aggregated protein with a freeze dryer to obtain the desired modified fibroin freeze-dried powder.
(2)人造フィブロイン繊維の製造
(ドープ液の調製)
 4.0質量%になるようにLiClを溶解させたジメチルスルホキシド(DMSO)を溶媒として用意し、そこに改変フィブロインの凍結乾燥粉末を、濃度18質量%又は24質量%となるよう添加し(表6参照)、シェーカーを使用して3時間溶解させた。その後、不溶物と泡を取り除き、改変フィブロイン溶液を得た。
(2) Manufacture of artificial fibroin fiber (preparation of dope solution)
Prepare dimethyl sulfoxide (DMSO) in which LiCl is dissolved to 4.0% by mass as a solvent, and add a lyophilized powder of modified fibroin to the concentration of 18% by mass or 24% by mass (Table). 6) and dissolved for 3 hours using a shaker. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution.
(紡糸)
 得られた改変フィブロイン溶液をドープ液(紡糸原液)とし、図6に示す紡糸装置10に準じた紡糸装置を用いた乾湿式紡糸によって、紡糸及び延伸された人造フィブロイン繊維を製造した。用いた紡糸装置は、図6に示す紡糸装置10において、未延伸糸製造装置2(第1浴)及び湿熱延伸装置3(第3浴)の間に、更に第2の未延伸糸製造装置(第2浴)を備えるものである。乾湿式紡糸の条件は以下のとおりである。
 押出しノズル直径:0.2mm
 第1浴~第3浴中の液体及び温度:表6参照
 総延伸倍率:表6参照
 乾燥温度:60℃
(spinning)
Using the obtained modified fibroin solution as a dope solution (spinning stock solution), spun and drawn artificial fibroin fibers were produced by dry and wet spinning using a spinning device similar to the spinning device 10 shown in FIG. The spinning device used is a spinning device 10 shown in FIG. 6, and a second undrawn yarn production device (a first bath) and a wet heat drawing device 3 (third bath) are further provided between the undrawn yarn production device 2 (first bath) and the wet heat drawing device 3 (third bath). A second bath). The dry and wet spinning conditions are as follows.
Extrusion nozzle diameter: 0.2 mm
Liquid and temperature in the first to third baths: see Table 6 Total draw ratio: see Table 6 Drying temperature: 60 ° C.
Figure JPOXMLDOC01-appb-T000006
Figure JPOXMLDOC01-appb-T000006
(3)高収縮人造フィブロイン繊維の製造及び評価
(収縮工程)
 製造例1~19で得た各人造フィブロイン繊維に対して、沸点未満の水に接触させる接触ステップを施すことにより、高収縮人造フィブロイン繊維を製造した。
(3) Manufacture and evaluation of high shrinkage artificial fibroin fiber (shrinkage process)
A high-shrinkage artificial fibroin fiber was produced by subjecting each of the artificial fibroin fibers obtained in Production Examples 1 to 19 to contact with water having a boiling point below.
 製造例1~19で得た人造フィブロイン繊維の巻回物から、それぞれ、長さ30cmの複数本の人造フィブロイン繊維を切り出した。それら複数本の人造フィブロイン繊維を束ねて、繊度150デニールの人造フィブロイン繊維束を得た。各人造フィブロイン繊維束に0.8gの鉛錘を取り付け、その状態で各人造フィブロイン繊維束を表7~10に示す温度の水に10分間浸漬した(接触ステップ)。その後、水中で各人造フィブロイン繊維束の長さを測定した。水中での人造フィブロイン繊維束の長さ測定は、人造フィブロイン繊維束の縮れを無くすために、人造フィブロイン繊維束に0.8gの鉛錘を取り付けたまま実施した。次いで、各人造フィブロイン繊維の収縮率(%)を、下記式Iに従って算出した。式I中、L0は紡糸後、水と接触する前の人造フィブロイン繊維束の長さ(ここでは30cm)を示し、Lwは収縮した人造フィブロイン繊維束の長さを示す。
 式I:収縮率={1-(Lw/L0)}×100(%)
A plurality of artificial fibroin fibers each having a length of 30 cm were cut out from the wound product of artificial fibroin fibers obtained in Production Examples 1 to 19. The plurality of artificial fibroin fibers were bundled to obtain an artificial fibroin fiber bundle having a fineness of 150 denier. A 0.8 g lead weight was attached to each artificial fibroin fiber bundle, and in this state, each artificial fibroin fiber bundle was immersed in water at a temperature shown in Tables 7 to 10 for 10 minutes (contact step). Thereafter, the length of each artificial fibroin fiber bundle was measured in water. The measurement of the length of the artificial fibroin fiber bundle in water was carried out with a 0.8 g lead weight attached to the artificial fibroin fiber bundle in order to eliminate the shrinkage of the artificial fibroin fiber bundle. Next, the shrinkage rate (%) of each artificial fibroin fiber was calculated according to the following formula I. In Formula I, L0 represents the length of the artificial fibroin fiber bundle (here 30 cm) after spinning and before contact with water, and Lw represents the length of the contracted artificial fibroin fiber bundle.
Formula I: Shrinkage rate = {1− (Lw / L0)} × 100 (%)
 結果を表7~10に示す。
Figure JPOXMLDOC01-appb-T000007
The results are shown in Tables 7-10.
Figure JPOXMLDOC01-appb-T000007
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000010
 本発明の高収縮人造フィブロイン繊維は、充分に高い収縮率を有しており、肌触り性及び柔軟性に優れたものであった。加えて、沸点未満の水と接触させる接触ステップにより製造することができるため、安全に製造が可能である。 The high-shrinkage artificial fibroin fiber of the present invention had a sufficiently high shrinkage rate and was excellent in touch and flexibility. In addition, since it can manufacture by the contact step made to contact with water below boiling point, it can manufacture safely.
〔参考例1:改変フィブロインの難燃性の評価〕
 試験例1と同様にして、改変フィブロイン(PRT799)の凍結乾燥粉末を得た。PRT799は、0以下の平均HIを有する親水性改変フィブロインである。
[Reference Example 1: Evaluation of flame retardancy of modified fibroin]
In the same manner as in Test Example 1, a freeze-dried powder of modified fibroin (PRT799) was obtained. PRT799 is a hydrophilic modified fibroin with an average HI of 0 or less.
 LiClのDMSO溶液(濃度:4.0質量%)に、改変フィブロイン(PRT799)の凍結乾燥粉末を、濃度24質量%となるよう添加し、シェーカーを使用して3時間混合することにより、溶解させた。その後、不溶物と泡を取り除き、改変フィブロイン溶液(紡糸原液)を得た。 A modified fibroin (PRT799) freeze-dried powder was added to a LiCl solution in DMSO (concentration: 4.0% by mass) to a concentration of 24% by mass, and dissolved by mixing for 3 hours using a shaker. It was. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution (spinning stock solution).
 紡糸原液を90℃にて目開き5μmの金属フィルターで濾過し、次いで30mLのステンレスシリンジ内で静置し、脱泡させた後に、ニードル径0.2mmのソリッドノズルから100質量%メタノール凝固浴槽中へ吐出させた。吐出温度は90℃であった。凝固後、得られた原糸を巻き取り、自然乾燥させて改変フィブロイン繊維(原料繊維)を得た。 The spinning dope is filtered through a metal filter with an opening of 5 μm at 90 ° C., then left to stand in a 30 mL stainless syringe and defoamed, and then in a 100 mass% methanol coagulation bath from a solid nozzle with a needle diameter of 0.2 mm. Was discharged. The discharge temperature was 90 ° C. After coagulation, the obtained raw yarn was wound up and naturally dried to obtain modified fibroin fiber (raw fiber).
 原料繊維を撚り合せた撚糸を使用して、丸編機を使用した丸編みで、編地(太さ:180デニール、ゲージ数:18)を製造した。得られた編地を20g切り出して、試験片として使用した。 A knitted fabric (thickness: 180 denier, number of gauges: 18) was manufactured by circular knitting using a circular knitting machine using twisted yarns obtained by twisting raw material fibers. 20 g of the obtained knitted fabric was cut out and used as a test piece.
 燃焼性試験を、「消防危50号(平成7年5月31日付け)」に記載の「粉粒状又は融点の低い合成樹脂の試験方法」に準拠して行った。試験は、温度22℃、相対湿度45%、気圧1021hPaの条件下で実施した。測定結果(酸素濃度(%)、燃焼率(%)、及び換算燃焼率(%))を表11に示す。
Figure JPOXMLDOC01-appb-T000011
The flammability test was conducted in accordance with “Test method for powdered or low melting point synthetic resin” described in “Fire Safety No. 50 (May 31, 1995)”. The test was performed under conditions of a temperature of 22 ° C., a relative humidity of 45%, and an atmospheric pressure of 1021 hPa. Table 11 shows the measurement results (oxygen concentration (%), combustion rate (%), and converted combustion rate (%)).
Figure JPOXMLDOC01-appb-T000011
 燃焼性試験の結果、改変フィブロイン(PRT799)繊維で編んだ編地の限界酸素指数(LOI)値は27.2であった。一般にLOI値が26以上であれば、難燃性であるとされる。改変フィブロインは、難燃性に優れていることが分かる。 As a result of the flammability test, the critical oxygen index (LOI) value of the knitted fabric knitted with the modified fibroin (PRT799) fiber was 27.2. Generally, if the LOI value is 26 or more, it is considered to be flame retardant. It can be seen that the modified fibroin is excellent in flame retardancy.
〔参考例2:改変フィブロインの吸湿発熱性の評価〕
 試験例1と同様にして、改変フィブロイン(PRT918及びPRT799)の凍結乾燥粉末を得た。PRT918は、配列番号37で示されるアミノ酸配列を有し、0超の平均HIを有する、疎水性改変フィブロインである。
[Reference Example 2: Evaluation of hygroscopic exothermic property of modified fibroin]
In the same manner as in Test Example 1, lyophilized powders of modified fibroin (PRT918 and PRT799) were obtained. PRT918 is a hydrophobically modified fibroin having the amino acid sequence set forth in SEQ ID NO: 37 and having an average HI greater than zero.
 LiClのDMSO溶液(濃度:4.0質量%)に、改変フィブロイン(PRT918及びPRT799)の凍結乾燥粉末を、濃度24質量%となるよう添加し、シェーカーを使用して3時間混合することにより、溶解させた。その後、不溶物と泡を取り除き、改変フィブロイン溶液(紡糸原液)を得た。 By adding a lyophilized powder of modified fibroin (PRT918 and PRT799) to a LiCl solution in DMSO (concentration: 4.0% by mass) to a concentration of 24% by mass and mixing for 3 hours using a shaker, Dissolved. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution (spinning stock solution).
 紡糸原液を60℃にて目開き5μmの金属フィルターで濾過し、次いで30mLのステンレスシリンジ内で静置し、脱泡させた後に、ニードル径0.2mmのソリッドノズルから100質量%メタノール凝固浴槽中へ吐出させた。吐出温度は60℃であった。凝固後、得られた原糸を巻き取り、自然乾燥させて改変フィブロイン繊維(原料繊維)を得た。 The spinning dope is filtered through a metal filter having a mesh size of 5 μm at 60 ° C., then left to stand in a 30 mL stainless syringe and defoamed, and then in a 100 mass% methanol coagulation bath from a solid nozzle having a needle diameter of 0.2 mm. Was discharged. The discharge temperature was 60 ° C. After coagulation, the obtained raw yarn was wound up and naturally dried to obtain modified fibroin fiber (raw fiber).
 比較のため、原料繊維として、市販されているウール繊維、コットン繊維、テンセル繊維、レーヨン繊維及びポリエステル繊維を用意した。 For comparison, commercially available wool fibers, cotton fibers, tencel fibers, rayon fibers and polyester fibers were prepared as raw fibers.
 各原料繊維を使用して、横編機を使用した横編みで編地をそれぞれ製造した。PRT918繊維又はPRT799繊維を使用した編地の太さ及びゲージ数を表12に示す。その他の原料繊維を使用した編地の太さ及びゲージ数は、カバーファクターが改変フィブロイン繊維の編地のカバーファクターとほぼ同一となるように調整した。具体的には、表12に示すとおりである。
Figure JPOXMLDOC01-appb-T000012
Each raw material fiber was used to produce knitted fabrics by flat knitting using a flat knitting machine. Table 12 shows the thickness and gauge number of the knitted fabric using PRT918 fiber or PRT799 fiber. The thickness and the number of gauges of the knitted fabric using other raw material fibers were adjusted so that the cover factor was almost the same as the cover factor of the knitted fabric of the modified fibroin fiber. Specifically, it is as shown in Table 12.
Figure JPOXMLDOC01-appb-T000012
 10cm×10cmに裁断した編地を2枚合わせにし、四辺を縫い合わせて試験片(試料)とした。試験片を低湿度環境(温度20±2℃、相対湿度40±5%)で4時間以上放置した後、高湿度環境(温度20±2℃、相対湿度90±5%)に移し、試験片内部中央に取り付けた温度センサーにより30分間、1分間隔で温度の測定を行った。 2 pieces of knitted fabric cut to 10 cm × 10 cm were put together, and four sides were sewn together to obtain a test piece (sample). After leaving the test piece in a low humidity environment (temperature 20 ± 2 ° C., relative humidity 40 ± 5%) for 4 hours or more, it is transferred to a high humidity environment (temperature 20 ± 2 ° C., relative humidity 90 ± 5%). The temperature was measured at intervals of 1 minute by a temperature sensor attached to the center of the interior for 30 minutes.
 測定結果から、下記式Aに従って、最高吸湿発熱度を求めた。
 式A:最高吸湿発熱度={(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移したときの試料温度の最高値)-(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移すときの試料温度)}(℃)/試料重量(g)
From the measurement results, the maximum moisture absorption exotherm was determined according to the following formula A.
Formula A: Maximum moisture absorption exotherm = {(maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) − (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment)} (° C.) / Sample weight (g)
 図9は、吸湿発熱性試験の結果の一例を示すグラフである。グラフの横軸は、試料を低湿度環境から高湿度環境に移した時点を0とし、高湿度環境での放置時間(分)を示す。グラフの縦軸は、温度センサーで測定した温度(試料温度)を示す。図9に示したグラフ中、Mで示した点が、試料温度の最高値に対応している。 FIG. 9 is a graph showing an example of the results of the hygroscopic exothermic test. The horizontal axis of the graph represents the time (minutes) left in the high humidity environment, with the time when the sample was transferred from the low humidity environment to the high humidity environment as 0. The vertical axis of the graph indicates the temperature (sample temperature) measured by the temperature sensor. In the graph shown in FIG. 9, the point indicated by M corresponds to the maximum value of the sample temperature.
 最高吸湿発熱度の算出結果を表13に示す。
Figure JPOXMLDOC01-appb-T000013
Table 13 shows the calculation results of the maximum moisture absorption exotherm.
Figure JPOXMLDOC01-appb-T000013
 表13に示すとおり、改変フィブロイン(PRT918及びPRT799)繊維は、既存の材料と比べて、最高吸湿発熱度が高く、吸湿発熱性に優れていることが分かる。 As shown in Table 13, it can be seen that the modified fibroin (PRT918 and PRT799) fibers have a higher maximum heat absorption exotherm and superior hygroscopic heat generation compared to existing materials.
〔参考例3:改変フィブロインの保温性の評価〕
 試験例1と同様にして、改変フィブロイン(PRT966及びPRT799)の凍結乾燥粉末を得た。PRT966は、配列番号40で示されるアミノ酸配列を有し、0超の平均HIを有する、疎水性改変フィブロインである。
[Reference Example 3: Evaluation of heat retention of modified fibroin]
In the same manner as in Test Example 1, lyophilized powders of modified fibroin (PRT966 and PRT799) were obtained. PRT966 is a hydrophobically modified fibroin having the amino acid sequence set forth in SEQ ID NO: 40 and having an average HI greater than zero.
 LiClのDMSO溶液(濃度:4.0質量%)に、改変フィブロイン(PRT966及びPRT799)の凍結乾燥粉末を、濃度24質量%となるよう添加し、シェーカーを使用して3時間混合することにより、溶解させた。その後、不溶物と泡を取り除き、改変フィブロイン溶液(紡糸原液)を得た。 By adding a lyophilized powder of modified fibroin (PRT966 and PRT799) to a LiCl solution in DMSO (concentration: 4.0% by mass) to a concentration of 24% by mass, and mixing for 3 hours using a shaker, Dissolved. Thereafter, insoluble matters and bubbles were removed to obtain a modified fibroin solution (spinning stock solution).
 紡糸原液を60℃にて目開き5μmの金属フィルターで濾過し、次いで30mLのステンレスシリンジ内で静置し、脱泡させた後に、ニードル径0.2mmのソリッドノズルから100質量%メタノール凝固浴槽中へ吐出させた。吐出温度は60℃であった。凝固後、得られた原糸を巻き取り、自然乾燥させて改変フィブロイン繊維(原料繊維)を得た。 The spinning dope is filtered through a metal filter having a mesh size of 5 μm at 60 ° C., then left to stand in a 30 mL stainless syringe and defoamed, and then in a 100 mass% methanol coagulation bath from a solid nozzle having a needle diameter of 0.2 mm. Was discharged. The discharge temperature was 60 ° C. After coagulation, the obtained raw yarn was wound up and naturally dried to obtain modified fibroin fiber (raw fiber).
 比較のため、原料繊維として、市販されているウール繊維、シルク繊維、綿繊維、レーヨン繊維及びポリエステル繊維を用意した。 For comparison, commercially available wool fibers, silk fibers, cotton fibers, rayon fibers and polyester fibers were prepared as raw fibers.
 各原料繊維を使用して、横編機を使用した横編みで編地をそれぞれ製造した。PRT966繊維及びPRT799繊維を使用した編地の、番手、撚り本数、ゲージ数、及び目付けを表14に示す。その他の原料繊維を使用した編地の太さ及びゲージ数は、カバーファクターが改変フィブロイン繊維の編地のカバーファクターとほぼ同一となるように調整した。具体的には、表14に示すとおりである。
Figure JPOXMLDOC01-appb-T000014
Each raw material fiber was used to produce knitted fabrics by flat knitting using a flat knitting machine. Table 14 shows the count, the number of twists, the number of gauges, and the basis weight of the knitted fabric using PRT966 fiber and PRT799 fiber. The thickness and the number of gauges of the knitted fabric using other raw material fibers were adjusted so that the cover factor was almost the same as the cover factor of the knitted fabric of the modified fibroin fiber. Specifically, it is as shown in Table 14.
Figure JPOXMLDOC01-appb-T000014
 保温性を、カトーテック株式会社製のKES-F7サーモラボII試験機を使用し、ドライコンタクト法を用いて評価した。ドライコンタクト法とは、皮膚と衣服が乾燥状態で直接触れたときを想定した方法である。20cm×20cmの矩形に裁断した編地1枚を試験片(試料)として使用した。試験片を、一定温度(30℃)に設定した熱板にセットし、風洞内風速30cm/秒の条件で、試験片を介して放散された熱量(a)を求めた。試験片をセットしない状態で、上記同様の条件で放散された熱量(b)を求め、下記の式に従い保温率(%)を算出した。
保温率(%)=(1-a/b)×100
Thermal insulation was evaluated using a dry contact method using a KES-F7 Thermolab II tester manufactured by Kato Tech. The dry contact method is a method assuming that the skin and clothes are directly touched in a dry state. One knitted fabric cut into a 20 cm × 20 cm rectangle was used as a test piece (sample). The test piece was set on a hot plate set at a constant temperature (30 ° C.), and the amount of heat (a) dissipated through the test piece was determined under the condition of the wind speed in the wind tunnel of 30 cm / second. With no test piece set, the amount of heat (b) dissipated under the same conditions as above was determined, and the heat retention rate (%) was calculated according to the following formula.
Thermal insulation rate (%) = (1−a / b) × 100
 測定結果から、下記式Bに従って、保温性指数を求めた。
 式B:保温性指数=保温率(%)/試料の目付け(g/m
From the measurement results, the heat retention index was determined according to the following formula B.
Formula B: Thermal insulation index = Heat retention ratio (%) / Sample weight (g / m 2 )
 保温性指数の算出結果を表15に示す。保温性指数が高いほど、保温性に優れる材料と評価することができる。 Table 15 shows the calculation results of the heat retention index. It can be evaluated that the higher the heat retention index, the better the heat retention material.
Figure JPOXMLDOC01-appb-T000015
Figure JPOXMLDOC01-appb-T000015
 表15に示すとおり、改変フィブロイン(PRT966及びPRT799)繊維は、既存の材料と比べて、保温性指数が高く、保温性に優れていることが分かる。 As shown in Table 15, it can be seen that the modified fibroin (PRT966 and PRT799) fibers have a higher heat retention index and superior heat retention compared to existing materials.
 1…押出し装置、2…未延伸糸製造装置、3…湿熱延伸装置、4…乾燥装置、6…ドープ液、10…紡糸装置、20…凝固液槽、21…延伸浴槽、36…人造フィブロイン繊維、38…高収縮人造フィブロイン繊維、40…製造装置、42…フィードローラ、44…ワインダー、46…ウォーターバス、48…乾燥機、54…ヒータ、56…テンションローラ、58…ホットローラ、60…加工装置、62…乾燥装置、64…乾熱板。 DESCRIPTION OF SYMBOLS 1 ... Extrusion apparatus, 2 ... Undrawn yarn manufacturing apparatus, 3 ... Wet heat drawing apparatus, 4 ... Drying apparatus, 6 ... Dope liquid, 10 ... Spinning apparatus, 20 ... Coagulating liquid tank, 21 ... Drawing bath, 36 ... Artificial fibroin fiber 38 ... High shrinkage artificial fibroin fiber, 40 ... Production equipment, 42 ... Feed roller, 44 ... Winder, 46 ... Water bath, 48 ... Dryer, 54 ... Heater, 56 ... Tension roller, 58 ... Hot roller, 60 ... Processing Apparatus, 62 ... drying apparatus, 64 ... dry heat plate.

Claims (19)

  1.  改変フィブロインを含む、収縮された人造フィブロイン繊維であって、
     下記式で定義される収縮率が2%以上である、高収縮人造フィブロイン繊維。
     収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
    Shrinked artificial fibroin fiber comprising modified fibroin,
    A highly shrinkable artificial fibroin fiber having a shrinkage rate defined by the following formula of 2% or more.
    Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
  2.  前記改変フィブロインが、改変クモ糸フィブロインである、請求項1に記載の高収縮人造フィブロイン繊維。 The high-shrinkage artificial fibroin fiber according to claim 1, wherein the modified fibroin is a modified spider silk fibroin.
  3.  沸点未満の水との接触により収縮されたものである、請求項1又は2に記載の高収縮人造フィブロイン繊維。 The high-shrinkage artificial fibroin fiber according to claim 1 or 2, which has been shrunk by contact with water having a boiling point below.
  4.  前記水の温度が、10~90℃である、請求項3に記載の高収縮人造フィブロイン繊維。 The high-shrinkage artificial fibroin fiber according to claim 3, wherein the temperature of the water is 10 to 90 ° C.
  5.  前記収縮率が7%以下である、請求項3又は4に記載の高収縮人造フィブロイン繊維。 The high shrinkage artificial fibroin fiber according to claim 3 or 4, wherein the shrinkage ratio is 7% or less.
  6.  改変フィブロインを含む人造フィブロイン繊維を、沸点未満の水と接触させて、収縮させる工程を備え、
     下記式で定義される収縮率が2%以上である、高収縮人造フィブロイン繊維の製造方法。
     収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
    A step of contacting an artificial fibroin fiber containing modified fibroin with water having a boiling point lower than that,
    The manufacturing method of the high shrinkage artificial fibroin fiber whose shrinkage rate defined by a following formula is 2% or more.
    Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
  7.  前記改変フィブロインが、改変クモ糸フィブロインである、請求項6に記載の高収縮人造フィブロイン繊維の製造方法。 The method for producing a high-shrinkage artificial fibroin fiber according to claim 6, wherein the modified fibroin is a modified spider silk fibroin.
  8.  前記水の温度が、10~90℃である、請求項6又は7に記載の高収縮人造フィブロイン繊維の製造方法。 The method for producing high-shrinkage artificial fibroin fiber according to claim 6 or 7, wherein the temperature of the water is 10 to 90 ° C.
  9.  前記収縮率が7%以下である、請求項6~8のいずれか一項に記載の高収縮人造フィブロイン繊維の製造方法。 The method for producing high-shrinkage artificial fibroin fiber according to any one of claims 6 to 8, wherein the shrinkage rate is 7% or less.
  10.  改変フィブロインを含む人造フィブロイン繊維を、沸点未満の水と接触させて、収縮させる工程を備え、
     下記式で定義される収縮率が2%以上である、人造フィブロイン繊維の収縮方法。
     収縮率={1-(水に接触させて湿潤状態にした人造フィブロイン繊維の長さ/紡糸後、水と接触する前の人造フィブロイン繊維の長さ)}×100(%)
    A step of contacting an artificial fibroin fiber containing modified fibroin with water having a boiling point lower than that,
    A shrinkage method of artificial fibroin fiber, wherein the shrinkage rate defined by the following formula is 2% or more.
    Shrinkage rate = {1− (length of artificial fibroin fiber made wet by contact with water / length of artificial fibroin fiber after spinning and before contact with water)} × 100 (%)
  11.  前記改変フィブロインが、改変クモ糸フィブロインである、請求項10に記載の人造フィブロイン繊維の収縮方法。 The method for shrinking artificial fibroin fiber according to claim 10, wherein the modified fibroin is a modified spider silk fibroin.
  12.  前記水の温度が、10~90℃である、請求項10又は11に記載の人造フィブロイン繊維の収縮方法。 The method for shrinking artificial fibroin fiber according to claim 10 or 11, wherein the temperature of the water is 10 to 90 ° C.
  13.  前記収縮率が7%以下である、請求項10~12のいずれか一項に記載の人造フィブロイン繊維の収縮方法。 The method for shrinking artificial fibroin fiber according to any one of claims 10 to 12, wherein the shrinkage ratio is 7% or less.
  14.  前記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
     前記ドメイン配列が、天然由来のフィブロインと比較して、少なくとも1又は複数の(A)モチーフが欠失したことに相当する、(A)モチーフの含有量が低減されたアミノ酸配列を有する、
    請求項1~5のいずれか一項に記載の高収縮人造フィブロイン繊維。
    [式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
    The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ;
    The domain sequence has an amino acid sequence with a reduced content of (A) n motif corresponding to deletion of at least one or more (A) n motifs compared to naturally occurring fibroin,
    The high shrinkage artificial fibroin fiber according to any one of claims 1 to 5.
    [In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
  15.  前記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
     前記ドメイン配列が、天然由来のフィブロインと比較して、少なくともREP中の1又は複数のグリシン残基が別のアミノ酸残基に置換されたことに相当する、グリシン残基の含有量が低減されたアミノ酸配列を有する、
    請求項1~5のいずれか一項に記載の高収縮人造フィブロイン繊維。
    [式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
    The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ;
    Compared with naturally occurring fibroin, the content of glycine residues corresponding to at least one or more glycine residues in REP being replaced with another amino acid residue was reduced in the domain sequence. Having an amino acid sequence,
    The high shrinkage artificial fibroin fiber according to any one of claims 1 to 5.
    [In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
  16.  前記改変フィブロインが、式1:[(A)モチーフ-REP]で表されるドメイン配列を含み、
     前記ドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のアミノ酸残基が疎水性指標の大きいアミノ酸残基に置換されたこと、及び/又はREP中に1又は複数の疎水性指標の大きいアミノ酸残基が挿入されたことに相当する、局所的に疎水性指標の大きい領域を含むアミノ酸配列を有する、
    請求項1~5のいずれか一項に記載の高収縮人造フィブロイン繊維。
    [式1中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が83%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
    The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m ;
    The domain sequence has one or more amino acid residues in REP substituted with amino acid residues having a higher hydrophobicity index and / or one or more hydrophobicity in REP compared to naturally occurring fibroin. Having an amino acid sequence including a region having a large hydrophobic index, which corresponds to insertion of an amino acid residue having a large sex index,
    The high shrinkage artificial fibroin fiber according to any one of claims 1 to 5.
    [In Formula 1, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues relative to the total number of amino acid residues in n motif is 83% or more. . REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
  17.  前記改変フィブロインが、式1:[(A)モチーフ-REP]、又は式2:[(A)モチーフ-REP]-(A)モチーフで表されるドメイン配列を含み、
     前記ドメイン配列が、天然由来のフィブロインと比較して、REP中の1又は複数のグルタミン残基を欠失したこと、又は他のアミノ酸残基に置換したことに相当する、グルタミン残基の含有量が低減されたアミノ酸配列を有する、
    請求項1~5のいずれか一項に記載の高収縮人造フィブロイン繊維。
    [式1及び式2中、(A)モチーフは2~27アミノ酸残基から構成されるアミノ酸配列を示し、かつ(A)モチーフ中の全アミノ酸残基数に対するアラニン残基数が80%以上である。REPは10~200アミノ酸残基から構成されるアミノ酸配列を示す。mは2~300の整数を示す。複数存在する(A)モチーフは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。複数存在するREPは、互いに同一のアミノ酸配列でもよく、異なるアミノ酸配列でもよい。]
    The modified fibroin comprises a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m- (A) n motif;
    Glutamine residue content corresponding to the domain sequence having one or more glutamine residues in REP deleted or substituted with other amino acid residues compared to naturally occurring fibroin Has a reduced amino acid sequence,
    The high shrinkage artificial fibroin fiber according to any one of claims 1 to 5.
    [In Formula 1 and Formula 2, (A) n motif represents an amino acid sequence composed of 2 to 27 amino acid residues, and (A) the number of alanine residues is 80% with respect to the total number of amino acid residues in n motif. That's it. REP indicates an amino acid sequence composed of 10 to 200 amino acid residues. m represents an integer of 2 to 300. A plurality of (A) n motifs may have the same or different amino acid sequences. Plural REPs may have the same amino acid sequence or different amino acid sequences. ]
  18.  前記改変フィブロインが、26.0以上の限界酸素指数(LOI)値を有する、請求項1~5のいずれか一項に記載の高収縮人造フィブロイン繊維。 The high-shrinkage artificial fibroin fiber according to any one of claims 1 to 5, wherein the modified fibroin has a limiting oxygen index (LOI) value of 26.0 or more.
  19.  前記改変フィブロインの下記式Aに従って求められる最高吸湿発熱度が0.025℃/g超である、請求項1~5のいずれか一項に記載の高収縮人造フィブロイン繊維。
     式A:最高吸湿発熱度={(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移したときの試料温度の最高値)-(試料を、試料温度が平衡に達するまで低湿度環境下に置いた後、高湿度環境下に移すときの試料温度)}(℃)/試料重量(g)
    [式A中、低湿度環境は、温度20℃及び相対湿度40%の環境を意味し、高湿度環境は、温度20℃及び相対湿度90%の環境を意味する。]
    The high-shrinkage artificial fibroin fiber according to any one of claims 1 to 5, wherein the maximum hygroscopic exotherm obtained according to the following formula A of the modified fibroin is more than 0.025 ° C / g.
    Formula A: Maximum moisture absorption exotherm = {(maximum value of sample temperature when the sample is placed in a low humidity environment until the sample temperature reaches equilibrium and then transferred to a high humidity environment) − (sample Sample temperature when placed in a low-humidity environment until the temperature reaches equilibrium and then moved to a high-humidity environment)} (° C.) / Sample weight (g)
    [In Formula A, a low humidity environment means an environment with a temperature of 20 ° C. and a relative humidity of 40%, and a high humidity environment means an environment with a temperature of 20 ° C. and a relative humidity of 90%. ]
PCT/JP2019/014895 2018-04-03 2019-04-03 High-shrinkage artificial fibroin fibers, method for producing same, and method for shrinking artificial fibroin fibers WO2019194260A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018071889A JP2021167470A (en) 2018-04-03 2018-04-03 High-shrinkage man-made fibroin fiber and its production method, and shrinkage method of man-made fibroin fiber
JP2018-071889 2018-04-03

Publications (1)

Publication Number Publication Date
WO2019194260A1 true WO2019194260A1 (en) 2019-10-10

Family

ID=68100479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/014895 WO2019194260A1 (en) 2018-04-03 2019-04-03 High-shrinkage artificial fibroin fibers, method for producing same, and method for shrinking artificial fibroin fibers

Country Status (2)

Country Link
JP (1) JP2021167470A (en)
WO (1) WO2019194260A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110297904A1 (en) * 2008-05-02 2011-12-08 The University Of Akron Humidity responsive materials and systems and methods using humidity responsive materials
JP2013506058A (en) * 2009-09-28 2013-02-21 タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ Stretched silk egel fiber and method for producing the same
JP2014198715A (en) * 2013-03-15 2014-10-23 岡本株式会社 Protein fiber
WO2016201369A1 (en) * 2015-06-11 2016-12-15 Bolt Threads, Inc. Recombinant protein fiber yarns with improved properties
WO2017188434A1 (en) * 2016-04-28 2017-11-02 Spiber株式会社 Modified fibroin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110297904A1 (en) * 2008-05-02 2011-12-08 The University Of Akron Humidity responsive materials and systems and methods using humidity responsive materials
JP2013506058A (en) * 2009-09-28 2013-02-21 タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ Stretched silk egel fiber and method for producing the same
JP2014198715A (en) * 2013-03-15 2014-10-23 岡本株式会社 Protein fiber
WO2016201369A1 (en) * 2015-06-11 2016-12-15 Bolt Threads, Inc. Recombinant protein fiber yarns with improved properties
WO2017188434A1 (en) * 2016-04-28 2017-11-02 Spiber株式会社 Modified fibroin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIESA, T. ET AL.: "Unraveling the Molecular Requirements for Macroscopic Silk Supercontraction", ACS NANO, vol. 11, no. 10, 28 August 2017 (2017-08-28), pages 9750 - 9758, XP055643122, ISSN: 1936-0851, DOI: 10.1021/acsnano.7b01532 *
TAISEI, Y. ET AL.: "NMR Investigation about Heterogeneous Structure and Dynamics of Recombinant Spider Silk in Dry and Hydrated States", MACROMOLECULES, vol. 50, no. 20, 13 October 2017 (2017-10-13), pages 8117 - 8128, XP055643118, ISSN: 0024-9297, DOI: 10.1021/acs.macromol.7b01862 *

Also Published As

Publication number Publication date
JP2021167470A (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP6337252B1 (en) High shrinkage artificial fibroin fiber, method for producing the same, and method for shrinking artificial fibroin fiber
WO2018164234A1 (en) Method for producing protein fiber, and method for shrinking protein fiber
WO2018164190A1 (en) Synthetic fibroin fiber
WO2018164020A1 (en) Method and device for manufacturing protein fiber
JP7320790B2 (en) Fiber for artificial hair, method for producing the same, and artificial hair
JP7340262B2 (en) High-shrinkage artificial fibroin spun yarn and its manufacturing method, and artificial fibroin spun yarn and its shrinkage method
WO2019194224A1 (en) Method for recovering dimensions of plastic deformation body of modified fibroin molded body
JPWO2019044982A1 (en) High-density knitted fabric and manufacturing method of high-density knitted fabric
WO2019194258A1 (en) Blended yarn, knitted/woven body of same, and method for manufacturing said knitted/woven body
JPWO2020158897A1 (en) How to make artificial hair fibers, artificial hair, artificial hair fibers, and how to make artificial hair
WO2019151437A1 (en) Manufacturing method for protein spun yarn
WO2019194261A1 (en) Artificial fibroin fibers
WO2019194263A1 (en) Highly contracted synthetic fibroin twisted yarn and production method therefor, and synthetic fibroin twisted yarn and method for contracting same
WO2019194230A1 (en) High-density non-woven cloth, and method for manufacturing high-density non-woven cloth
WO2020067545A1 (en) Composite yarn and method for manufacturing the same, and cloth
WO2020067513A1 (en) Synthetic fiber cotton
WO2020067546A1 (en) Composite yarn, method for producing same, and fabric
WO2020067547A1 (en) Modified fibroin fibers
WO2019194260A1 (en) High-shrinkage artificial fibroin fibers, method for producing same, and method for shrinking artificial fibroin fibers
JP7401062B2 (en) Fabric manufacturing method
WO2019194262A1 (en) High-density woven fabric and method for manufacturing same
WO2019151433A1 (en) Opened tow of protein filament and method for manufacturing same
JP2020122251A (en) Formativeness-giving material, formativeness fiber product and manufacturing method thereof, and, figure-given fiber product and manufacturing method thereof
JP2019183301A (en) Shrink proofing method for artificial fibroin fiber, artificial fibroin fiber, and method for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19782099

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19782099

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP